Document

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

0001356090-16-000129.txt : 20161109 0001356090-16-000129.hdr.sgml : 20161109 20161109162313 ACCESSION NUMBER: 0001356090-16-000129 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 107 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161109 DATE AS OF CHANGE: 20161109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTREXON CORP CENTRAL INDEX KEY: 0001356090 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36042 FILM NUMBER: 161984536 BUSINESS ADDRESS: STREET 1: 1750 KRAFT DRIVE STREET 2: SUITE 1400 CITY: BLACKSBURG STATE: VA ZIP: 24060 BUSINESS PHONE: 301-556-9809 MAIL ADDRESS: STREET 1: 1750 KRAFT DRIVE STREET 2: SUITE 1400 CITY: BLACKSBURG STATE: VA ZIP: 24060 10-Q 1 xon-20160930x10q.htm 10-Q Document

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 001-36042

INTREXON CORPORATION

(Exact name of registrant as specified in its charter)



Virginia		26-0084895
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

20374 Seneca Meadows Parkway Germantown, Maryland		20876
(Address of principal executive offices)		(Zip Code)

(301) 556-9900

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report date)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of October 31, 2016, 118,575,964 shares of common stock, no par value per share, were outstanding.

Table of Contents

INTREXON CORPORATION

FORM 10-Q

TABLE OF CONTENTS



Item No.		Page
PART I - FINANCIAL INFORMATION
1.	Consolidated Financial Statements (unaudited):	5
	Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015	5
	Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2016 and 2015	7
	Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2016 and 2015	8
	Consolidated Statements of Shareholders' and Total Equity for the Nine Months Ended September 30, 2016	9
	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015	10
	Notes to Consolidated Financial Statements	12
2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	39
3.	Quantitative and Qualitative Disclosures About Market Risk	52
4.	Controls and Procedures	53

PART II - OTHER INFORMATION
1.	Legal Proceedings	55
1A.	Risk Factors	55
2.	Unregistered Sales of Equity Securities and Use of Proceeds	57
6.	Exhibits	58
	Signatures	59

Intrexon^®, Arctic^®, ActoBiotics^®, UltraVector^®, RheoSwitch^®, RheoSwitch Therapeutic System^®, RTS^®, Trans Ova Genetics^® and LEAP^® are our and/or our affiliates registered trademarks in the United States and AttSite™, Design-Build-Test-Learn™ and Okanagan Specialty Fruits™ are our common law trademarks in the United States. This quarterly report and the information incorporated herein by reference contain references to trademarks, service marks and trade names owned by us or other companies. Solely for convenience, trademarks, service marks and trade names referred to in this quarterly report and the information incorporated herein, including logos, artwork, and other visual displays, may appear without the ^® or ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. We do not intend our use or display of other companies' trade names, service marks or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Other trademarks, trade names and service marks appearing in this quarterly report are the property of their respective owners.

Table of Contents

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q regarding our strategy, future events, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:


•	our current and future exclusive channel collaborations ("ECCs"), license agreements and other collaborations;


•	developments concerning our collaborators and licensees;


•	our ability to successfully enter new markets or develop additional products, whether with our collaborators or independently;


•	competition from existing technologies and products or new technologies and products that may emerge;


•	actual or anticipated variations in our operating results;


•	actual or anticipated fluctuations in our competitors' or our collaborators' and licensees' operating results or changes in their respective growth rates;


•	our cash position;


•	market conditions in our industry;


•	our ability, and the ability of our collaborators and licensees, to protect our intellectual property and other proprietary rights and technologies;


•	our ability, and the ability of our collaborators and licensees, to adapt to changes in laws or regulations and policies;


•	the ability of our collaborators and licensees to secure any necessary regulatory approvals to commercialize any products developed under the ECCs, license agreements and joint ventures;


•	the ability of our collaborators and licensees to develop and successfully commercialize products enabled by our technologies;


•	the rate and degree of market acceptance of any products developed by a collaborator under an ECC or through a joint venture or license under a license agreement;


•	our ability to retain and recruit key personnel;


•	the result of litigation proceedings that we face currently or may face in the future;


•	our expectations related to the use of proceeds from our public offerings and other financing efforts; and


•	our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Forward-looking statements may also concern our expectations relating to our subsidiaries and other affiliates. We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the

Table of Contents

cautionary statements included in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. "Risk Factors," that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.

You should read this Quarterly Report on Form 10-Q, the documents that we reference in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2015 and the documents that we have filed as exhibits to our filings with the Securities and Exchange Commission completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

Intrexon Corporation and Subsidiaries

Consolidated Balance Sheets

(Unaudited)



(Amounts in thousands, except share data)	September 30, 2016		December 31, 2015
Assets
Current assets
Cash and cash equivalents	$	69,707	$	135,782
Restricted cash	6,987		—
Short-term investments	166,839		102,528
Receivables
Trade, net	22,034		25,101
Related parties	16,159		23,597
Notes, net	1,505		601
Other	2,521		2,995
Inventory	21,880		26,563
Prepaid expenses and other	8,591		6,634
Total current assets	316,223		323,801
Long-term investments	44,122		105,447
Equity securities	39,432		83,653
Investment in preferred stock	123,676		—
Property, plant and equipment, net	54,429		42,739
Intangible assets, net	238,581		247,535
Goodwill	159,793		165,169
Investments in affiliates	25,847		9,977
Other assets	3,485		3,725
Total assets	$	1,005,588	$	982,046

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Intrexon Corporation and Subsidiaries

Consolidated Balance Sheets

(Unaudited)



(Amounts in thousands, except share data)	September 30, 2016			December 31, 2015
Liabilities and Total Equity
Current liabilities
Accounts payable	$	7,866		$	4,967
Accrued compensation and benefits	11,011			19,050
Other accrued liabilities	16,353			7,949
Deferred revenue	54,937			35,366
Lines of credit	549			561
Current portion of long term debt	471			930
Current portion of deferred consideration	8,723			6,931
Related party payables	611			150
Total current liabilities	100,521			75,904
Long term debt, net of current portion	7,950			7,598
Deferred consideration, net of current portion	—			8,698
Deferred revenue, net of current portion	267,460			162,363
Deferred tax liabilities	18,060			21,802
Other long term liabilities	3,177			795
Total liabilities	397,168			277,160
Commitments and contingencies (Note 17)
Total equity
Common stock, no par value, 200,000,000 shares authorized as of September 30, 2016 and December 31, 2015; 118,446,717 and 116,658,886 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	—			—
Additional paid-in capital	1,310,979			1,249,559
Accumulated deficit	(685,204		)	(542,729		)
Accumulated other comprehensive loss	(25,302		)	(12,752		)
Total Intrexon shareholders' equity	600,473			694,078
Noncontrolling interests	7,947			10,808
Total equity	608,420			704,886
Total liabilities and total equity	$	1,005,588		$	982,046

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Intrexon Corporation and Subsidiaries

Consolidated Statements of Operations

(Unaudited)



(Amounts in thousands, except share and per share data)	Three Months Ended September 30,						Nine Months Ended September 30,
(Amounts in thousands, except share and per share data)	2016			2015			2016			2015
Revenues
Collaboration and licensing revenues	$	30,590		$	34,726		$	82,144		$	66,690
Product revenues	9,260			9,446			28,699			32,645
Service revenues	8,706			8,945			33,298			32,157
Other revenues	429			250			783			615
Total revenues	48,985			53,367			144,924			132,107
Operating Expenses
Cost of products	9,156			11,215			29,471			31,654
Cost of services	5,803			5,451			17,807			17,316
Research and development	29,035			21,598			83,266			121,286
Selling, general and administrative	33,812			23,019			106,956			74,320
Total operating expenses	77,806			61,283			237,500			244,576
Operating loss	(28,821		)	(7,916		)	(92,576		)	(112,469		)
Other Income (Expense), Net
Unrealized and realized appreciation (depreciation) in fair value of equity securities	412			(30,453		)	(45,388		)	64,392
Interest expense	(227		)	(310		)	(759		)	(1,012		)
Interest and dividend income	4,494			567			5,817			1,211
Other income (expense), net	(32		)	589			1,205			530
Total other income (expense), net	4,647			(29,607		)	(39,125		)	65,121
Equity in net loss of affiliates	(6,255		)	(2,429		)	(16,951		)	(6,565		)
Loss before income taxes	(30,429		)	(39,952		)	(148,652		)	(53,913		)
Income tax benefit (expense)	418			923			3,290			(806		)
Net loss	$	(30,011	)	$	(39,029	)	$	(145,362	)	$	(54,719	)
Net loss attributable to the noncontrolling interests	1,029			816			2,887			2,940
Net loss attributable to Intrexon	$	(28,982	)	$	(38,213	)	$	(142,475	)	$	(51,779	)
Net loss attributable to Intrexon per share, basic and diluted	$	(0.24	)	$	(0.34	)	$	(1.21	)	$	(0.47	)
Weighted average shares outstanding, basic and diluted	118,346,782			112,244,129			117,785,160			109,244,641

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Intrexon Corporation and Subsidiaries

Consolidated Statements of Comprehensive Loss

(Unaudited)



	Three Months Ended September 30,						Nine Months Ended September 30,
(Amounts in thousands)	2016			2015			2016			2015
Net loss	$	(30,011	)	$	(39,029	)	$	(145,362	)	$	(54,719	)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	(151		)	230			588			249
Foreign currency translation adjustments	(3,495		)	(3,102		)	(13,167		)	(5,374		)
Comprehensive loss	(33,657		)	(41,901		)	(157,941		)	(59,844		)
Comprehensive loss attributable to the noncontrolling interests	1,024			778			2,916			2,874
Comprehensive loss attributable to Intrexon	$	(32,633	)	$	(41,123	)	$	(155,025	)	$	(56,970	)

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Intrexon Corporation and Subsidiaries

Consolidated Statements of Shareholders' and Total Equity

(Unaudited)



(Amounts in thousands, except share data)	Common Stock			Additional Paid-in Capital		Accumulated Other Comprehensive Loss			Accumulated Deficit			Total Intrexon Shareholders' Equity			Noncontrolling Interests			Total Equity
(Amounts in thousands, except share data)	Shares	Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Loss			Accumulated Deficit			Total Intrexon Shareholders' Equity			Noncontrolling Interests			Total Equity
Balances at December 31, 2015	116,658,886	$	—	$	1,249,559	$	(12,752	)	$	(542,729	)	$	694,078		$	10,808		$	704,886
Stock-based compensation expense	—	—		30,555		—			—			30,555			55			30,610
Exercises of stock options and warrants	1,322,843	—		18,180		—			—			18,180			—			18,180
Shares issued as payment for services	328,648	—		8,284		—			—			8,284			—			8,284
Shares issued in asset acquisition	136,340	—		4,401		—			—			4,401			—			4,401
Net loss	—	—		—		—			(142,475		)	(142,475		)	(2,887		)	(145,362		)
Other comprehensive loss	—	—		—		(12,550		)	—			(12,550		)	(29		)	(12,579		)
Balances at September 30, 2016	118,446,717	$	—	$	1,310,979	$	(25,302	)	$	(685,204	)	$	600,473		$	7,947		$	608,420

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

Intrexon Corporation and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited)



	Nine Months Ended September 30,
(Amounts in thousands)	2016			2015
Cash flows from operating activities
Net loss	$	(145,362	)	$	(54,719	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	17,657			12,202
Loss on disposal of property, plant and equipment	297			519
Unrealized and realized (appreciation) depreciation on equity securities	45,388			(64,392		)
Noncash dividend income	(3,676		)	—
Amortization of discount/premium on investments	862			298
Equity in net loss of affiliates	16,951			6,565
Stock-based compensation expense	30,631			26,524
Shares issued as payment for services	8,284			480
Shares issued as consideration for license agreement	—			59,579
Provision for bad debts	1,609			1,562
Deferred income taxes	(2,967		)	374
Other noncash items	1,259			305
Changes in operating assets and liabilities:
Restricted cash	(6,987		)	—
Receivables:
Trade	2,118			(12,014		)
Related parties	7,438			(11,182		)
Notes	(42		)	1
Other	381			6,390
Inventory	4,683			3,451
Prepaid expenses and other	(985		)	(4,005		)
Other assets	2,134			(3,817		)
Accounts payable	2,901			(3,560		)
Accrued compensation and benefits	(8,001		)	5,895
Other accrued liabilities	7,771			1,323
Deferred revenue	(14,099		)	52,400
Deferred consideration	(630		)	(943		)
Related party payables	479			(67		)
Other long term liabilities	126			168
Net cash provided by (used in) operating activities	(31,780		)	23,337

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Intrexon Corporation and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited)



	Nine Months Ended September 30,
(Amounts in thousands)	2016			2015
Cash flows from investing activities
Purchases of investments	(75,246		)	(181,572		)
Maturities of investments	71,987			70,000
Purchases of equity securities and warrants	(2,308		)	(17,080		)
Acquisitions of businesses, net of cash received	—			(114,480		)
Acquisition of noncontrolling interest	—			(1,566		)
Investments in affiliates	(9,415		)	(4,699		)
Cash paid in asset acquisition	(7,244		)	—
Purchases of property, plant and equipment	(20,197		)	(9,841		)
Proceeds from sale of property, plant and equipment	243			420
Issuances of notes receivable	(2,964		)	—
Proceeds from notes receivable	—			1,500
Net cash used in investing activities	(45,144		)	(257,318		)
Cash flows from financing activities
Proceeds from issuance of shares in public offerings, net of issuance costs	—			328,234
Advances from lines of credit	2,308			13,719
Repayments of advances from lines of credit	(2,320		)	(15,517		)
Proceeds from long term debt	547			81
Payments of long term debt	(848		)	(1,032		)
Payments of deferred consideration	(6,705		)	(6,252		)
Proceeds from stock option exercises	18,180			12,208
Net cash provided by financing activities	11,162			331,441
Effect of exchange rate changes on cash and cash equivalents	(313		)	507
Net increase (decrease) in cash and cash equivalents	(66,075		)	97,967
Cash and cash equivalents
Beginning of period	135,782			27,466
End of period	$	69,707		$	125,433
Supplemental disclosure of cash flow information
Cash paid during the period for interest	$	875		$	1,119
Cash paid during the period for income taxes	—			1,165
Significant noncash financing and investing activities
Note receivable as consideration for collaboration agreement	$	—		$	5,000
Stock received as consideration for collaboration agreements	18,766			4,667
Preferred stock received as consideration for collaboration amendments	120,000			—
Stock issued in business combinations	—			126,863
Stock issued to acquire noncontrolling interest	—			9,412
Stock issued in asset acquisition	4,401			—
Contingent consideration assumed in asset acquisition	3,660			—
Noncash dividend to shareholders	—			172,419
Deferred consideration payable related to acquisition	—			11,440
Purchases of equipment included in accounts payable and other accrued liabilities	926			533

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Intrexon Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(Unaudited)

(Amounts in thousands, except share and per share data)

1. Organization

Intrexon Corporation ("Intrexon"), a Virginia corporation, forms collaborations to create biologically based products and processes using synthetic biology. Intrexon's primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. There have been no commercialized products derived from Intrexon's collaborations to date.

Trans Ova Genetics, L.C. ("Trans Ova"), a provider of bovine reproductive technologies and other genetic processes to cattle breeders and producers, is a wholly owned subsidiary of Intrexon with primary operations in Iowa, Maryland, Missouri, Oklahoma, and Texas.

Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil.

Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, is a wholly owned subsidiary of IPHI with primary operations in Canada. Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington.

ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, and Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, are wholly owned subsidiaries with primary operations in Texas and Iowa, respectively.

As of September 30, 2016, Intrexon owned approximately 63% of AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture, and approximately 51% of Biological & Popular Culture, Inc. ("BioPop"), a company developing artwork, children's toys and novelty goods that are derived from living organisms or enabled by synthetic biology.

Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company."

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2016 and results of operations and cash flows for the interim periods ended September 30, 2016 and 2015. The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2016, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.

The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.

Restricted Cash

Restricted cash represents funds deposited with the U.S. Treasury, as required by a court decision resulting from litigation against Trans Ova (Note 17).

Table of Contents

Investment in Preferred Stock

The Company holds preferred stock received from one of its collaborators, ZIOPHARM Oncology, Inc. ("ZIOPHARM"), which may be converted to common stock upon the occurrence of certain events in the future (Note 7). The Company elected the fair value option to account for its investment in preferred stock whereby the value of preferred stock is adjusted to fair value as of each reporting date and unrealized gains and losses are reported in the consolidated statement of operations. This investment is subject to fluctuation in the future due to, among other things, the likelihood and timing of conversion of the preferred stock into common stock, the volatility of ZIOPHARM's common stock, and changes in general economic and financial conditions of ZIOPHARM. The investment is classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell the investment nor expect it to be converted into shares of common stock within one year.

Until such time as the Company converts the instrument into common stock, the Company is entitled to a monthly dividend payable in additional shares of preferred stock and records dividend income based on the fair value of the preferred shares.

Equity Method Investments

The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest") (Note 18) using the equity method of accounting because the Company has the ability to exercise significant influence, but not control, over the operating activities of these entities. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets.

The Company determined that it had significant influence over Oragenics, Inc. ("Oragenics"), one of its collaborators, as of September 30, 2016 and December 31, 2015, based on its ownership interest and other qualitative factors. The Company accounts for its investment in Oragenics using the fair value option.

The fair value of the Company's equity securities of Oragenics was $6,171 and $16,601 as of September 30, 2016 and December 31, 2015, respectively, and is included as equity securities in the accompanying consolidated balance sheets. The Company's ownership percentage of Oragenics was 29.5% and 30.7% at September 30, 2016 and December 31, 2015, respectively. Unrealized appreciation (depreciation) in the fair value of these securities was $(455) and $2,404 for the three months ended September 30, 2016 and 2015, respectively, and $(11,597) and $6,283 for the nine months ended September 30, 2016 and 2015, respectively.

Summarized unaudited financial data as of September 30, 2016 and December 31, 2015 and for the three and nine months ended September 30, 2016 and 2015, for the Company's equity method investments are shown in the following tables. Summarized unaudited financial data for ZIOPHARM has been included through June 30, 2015 for the nine months ended September 30, 2015 as the Company determined it had significant influence over ZIOPHARM until the Company distributed its investment in ZIOPHARM to shareholders in June 2015.



	September 30, 2016		December 31, 2015
Current assets	$	81,049	$	28,123
Non-current assets	10,992		1,539
Total assets	92,041		29,662
Current liabilities	8,325		6,274
Net assets	$	83,716	$	23,388



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Revenues	$	65		$	330		$	394		$	1,480
Operating expenses	18,363			8,687			50,406			118,180
Operating loss	(18,298		)	(8,357		)	(50,012		)	(116,700		)
Other	75			(34		)	1,502			(31		)
Net loss	$	(18,223	)	$	(8,391	)	$	(48,510	)	$	(116,731	)

Table of Contents

Variable Interest Entities

As of September 30, 2016 and December 31, 2015, the Company determined that certain of its collaborators and joint ventures as well as Harvest were variable interest entities ("VIE" or "VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of September 30, 2016 and December 31, 2015 was $145,786 and $3,598, respectively, which represents the Company's maximum risk of loss related to the identified VIEs.

Net Loss per Share

Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.

Segment Information

While the Company generates revenues from multiple sources, including collaboration agreements, licensing, and products and services associated with bovine reproduction, management is organized around a singular research and development focus to further the development of the Company's underlying synthetic biology technologies. Accordingly, the Company has determined that it operates in one segment. As of September 30, 2016 and December 31, 2015, the Company had $11,331 and $3,877, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $3,502 and $1,183 for the three months ended September 30, 2016 and 2015, respectively, and $8,678 and $3,446 for the nine months ended September 30, 2016 and 2015, respectively.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Recently Issued Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-15, Statement of Cash Flows (Topic 230) - Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). The provisions of ASU 2016-15 address eight specific cash flow issues and how those certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017, with early adoption permitted, and is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Stock Compensation (Topic 718) - Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). The provisions of ASU 2016-09 simplify various aspects of the accounting for employee share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, with early adoption permitted, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In March 2016, the FASB issued ASU 2016-07, Investments-Equity Method and Joint Ventures (Topic 323) - Simplifying the Transition to the Equity Method of Accounting ("ASU 2016-07"). The provisions of ASU 2016-07 eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15,

Table of Contents

2016, with early adoption permitted, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The provisions of ASU 2016-02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases today. ASU 2016-02 supersedes the previous lease standard, Topic 840 Leases. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). The provisions of ASU 2016-01 make targeted improvements to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017, and is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes ("ASU 2015-17"). The provisions of ASU 2015-17 simplify the presentation of deferred income taxes by requiring an entity to classify deferred tax liabilities and assets as noncurrent on a classified balance sheet. The Company elected to early adopt this guidance during the first quarter of 2016 and applied it prospectively, and there was no significant impact on the Company's consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) - Simplifying the Measurement of Inventory ("ASU 2015-11"). The provisions of ASU 2015-11 provide guidance for simplifying the calculation for subsequent measurement of inventory measured using the first-in-first-out or average cost methods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). The FASB issued ASU 2014-09 to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance was originally effective for annual periods and interim periods within those annual periods beginning after December 15, 2016 and early adoption was not permitted. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date ("ASU 2015-14"), which deferred the effective date of the guidance in ASU 2014-09 by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016, and is effective for the Company for the year ending December 31, 2018. In March, April and May 2016, the FASB clarified the implementation guidance on principal versus agent, identifying performance obligations, licensing, narrow-scope improvements and practical expedients by issuing ASU 2016-08, Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations ("ASU 2016-08"), ASU 2016-10, Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing ("ASU 2016-10"), and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) - Narrow-Scope Improvements and Practical Expedients ("ASU 2016-12"). The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

Table of Contents

3. Mergers and Acquisitions

Oxitec Acquisition

In September 2015, pursuant to a Stock Purchase Agreement (the "Oxitec Purchase Agreement"), the Company acquired 100% of the issued outstanding share capital of Oxitec. The aggregated consideration paid consisted of (i) 1,359,343 shares of the Company's common stock (the "Stock Consideration") and (ii) $90,199 in cash (the "Cash Consideration"), inclusive of net cash and working capital adjustments, as defined in the Oxitec Purchase Agreement, totaling $9,449. Stock Consideration totaling 480,422 shares and Cash Consideration totaling $1,991 were withheld as escrow at closing and are issuable and payable, respectively, eighteen months after closing, subject to reduction for satisfaction of any claims for indemnification made by the Company under the Oxitec Purchase Agreement. Cash Consideration withheld is included in deferred consideration as of September 30, 2016. The results of Oxitec's operations subsequent to the acquisition date have been included in the consolidated financial statements.

The fair value of the total consideration transferred was $146,394. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:



Cash	$	90,199
Common shares	56,195
	$	146,394

The fair value of the shares of the Company common stock issued was based on the quoted closing price of the Company's common stock as of the closing date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	3,780
Trade receivables	125
Other receivables	7,395
Prepaid expenses and other	121
Property, plant, and equipment	1,198
Intangible assets	96,854
Total assets acquired	109,473
Accounts payable	1,187
Accrued compensation and benefits	246
Other accrued liabilities	210
Deferred revenue	120
Deferred tax liabilities	12,584
Total liabilities assumed	14,347
Net assets acquired	95,126
Goodwill	51,268
Total consideration	$	146,394

The acquired intangible assets primarily include in-process research and development, the fair value of which was determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The in-process research and development are currently indefinite-lived intangible assets and, accordingly, are not being amortized. Goodwill, which is not expected to be deductible for tax purposes, represents the assembled workforce and the potential for future Oxitec products and technologies.

The Company incurred $1,675 of acquisition-related costs, of which $1,644 are included in selling, general and administrative expenses in the accompanying consolidated statements of operations for three and nine months ended September 30, 2015.

Table of Contents

Okanagan Acquisition

In April 2015, pursuant to a Stock Purchase Agreement (the "Okanagan Purchase Agreement"), the Company acquired 100% of the outstanding shares of Okanagan. Pursuant to the Okanagan Purchase Agreement, the former shareholders of Okanagan received an aggregate of 707,853 shares of the Company's common stock, and $10,000 cash in exchange for all shares in Okanagan. The results of Okanagan's operations subsequent to the acquisition date have been included in the consolidated financial statements.

The fair value of the total consideration transferred was $40,933. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	10,000
Common shares	30,933
	$	40,933

The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the closing date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	58
Trade receivables	16
Other receivables	49
Property, plant, and equipment	32
Intangible assets	36,500
Total assets acquired	36,655
Accounts payable	181
Deferred revenue	181
Deferred tax liabilities	8,847
Total liabilities assumed	9,209
Net assets acquired	27,446
Goodwill	13,487
Total consideration	$	40,933

The acquired intangible assets primarily include developed technology, patents and know-how and the fair values of the acquired assets were determined using the with-and-without method, which is a variation of the income approach that utilizes estimated cash flows with all assets in place at the valuation date and estimated cash flows with all assets in place except the intangible assets at the valuation date. The intangible assets are being amortized over a useful life of fourteen years. Goodwill, which is not expected to be deductible for tax purposes, represents potential future applications of Okanagan's technology to other fruits, including additional apple varietals, and anticipated buyer-specific synergies arising from the combination of the Company's and Okanagan's technologies.

The Company incurred $341 of acquisition-related costs, of which $267 are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2015.

ActoGeniX Acquisition

In February 2015, the Company acquired 100% of the membership interests of ActoGeniX NV ("ActoGeniX"), a European biopharmaceutical company, pursuant to a Stock Purchase Agreement (the "ActoGeniX Purchase Agreement"). ActoGeniX's platform technology complements the Company's suite of proprietary technologies available for current and future collaborators. Pursuant to the ActoGeniX Purchase Agreement, the former members of ActoGeniX received an aggregate of 965,377 shares of the Company's common stock and $32,739 in cash in exchange for all membership interests of ActoGeniX. The results of ActoGeniX's operations subsequent to the acquisition date have been included in the consolidated financial statements.

Table of Contents

The fair value of the total consideration transferred was $72,474. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	32,739
Common shares	39,735
	$	72,474



Cash	$	3,180
Other receivables	305
Prepaid expenses and other	31
Property, plant and equipment	209
Intangible assets	68,100
Other non-current assets	23
Total assets acquired	71,848
Accounts payable	230
Accrued compensation and benefits	196
Other accrued liabilities	253
Deferred revenue	732
Deferred tax liabilities	612
Total liabilities assumed	2,023
Net assets acquired	69,825
Goodwill	2,649
Total consideration	$	72,474

The acquired intangible assets primarily include in-process research and development, the fair value of which was determined using the multi-period excess earnings and with-and-without methods, which are both variations of the income approach that convert future cash flows to single discounted present value amounts. In August 2015, the Company re-evaluated the acquired in-process research and development and determined that it was placed in service as developed technology and began amortizing the original amount capitalized using a useful life of eighteen years. Goodwill, which is not expected to be deductible for tax purposes, represents the assembled workforce and anticipated buyer-specific synergies arising from the combination of the Company's and ActoGeniX's technologies.

The Company incurred $418 of acquisition-related costs, of which $381 is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2015.

Table of Contents

Unaudited Condensed Pro Forma Financial Information

The results of operations of the 2015 acquisitions discussed above are included in the consolidated statements of operations beginning on the day after their respective acquisition dates. The following unaudited condensed pro forma financial information for the three and nine months ended September 30, 2015 is presented as if the acquisitions had been consummated on January 1, 2014:



	Three Months Ended September 30, 2015			Nine Months Ended September 30, 2015
	Pro Forma
Revenues	$	53,754		$	133,060
Loss before income taxes	(43,979		)	(66,686		)
Net loss	(43,057		)	(66,319		)
Net loss attributable to the noncontrolling interests	816			2,940
Net loss attributable to Intrexon	(42,241		)	(63,379		)

4. Investments in Joint Ventures

Intrexon T1D Partners

In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a joint venture formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners which provides the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50%. Intrexon has committed to make capital contributions of up to $5,000, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, have committed to make additional capital contributions of up to $5,000, at the request of Intrexon T1D Partners' board of managers (the "Intrexon T1D Partners Board") and subject to certain limitations. As of September 30, 2016, the Company's remaining commitment was $3,650. Intrexon T1D Partners is governed by the Intrexon T1D Partners Board, which has five members. Two members of the Intrexon T1D Partners Board are designated by the Company and three members are designated by a majority of the T1D Investors. The Company and the T1D Investors have the right, but not the obligation, to make additional capital contributions above these limits when and if solicited by the Intrexon T1D Partners Board.

The Company's investment in Intrexon T1D Partners was $1,078 as of September 30, 2016 and is included in investments in affiliates in the accompanying consolidated balance sheet.

EnviroFlight

In February 2016, the Company entered into a series of transactions involving EnviroFlight, LLC ("Old EnviroFlight"), Darling Ingredients Inc. ("Darling") and a newly formed venture between the Company and Darling ("New EnviroFlight"). The Company determined that the series of integrated transactions to acquire substantially all of the assets of Old EnviroFlight for cash, common stock, and contingent consideration should be accounted for as a single transaction, which constituted a business, and considered New EnviroFlight to be the accounting acquirer pursuant to Accounting Standards Codification ("ASC") 805, Business Combinations. Consideration paid to Old EnviroFlight was $4,244 in cash, 136,340 shares of the Company's common stock valued at $4,401 and contingent consideration estimated at $3,660. Contemporaneously, all the assets acquired from Old EnviroFlight, with the exception of certain developed technology, and $3,000 of cash were contributed to New EnviroFlight in exchange for a non-controlling, 50% membership interest in New EnviroFlight. The Company's contributions to New EnviroFlight included an exclusive license to the developed technology that was retained by the Company. Darling received the remaining 50% membership interest in New EnviroFlight as consideration for terminating rights previously held in the developed technology with Old EnviroFlight. New EnviroFlight was formed to generate high-nutrition, low environmental impact animal and fish feed, as well as fertilizer products. The Company and Darling as members have each agreed to make additional capital contributions of up to $5,000 to fund ongoing operations of New EnviroFlight. All of the employees of Old EnviroFlight became employees of New EnviroFlight.

Table of Contents

The Company determined that its investment in New EnviroFlight should be accounted for using the equity method of accounting. The Company recorded an estimated fair value of $5,425 for its investment in New EnviroFlight and $9,880 for the retained developed technology intangible asset. The developed technology will be amortized over a period of twenty-one years. The contingent consideration liability payable to the members of Old EnviroFlight is considered a freestanding financial instrument in accordance with ASC 480, Distinguishing Liabilities and Equity, and will be recorded at fair value each reporting period. The value of this liability was estimated at $3,839 as of September 30, 2016. New EnviroFlight met a regulatory milestone, as defined in the asset purchase agreement, and the members of Old EnviroFlight received a portion of the contingent consideration consisting of 59,337 shares of the Company's common stock valued at $1,583 in October 2016. The members of Old EnviroFlight may receive up to $4,000 of additional shares of the Company's common stock if certain commercial milestones are met prior to February 2019.

The Company's investment in New EnviroFlight was $4,611 as of September 30, 2016 and is included in investments in affiliates in the accompanying consolidated balance sheet.

Intrexon Energy Partners II

In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a joint venture formed to utilize the Company's natural gas bioconversion platform for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II which provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Intrexon has committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board.

The Company's investment in Intrexon Energy Partners II was $1,591 and $2,000 as of September 30, 2016 and December 31, 2015, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.

Intrexon Energy Partners

In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's gas-to-liquid bioconversion platform for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Intrexon has committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of September 30, 2016, the Company's remaining commitment was $12,367. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board.

The Company's investment in Intrexon Energy Partners was $(627) and $(1,270) as of September 30, 2016 and December 31, 2015, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.

Table of Contents

OvaXon

In December 2013, the Company and OvaScience, Inc. ("OvaScience"), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, entered into a Limited Liability Company Agreement ("OvaXon LLC Agreement") to form OvaXon, LLC ("OvaXon"), a joint venture to create new applications for improving human and animal health. Both the Company and OvaScience made an initial capital contribution of $1,500 in January 2014 for a 50% membership interest in OvaXon. OvaXon is governed by the OvaXon board of managers ("OvaXon Board") which has four members, two each from the Company and OvaScience. In cases in which the OvaXon Board determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations, each of the Company and OvaScience has the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement.

The Company's investment in OvaXon was $435 and $(144) as of September 30, 2016 and December 31, 2015, respectively, and is included in investments in affiliates and other accrued liabilities, respectively, in the accompanying consolidated balance sheets.

S & I Ophthalmic

In September 2013, the Company entered into a Limited Liability Company Agreement ("Sun LLC Agreement") with Caraco Pharmaceutical Laboratories, Ltd. ("Sun Pharmaceutical Subsidiary"), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceutical"), an international specialty pharmaceutical company focused on chronic diseases, to form S & I Ophthalmic, LLC ("S & I Ophthalmic"). The Sun LLC Agreement governs the affairs and the conduct of business of S & I Ophthalmic. S & I Ophthalmic leverages experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of $5,000 in October 2013 for a 50% membership interest in S & I Ophthalmic. S & I Ophthalmic is governed by a board of managers ("S & I Ophthalmic Board") which has four members, two each from the Company and Sun Pharmaceutical Subsidiary. In cases in which the S & I Ophthalmic Board determines that additional capital contributions are necessary in order for S & I Ophthalmic to conduct business and comply with its obligations, each of the Company and Sun Pharmaceutical Subsidiary has committed to making additional capital contributions to S & I Ophthalmic subject to certain limits defined in the agreement. Each has the right, but not the obligation, to make additional capital contributions above the defined limits when and if solicited by the S & I Ophthalmic Board. In 2015, both the Company and Sun Pharmaceutical Subsidiary made subsequent capital contributions of $5,000.

Beginning on the seventh anniversary of the effective date of the Sun LLC Agreement, and upon the second anniversary thereafter, the Company, as well as Sun Pharmaceutical Subsidiary, may make a cash offer to purchase all of the other party's interest in S & I Ophthalmic. Upon receipt of such an offer, the other party must either agree to tender its interests at the offered price or submit a counteroffer at a price higher than the original offer. Such offer and counteroffer may continue until one party agrees to the other's price.

The Company's investment in S & I Ophthalmic was $3,737 and $6,379 as of September 30, 2016 and December 31, 2015, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.

Table of Contents

5. Collaboration and Licensing Revenue

The Company generates revenue through contractual agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensees obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Upfront and milestone payments are typically deferred and recognized over the expected life of the Company's technology platform using a straight-line approach. The Company recognizes the reimbursement payments received for research and development services in the period in which the services are performed and collection is reasonably assured. The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the three and nine months ended September 30, 2016 and 2015.



	Three Months Ended September 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	4,843	$	5,586	$	10,429
Oragenics, Inc.	262		294		556
Fibrocell Science, Inc.	604		563		1,167
Genopaver, LLC	68		1,625		1,693
S & I Ophthalmic, LLC	—		2,782		2,782
OvaXon, LLC	—		709		709
Intrexon Energy Partners, LLC	625		4,230		4,855
Persea Bio, LLC	125		208		333
Ares Trading S.A.	1,597		719		2,316
Thrive Agrobiotics, Inc.	46		379		425
Intrexon Energy Partners II, LLC	500		372		872
Exotech Bio, Inc.	139		82		221
Relieve Genetics, Inc.	120		342		462
Intrexon T1D Partners, LLC	276		511		787
AD Skincare, Inc.	120		65		185
Other	895		1,903		2,798
Total	$	10,220	$	20,370	$	30,590



	Three Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	645	$	4,006	$	4,651
Oragenics, Inc.	4,868		332		5,200
Fibrocell Science, Inc.	4,823		1,317		6,140
Genopaver, LLC	68		993		1,061
S & I Ophthalmic, LLC	—		1,193		1,193
OvaXon, LLC	—		549		549
Intrexon Energy Partners, LLC	625		3,185		3,810
Persea Bio, LLC	125		297		422
Ares Trading S.A.	1,597		260		1,857
Other	7,841		2,002		9,843
Total	$	20,592	$	14,134	$	34,726

Table of Contents



	Nine Months Ended September 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	6,687	$	17,693	$	24,380
Oragenics, Inc.	786		1,083		1,869
Fibrocell Science, Inc.	1,814		2,604		4,418
Genopaver, LLC	205		4,703		4,908
S & I Ophthalmic, LLC	—		6,326		6,326
OvaXon, LLC	—		2,211		2,211
Intrexon Energy Partners, LLC	1,875		11,180		13,055
Persea Bio, LLC	375		613		988
Ares Trading S.A.	4,791		2,148		6,939
Thrive Agrobiotics, Inc.	138		1,171		1,309
Intrexon Energy Partners II, LLC	1,500		816		2,316
Exotech Bio, Inc.	278		82		360
Relieve Genetics, Inc.	240		572		812
Intrexon T1D Partners, LLC	554		543		1,097
AD Skincare, Inc.	120		65		185
Other	4,684		6,287		10,971
Total	$	24,047	$	58,097	$	82,144



	Nine Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	1,933	$	11,769	$	13,702
Oragenics, Inc.	5,437		408		5,845
Fibrocell Science, Inc.	5,719		4,500		10,219
Genopaver, LLC	205		2,460		2,665
S & I Ophthalmic, LLC	—		2,838		2,838
OvaXon, LLC	—		1,855		1,855
Intrexon Energy Partners, LLC	1,875		8,101		9,976
Persea Bio, LLC	375		553		928
Ares Trading S.A.	2,336		260		2,596
Other	9,446		6,620		16,066
Total	$	27,326	$	39,364	$	66,690

Except for the agreements discussed below, there have been no significant changes to arrangements with our collaborators and licensees in the nine months ended September 30, 2016. See Note 5 in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 for additional details of the Company's existing collaboration and licensing agreements.

Exotech Bio Collaboration

Table of Contents

agreement. Exotech Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Exotech Bio upon 90 days written notice to the Company.

Relieve Genetics Collaboration

In March 2016, the Company entered into an ECC with Relieve Genetics, Inc. ("Relieve Genetics"), an affiliate of Harvest and a related party. Relieve Genetics was formed for the purpose of entering into the ECC and developing and commercializing products using a viral vector expressing interleukin-10 for the treatment of chronic neuropathic pain resultant from cancer in humans. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Relieve Genetics valued at $4,333 as upfront consideration. The Company is also entitled to up to $52,500 of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. Relieve Genetics will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. Relieve Genetics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Relieve Genetics upon 90 days written notice to the Company.

Intrexon T1D Partners Collaboration

In March 2016, the Company entered into an ECC with Intrexon T1D Partners, a related party. Pursuant to the ECC, Intrexon T1D Partners received an exclusive license to the Company's technology platform to develop and commercialize products to treat type 1 diabetes. Upon execution of the ECC, the Company received a technology access fee of $10,000 and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2016 and continues until March 2036; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated Intrexon T1D Partners upon 90 days written notice to the Company.

AD Skincare Collaboration

In June 2016, the Company entered into an ECC with AD Skincare, Inc. ("AD Skincare"), an affiliate of Harvest and a related party. AD Skincare was formed for the purpose of entering into the ECC and developing an advanced topical delivery system to improve the efficacy of biologically active ingredients aimed at improving signs of aging human skin. Upon execution of the ECC, the Company received a technology access fee in the form of equity in AD Skincare valued at $4,333 as upfront consideration. The Company is also entitled to up to $2,000 of potential payments for substantive and non-substantive development milestones for each product developed under the ECC, as well as up to $17,000 in one-time commercial milestones. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. AD Skincare will pay the Company royalties as a percentage in the low double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. AD Skincare is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in June 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by AD Skincare upon 90 days written notice to the Company.

ZIOPHARM Collaborations

In June 2016, the Company amended each of its two existing collaboration agreements with ZIOPHARM and as a result the rate of the royalty which the Company is entitled to receive on certain products commercialized pursuant to the agreements was reduced from 50% to 20%. As consideration for execution of the amendments, ZIOPHARM issued the Company 100,000 shares of ZIOPHARM's Series 1 Preferred Stock valued at $120,000. The Company allocated the consideration received to each ECC based on the cumulative value of upfront and milestone payments previously received pursuant to that ECC. Because the Company has remaining performance obligations under each of the ZIOPHARM ECCs, the Company recorded the initial fair value received as deferred revenue and will recognize this amount straight-line over the remaining performance period for each ZIOPHARM ECC. No other financially significant terms of the ZIOPHARM ECCs were changed as a result of the amendments. See Note 7 for additional discussion of the terms of the preferred stock and the accounting treatment.

Table of Contents

Genten Therapeutics Collaboration

In September 2016, the Company entered into an ECC with Genten Therapeutics, Inc. ("Genten Therapeutics"), an affiliate of Harvest and a related party. Genten Therapeutics was formed for the purpose of entering into the ECC and developing and commercializing products using the Company's technology for expression of gluten peptides, alone or in combination with immunomodulatory cytokines, to reestablish immune tolerance for patients with celiac disease. Upon execution of the ECC, the Company received a technology access fee in the form of a $1,500 cash payment and equity in Genten Therapeutics valued at $3,000 as upfront consideration. The Company is entitled to receive additional equity interests in Genten Therapeutics upon the first instance of the achievement of a certain non-substantive development milestone. The Company is also entitled to up to $82,000 of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. Genten Therapeutics will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. Genten Therapeutics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Genten Therapeutics upon 90 days written notice to the Company.

CRS Bio Collaboration

In September 2016, the Company entered into an ECC with CRS Bio, Inc. ("CRS Bio"), an affiliate of Harvest and a related party. CRS Bio was formed for the purpose of entering into the ECC and developing and commercializing products through targeted delivery of antibodies for treatment of chronic rhinosinusitis with and without nasal polyps, by utilizing the Company's technology to block inflammatory mediators in the nasal passage, leading to improved breathing and, importantly, patients' quality of life. Upon execution of the ECC, the Company received a technology access fee in the form of equity in CRS Bio valued at $2,100. The Company is entitled to receive additional equity interests in CRS Bio upon the first instance of the achievement of a certain non-substantive development milestone. The Company is also entitled to up to $75,000 of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. CRS Bio will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. CRS Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by CRS Bio upon 90 days written notice to the Company.

Deferred Revenue

Deferred revenue primarily consists of consideration received for upfront and milestone payments in connection with the Company's collaborations and licensing agreements, prepayments for research and development services performed for collaborators and licensees, and prepayments for product and service revenues. Deferred revenue consists of the following:



	September 30, 2016		December 31, 2015
Upfront and milestone payments	$	309,126	$	181,331
Prepaid research and development services	7,057		10,938
Prepaid product and service revenues	5,594		4,759
Other	620		701
Total	$	322,397	$	197,729
Current portion of deferred revenue	$	54,937	$	35,366
Long-term portion of deferred revenue	267,460		162,363
Total	$	322,397	$	197,729

Table of Contents

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement:



	September 30, 2016		December 31, 2015
ZIOPHARM Oncology, Inc.	$	143,651	$	30,338
Oragenics, Inc.	8,027		8,813
Fibrocell Science, Inc.	19,631		21,445
Genopaver, LLC	2,045		2,250
Intrexon Energy Partners, LLC	18,750		20,625
Persea Bio, LLC	4,125		4,500
Ares Trading S.A.	48,776		53,567
Thrive Agrobiotics, Inc.	1,483		1,621
Intrexon Energy Partners II, LLC	16,333		17,833
Exotech Bio, Inc.	4,722		—
Relieve Genetics, Inc.	4,093		—
Intrexon T1D Partners, LLC	9,383		—
AD Skincare, Inc.	4,213		—
Genten Therapeutics, Inc.	4,523		—
CRS Bio, Inc.	2,111		—
Other	17,260		20,339
Total	$	309,126	$	181,331

6. Short-term and Long-term Investments

The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of September 30, 2016:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	210,620	$	79	$	(10	)	$	210,689
Certificates of deposit	272		—		—			272
Total	$	210,892	$	79	$	(10	)	$	210,961

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2015:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	208,223	$	21	$	(540	)	$	207,704
Certificates of deposit	271		—		—			271
Total	$	208,494	$	21	$	(540	)	$	207,975

For more information on the Company's method for determining the fair value of its assets, see Note 2 – "Fair Value of Financial Instruments" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.

Table of Contents

The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2016 was:



Due within one year	$	166,839
After one year through two years	44,122
Total	$	210,961

Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and have been in a loss position for less than 12 months.

As of September 30, 2016 and December 31, 2015, the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.

7. Investment in Preferred Stock

In June 2016, the Company received 100,000 shares of ZIOPHARM's Series 1 Preferred Stock (the "Preferred Shares"), with a per share stated value of $1,200, as consideration for amending their two previously existing ECC agreements (Note 5). A summary of the terms of the Preferred Shares are as follows.

Conversion. The Preferred Shares shall automatically convert into shares of ZIOPHARM common stock upon the date the first approval in the United States of (i) a ZIOPHARM product, as defined in and developed under one of the ECC agreements, or (ii) a product, as defined and developed under the License and Collaboration Agreement with Ares Trading S.A., a subsidiary of the biopharmaceutical business of Merck KGaA, and ZIOPHARM, is publicly announced (the "Conversion Event Date"). The Preferred Shares shall convert into a number of shares of ZIOPHARM common stock equal to the stated value of such Preferred Share, divided by the greater of: (i) the volume weighted average closing price of ZIOPHARM's common stock over the twenty trading days ending on the Conversion Event Date or (ii) $1.00. The number of converted shares is subject to certain limitations defined in the amended and restated Certificate of Designation, Preferences, and Rights of Series 1 Preferred Stock (the "A&R Certificate of Designation").

Dividend Rights. The Company shall receive a monthly dividend, payable in additional Preferred Shares, equal to $12.00 per Preferred Share held per month divided by the stated value of the Preferred Shares, which is referred to as the PIK Dividend. For any Preferred Shares that are not converted on the Conversion Event Date, the rate of PIK Dividend on these unconverted Preferred Shares will automatically increase from $12.00 to $24.00 per Preferred Share per month.

Voting Rights. The Preferred Shares do not have any voting rights except for certain protective voting rights defined in the A&R Certificate of Designation.

Liquidation Rights. In the event of any voluntary or involuntary liquidation, dissolution or winding up of ZIOPHARM or a deemed liquidation event, as defined in the A&R Certificate of Designation, including a change of control or the sale, lease transfer or exclusive license of all or substantially all of ZIOPHARM's assets, the holders of the Preferred Shares shall be entitled to receive a portion of all funds to be distributed in proportion to the holders' proportionate share of ZIOPHARM's common stock on an as-converted to common stock basis (the "Series 1 Liquidation Amount"). For purposes of calculating the Series 1 Liquidation Amount, if such liquidation event occurs prior to the Conversion Event Date, each Preferred Share shall be deemed to be convertible into the number of shares of ZIOPHARM's common stock equal to (i) the stated value of each Preferred Share, divided by (ii) the volume weighted average price of ZIOPHARM's common stock for the twenty day period ending on the date of the public announcement of the liquidation event. In addition, ZIOPHARM may elect to redeem the Preferred Shares in connection with or following a deemed liquidation event at a price per share equal to the Series 1 Liquidation Amount.

The Company elected the fair value option to account for its investment in ZIOPHARM preferred stock (the "investment in preferred stock"). The investment in preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Preferred Shares are not traded on a public exchange. The fair value of the investment in preferred stock was estimated using a probability-weighted expected return ("PWERM") model. The key inputs used in the PWERM model were (i) estimating the future returns for conversion of the Preferred Shares for both product approval and a change in control of

Table of Contents

ZIOPHARM (the "conversion events") using market data of the change in value for guideline companies as a result of these conversion events; (ii) estimating the expected date and likelihood of each conversion event; and (iii) discounting these estimated future returns using a discount rate for the Preferred Shares considering industry debt issuances originated by public funds and venture capital rates of return. There have been no significant changes in the fair value of the Preferred Shares during the three months ended September 30, 2016. A significant change in unobservable inputs discussed above could result in a significant impact to the fair value of the Company's investment in preferred stock. The fair value of the Company's investment in preferred stock, including additional Preferred Shares received as dividends, is $123,676 as of September 30, 2016. During the three and nine months ended September 30, 2016, the Company received 3,063 shares of additional Preferred Shares and recognized $3,676 of dividend income in the accompanying consolidated statements of operations. The only change in the Level 3 investment during the three months ended September 30, 2016 was this receipt of additional Preferred Shares arising from the dividend.

8. Fair Value Measurements

The carrying amount of cash and cash equivalents, restricted cash, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at September 30, 2016:



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		September 30, 2016
Assets
U.S. government debt securities	$	—	$	210,689	$	—	$	210,689
Equity securities	31,245		8,187		—		39,432
Preferred stock	—		—		123,676		123,676
Other	—		2,296		—		2,296
Total	$	31,245	$	221,172	$	123,676	$	376,093



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2015
Assets
U.S. government debt securities	$	—	$	207,704	$	—	$	207,704
Equity securities	65,850		17,803		—		83,653
Other	—		405		—		405
Total	$	65,850	$	225,912	$	—	$	291,762

The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term and long-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability. The method used to estimate the fair value of the Level 3 asset is discussed in Note 7.

There were no transfers between levels of the fair value hierarchy in the nine months ended September 30, 2016.

Table of Contents

The carrying values of the Company's long term debt approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. Significant financial liabilities measured on a recurring basis were $3,839 at September 30, 2016. The Company accounted for the contingent consideration liability to the members of Old EnviroFlight by recording its fair value as a liability on the date of the asset acquisition (Note 4) whereby the regulatory and commercial milestones were valued using a probability-weighted discounted cash flow model using discount rates reflecting the time value of money and additional risk inherent in meeting the milestones. These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. The contingent consideration liability is remeasured to fair value at each reporting date until the contingency is resolved, and those changes in fair value are recognized in earnings. The fair value of this liability increased $179 during the three months ended September 30, 2016 (Note 4). Financial liabilities measured on a recurring basis were not significant at December 31, 2015.

9. Inventory

Inventory consists of the following:



	September 30, 2016		December 31, 2015
Supplies, semen and embryos	$	1,278	$	1,402
Work in process	5,831		6,290
Livestock	12,588		16,907
Feed	2,183		1,964
Total inventory	$	21,880	$	26,563

10. Property, Plant and Equipment, Net

Property, plant and equipment consist of the following:



	September 30, 2016			December 31, 2015
Land and land improvements	$	11,276		$	9,119
Buildings and building improvements	7,965			7,520
Furniture and fixtures	1,234			1,283
Equipment	41,343			36,016
Leasehold improvements	10,479			6,888
Computer hardware and software	6,912			5,960
Construction and other assets in progress	7,523			2,193
	86,732			68,979
Less: Accumulated depreciation and amortization	(32,303		)	(26,240		)
Property, plant and equipment, net	$	54,429		$	42,739

Depreciation expense was $2,332 and $1,987 for the three months ended September 30, 2016 and 2015, respectively, and $6,769 and $5,768 for the nine months ended September 30, 2016 and 2015, respectively.

11. Goodwill and Intangible Assets, Net

The changes in the carrying amount of goodwill for the nine months ended September 30, 2016 are as follows:



Balance at December 31, 2015	$	165,169
Foreign currency translation adjustments	(5,376		)
Balance at September 30, 2016	$	159,793

No goodwill or accumulated impairment losses existed as of September 30, 2016 and December 31, 2015.

Table of Contents

Intangible assets consist of the following at September 30, 2016:



	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Patents, related technologies and know-how	15.3	$	170,520	$	(26,596	)	$	143,924
Customer relationships	6.5	10,700		(4,189		)	6,511
Trademarks	9.3	6,800		(1,598		)	5,202
Covenant not to compete	2.0	395		(312		)	83
In-process research and development		82,861		—			82,861
Total		$	271,276	$	(32,695	)	$	238,581

Intangible assets consist of the following at December 31, 2015:



	Gross Carrying Amount		Accumulated Amortization			Net
Patents, related technologies and know-how	$	157,411	$	(17,775	)	$	139,636
Customer relationships	10,700		(2,739		)	7,961
Trademarks	6,800		(1,018		)	5,782
Covenant not to compete	384		(160		)	224
In-process research and development	93,932		—			93,932
Total	$	269,227	$	(21,692	)	$	247,535

The balance of in-process research and development as of September 30, 2016 primarily includes the in-process research and development acquired in the Company's Oxitec acquisition and amortization will begin once certain regulatory approvals have been obtained.

Amortization expense was $3,651 and $2,857 for the three months ended September 30, 2016 and 2015, respectively, and $10,888 and $6,434 for the nine months ended September 30, 2016 and 2015, respectively.

12. Lines of Credit and Long Term Debt

Lines of Credit

Trans Ova has a $6,000 revolving line of credit with First National Bank of Omaha which matures on May 1, 2017. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% and, and the actual rate was 3.48% at September 30, 2016. As of September 30, 2016, there were no amounts outstanding. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth, maximum allowable annual capital expenditures and working capital. Trans Ova was in compliance with these covenants as of September 30, 2016.

Exemplar has a $700 revolving line of credit with American State Bank which matures on October 30, 2017. The line of credit bears interest at 4.50% per annum. As of September 30, 2016, there was an outstanding balance of $549.

Long Term Debt

Long term debt consists of the following:



	September 30, 2016		December 31, 2015
Notes payable	$	5,769	$	6,477
Royalty-based financing	2,003		1,807
Other	649		244
Long term debt	8,421		8,528
Less current portion	471		930
Long term debt, less current portion	$	7,950	$	7,598

Trans Ova has a note payable to American State Bank which matures in April 2033 and has an outstanding principal balance of $5,338 as of September 30, 2016. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.

Exemplar has notes payable with outstanding principal balances totaling $431 as of September 30, 2016. Exemplar pays monthly installments ranging from $1 to $4 with interest rates ranging from 0% to 3.00%. These notes mature from September 2018 to May 2020 and are collateralized by certain of Exemplar's real estate or letters of credit of certain of its members.

In August 2016, AquaBounty obtained a loan from Finance PEI ("FPEI"), a Canadian government-owned corporation. As of September 30, 2016 there was an outstanding balance of $543. AquaBounty pays monthly installments of $4, which includes interest of 4.00%, with a balloon payment due in July 2021. The loan is collateralized by certain of AquaBounty's assets.

AquaBounty has a royalty-based financing grant from the Atlantic Canada Opportunities Agency ("ACOA"), a Canadian government agency, to provide funding of a research and development project. The total amount available under the award was $2,185, which AquaBounty claimed over a five year period. All amounts claimed by AquaBounty must be repaid in the form of a 10% royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to additional regulatory considerations, the timing of repayment is uncertain. As of the acquisition date in March 2013, AquaBounty had claimed $1,952 of the available funds and this amount was recorded at its acquisition date fair value of $1,107. The Company accretes the difference of $845 between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Since the acquisition date, AquaBounty has claimed the remaining balance available under the grant, resulting in total long term debt of $2,003 as of September 30, 2016.

Future maturities of long term debt are as follows:



2016	$	168
2017	404
2018	549
2019	364
2020	335
2021	774
Thereafter	3,824
Total	$	6,418

The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.

13. Income Taxes

Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the three and nine months ended September 30, 2016, the Company had U.S. taxable income of

approximately $8,334 and U.S. taxable loss of approximately $9,346, respectively, for which no income tax benefit was recognized. For the three and nine months ended September 30, 2016, the Company recognized $110 and $323 of current foreign income tax benefit, respectively. For the three months ended September 30, 2015, the Company had U.S. taxable loss of approximately $15,865, which resulted in an income tax benefit of $318. For the nine months ended September 30, 2015, the Company had U.S. taxable income of approximately $22,935, which resulted in $459 of current income tax expense due to the corporate alternative minimum tax. For the three and nine months ended September 30, 2015, the Company recognized $27 of current foreign income tax benefit. For the three and nine months ended September 30, 2016, the Company recorded deferred tax benefit of $308 and $2,967, respectively. For the three and nine months ended September 30, 2015, the Company recorded deferred tax benefit of $578 and deferred tax expense of $374, respectively. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $18,060, are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

At September 30, 2016, the Company has loss carryforwards for U.S. federal income tax purposes of approximately $257,700 available to offset future taxable income and federal and state research and development tax credits of approximately $7,060, prior to consideration of annual limitations that may be imposed under Section 382. These carryforwards will begin to expire in 2022. Of these loss carryforwards, approximately $54,400 relates to benefits from stock compensation deductions that will be recorded as a component of paid-in capital when realized. The Company's direct foreign subsidiaries have foreign loss carryforwards of approximately $120,600, most of which do not expire.

14. Shareholders' Equity

Dividend to Shareholders

In June 2015, the Company distributed to its shareholders 17,830,305 shares of ZIOPHARM common stock, representing all of the equity interests of ZIOPHARM held by the Company at the time of the distribution and resulting in a realized gain of $81,401. The distribution constituted a dividend to shareholders of record as of June 4, 2015. In connection with the distribution, pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's common stock as of June 4, 2015 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock by decreasing the exercise prices and increasing the number of shares. This adjustment resulted in 312,795 additional shares at a weighted average exercise price of $25.40.

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	September 30, 2016			December 31, 2015
Unrealized gain (loss) on investments	$	69		$	(519	)
Foreign currency translation adjustments	(25,371		)	(12,233		)
Total accumulated other comprehensive loss	$	(25,302	)	$	(12,752	)

15. Share-Based Payments

The Company records the fair value of stock options issued to employees and non-employees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and non-employees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Cost of products	$	21	$	21	$	61	$	76
Cost of services	68		98		206		301
Research and development	2,236		2,234		6,979		6,141
Selling, general and administrative	8,467		6,032		23,385		20,006
Total	$	10,792	$	8,385	$	30,631	$	26,524

Intrexon Stock Option Plans

In April 2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's Board of Directors may grant share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of September 30, 2016, there were 570,977 stock options outstanding under the 2008 Plan.

Intrexon adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's Board of Directors may grant share based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors and nonemployee directors. The 2013 Plan became effective upon the closing of the Company's initial public offering in August 2013, and as of September 30, 2016, there were 16,000,000 shares authorized for issuance under the 2013 Plan, of which 10,532,430 stock options were outstanding and 3,982,064 shares were available for grant.

As of September 30, 2016, an additional 1,000,000 options were issued and outstanding outside the 2008 Plan and 2013 Plan. These options were awarded as an inducement grant to an executive officer in accordance with New York Stock Exchange Rule 303A.08 and are generally subject to the same terms and conditions as awards granted under the 2013 Plan.

Stock option activity was as follows:



	Number of Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2015	11,043,528		$	32.66		8.49
Granted	4,384,860		29.42
Exercised	(1,162,843	)	(15.63		)
Forfeited	(2,127,334	)	(43.29		)
Expired	(34,804	)	(35.76		)
Balances at September 30, 2016	12,103,407		31.24			8.50
Exercisable at September 30, 2016	3,369,252		27.99			7.25
Vested and Expected to Vest at September 30, 2016(1)	10,177,058		30.99			8.37


(1)	The number of stock options expected to vest takes into account an estimate of expected forfeitures.

Total unrecognized compensation costs related to unvested awards at September 30, 2016 and December 31, 2015 were $106,649 and $113,655, respectively, and are expected to be recognized over a weighted-average period of approximately three years.

Intrexon currently uses authorized and unissued shares to satisfy share award exercises.

In October 2015, the Compensation Committee and the independent members of Intrexon's Board of Directors approved a compensation arrangement whereby the Company's Chief Executive Officer ("CEO") would receive a monthly salary. Previously, the CEO did not receive compensation for his services as an employee of the Company other than through his participation in the Company's Annual Executive Incentive Plan which became effective January 1, 2015. Pursuant to the compensation agreement, the CEO receives a base salary of $200 per month payable in fully vested shares of Intrexon common stock with such shares subject to a three-year lock-up on resale. The monthly number of shares of common stock is calculated based on the closing price on the last trading day of each month and the shares are issued pursuant to the terms of a Restricted Stock Unit Agreement (the "RSU Agreement") which was executed between Intrexon and the CEO pursuant to the terms of the 2013 Plan. The RSU Agreement became effective in November 2015, has an initial term of 12 months, and is renewable annually at the discretion of Intrexon's Board of Directors. In October 2016, the independent members of Intrexon's Board of Directors, with the recommendation of the Compensation Committee of the Board of Directors, approved a new Restricted Stock Unit Agreement for the CEO providing for a term of two months. The new RSU Agreement, which will expire on December 31, 2016, provides for the same monthly salary payable in fully vested shares of common stock pursuant to the same terms as the original RSU Agreement. The fair value of the shares issued as compensation for services is included in selling, general and administrative expenses in the Company's consolidated statements of operations and totaled $463 and $1,397 for the three and nine months ended September 30, 2016, respectively.

Other Plans

As of September 30, 2016, there were 5,567,000 options, which are exercisable into shares of AquaBounty common stock, outstanding under the AquaBounty 2006 Equity Incentive Plan ("AquaBounty 2006 Plan") at a weighted average exercise price of $0.26 per share of which 5,321,598 were exercisable. As of December 31, 2015, there were 5,382,000 options outstanding under the AquaBounty 2006 Plan at a weighted average exercise price of $0.26 per share of which 4,320,333 were exercisable.

In March 2016, AquaBounty's Board of Directors adopted the AquaBounty 2016 Equity Incentive Plan ("AquaBounty 2016 Plan") to replace the AquaBounty 2006 Plan. The AquaBounty 2016 Plan provides for the issuance of incentive stock options, non-qualified stock options and awards of restricted and direct stock purchases to directors, officers, employees and consultants of AquaBounty. The AquaBounty 2016 Plan was approved by AquaBounty's shareholders at its annual meeting in April 2016. Upon the effectiveness of the AquaBounty 2016 Plan, no new awards may be granted under the AquaBounty 2006 Plan. As of September 30, 2016, there were no options outstanding under the AquaBounty 2016 Plan.

16. License Agreement

In January 2015, the Company and ZIOPHARM jointly entered into a license agreement with the University of Texas System Board of Regents on behalf of the University of Texas MD Anderson Cancer Center ("MD Anderson") whereby the Company received an exclusive license to certain research and development technologies owned and licensed by MD Anderson, including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies, as well as co-licenses and non-exclusive licenses to certain other related technologies. ZIOPHARM received access to these technologies pursuant to the terms of the Company's ECC with ZIOPHARM. The Company issued 2,100,085 shares of its common stock valued at $59,579 to MD Anderson as consideration, which is included in research and development expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2015. Subject to certain exceptions, the license agreement expires on the last to occur of (i) the expiration of all patents licensed thereunder, or (ii) the twentieth anniversary of the date of the license agreement.

In connection with the license agreement, the Company, ZIOPHARM, and MD Anderson entered into a research and development agreement which governs certain operational activities between the parties and pursuant to which ZIOPHARM provides funding for certain research and development activities of MD Anderson for a period of three years, in an amount between $15,000 and $20,000 per year. The Company and ZIOPHARM reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies.

Table of Contents

17. Commitments and Contingencies

Operating Leases

The Company leases certain facilities and equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. At September 30, 2016, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:



2016	$	705
2017	6,362
2018	5,695
2019	5,434
2020	5,487
2021	4,888
Thereafter	20,179
Total	$	48,750

Rent expense, including other facility expenses, was $2,075 and $2,167 for the three months ended September 30, 2016 and 2015, respectively, and $6,410 and $6,548 for the nine months ended September 30, 2016 and 2015, respectively.

The Company maintains subleases for certain of its facilities. Rental income under sublease agreements was $184 and $334 for the three months ended September 30, 2016 and 2015, respectively, and $854 and $1,153 for the nine months ended September 30, 2016 and 2015, respectively. Future rental income is expected to be $9 for 2016 and $36 for 2017.

Contingencies

In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY") alleging that certain of Trans Ova's activities breach a licensing agreement and infringe on patents that XY allegedly owns. Trans Ova filed a number of counterclaims in the case. The matter proceeded to a jury trial in January 2016, and in February 2016, the jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed the intellectual property of XY. In April 2016, the court issued its order, entering a jury award of damages to Trans Ova in the amount of $528 and a jury award of damages to XY in the amount of $6,066, each with prejudgment interest. The order provides for the continuation of Trans Ova's license to XY's technology, subject to an ongoing royalty for Trans Ova which is subject to a post-judgment motion, including XY's motion for enhanced damages, and potential appeals therefrom. Since the inception of the license, Trans Ova has remitted payments to XY pursuant to the terms of the original license agreement and has recorded these payments in cost of services in the consolidated statements of operations for the respective periods. For the period from inception of the agreement through the court's order, aggregate royalty and license payments were $3,170, of which $2,759 had not yet been deposited by XY. For the nine months ended September 30, 2016, the Company recorded litigation expense of $4,228, which is included in selling, general and administrative expenses on the accompanying consolidated statement of operations and represents the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the court's treasury, to be held until the appeals process is complete and final judgment amounts are determined. As of September 30, 2016, this amount is included in restricted cash on the accompanying consolidated balance sheet. The Company and Trans Ova believe they have compelling grounds to overturn the adverse rulings of the order through appellate actions and that, as a result, the amount of damages could be reduced or eliminated. No assurances can be given, however, that such matters will ultimately be ruled in Trans Ova's favor, and XY may also elect to appeal aspects of the ruling that were in Trans Ova's favor. Moreover, Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation, to modify the license to XY's technologies, or to recover monetary damages related to Trans Ova's antitrust counterclaims.

In May 2016, two purported shareholder class action lawsuits, captioned Hoffman v. Intrexon Corporation et al. and Gibrall v. Intrexon Corporation et al., were filed in the U.S. District Court for the Northern District of California on behalf of purchasers of Intrexon's common stock between May 12, 2015 and April 20, 2016 (the "Class Period"). In July 2016, the court consolidated the lawsuits and appointed a lead plaintiff. The consolidated amended complaint names as defendants Intrexon and certain of Intrexon's current and former officers (the "Defendants"). It alleges, among other things, that the Defendants made materially false and/or misleading statements during the Class Period with respect to the Company's business, operations, and prospects in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended. The plaintiffs' claims are based

Table of Contents

upon allegations in a report published in April 2016 on the Seeking Alpha financial blog. The plaintiffs seek compensatory damages, interest and an award of reasonable attorneys' fees and costs. The Company intends to defend the lawsuit vigorously; however, there can be no assurance regarding the ultimate outcome of this case.

In July 2016, a purported shareholder derivative action captioned Basile v. Kirk et al. was filed in the Circuit Court of Fairfax County, Virginia, against certain of the Company's directors, the Company's CEO, and Third Security, and naming the Company as a nominal defendant. The complaint alleges causes of action for breaches of fiduciary duty and unjust enrichment relating to the entry by the Company into the Services Agreement with Third Security. The plaintiff seeks, among other things, damages in an unspecified amount, disgorgement of improper benefits, appropriate equitable relief, and an award of attorney fees and other costs and expenses. The Board of Directors of the Company appointed a Special Litigation Committee consisting of independent directors to investigate the claims and allegations made in the derivative action and to decide on behalf of the Company whether the claims and allegations should be pursued. The action has been stayed pending the report of the Special Litigation Committee.

The Company may become subject to other claims and assessments from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of September 30, 2016 and December 31, 2015, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

18. Related Party Transactions

Third Security and Affiliates

The Company's CEO and Chairman of the Board of Directors of the Company is also the manager of Third Security.

In November 2015, the independent members of Intrexon's Board of Directors, with the recommendation of the Audit Committee of the Board of Directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provides the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its CEO. As consideration for providing these services, Third Security is entitled to a fee of $800 per month to be paid in the form of fully vested shares of the Company's common stock. The number of shares of common stock is calculated based on the closing price of the Company's common stock on the 15th day of each month. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan (Note 15). The Services Agreement had a term of one year, can be terminated by the Company at any time, and may be extended only by agreement of the parties, including approval of a majority of the independent members of Intrexon's Board of Directors. In October 2016, the independent members of Intrexon's Board of Directors, with the recommendation of the Audit Committee of the Board of Directors, approved the extension of the Services Agreement through December 2016. For the three and nine months ended September 30, 2016, the Company issued 89,326 shares and 254,496 shares, respectively, with values of $2,132 and $6,542, respectively, to Third Security as payment for services pursuant to the Services Agreement. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf and the total expenses incurred by the Company under this arrangement was $156 and $142 for the three months ended September 30, 2016 and 2015, respectively, and $301 and $294 for the nine months ended September 30, 2016 and 2015, respectively.

See also Note 15 regarding compensation arrangements between the Company and its CEO.

Transactions with ECC Parties

In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and which also are party to a collaboration with the Company are considered to be related parties.

In September 2016, Fibrocell Science, Inc. ("Fibrocell"), one of the Company's collaborators, sold promissory notes convertible into shares of Fibrocell common stock ("convertible note") and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid $2,604 for a convertible note and warrants. As of September 30, 2016, the value of the convertible note and warrants totaled $1,990 and is included in other assets on the accompanying consolidated balance sheet.

Table of Contents

In conjunction with the ECC with Oragenics, the Company is entitled to, at its election, purchase up to 30% of securities offerings that may be conducted by Oragenics in the future, subject to certain conditions and limitations. In June 2016, the Company purchased 2,261,419 shares of Oragenics common stock at $0.52 per share.

The Company recognized $26,688 and $31,740 of collaboration revenues from related parties in the three months ended September 30, 2016 and 2015, respectively, and $70,299 and $59,775 in the nine months ended September 30, 2016 and 2015, respectively.

Other Related Parties

In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development opportunities that the Company offers to Harvest. These are investment proposals that are suitable for pursuit by a start-up venture, characterized by the agreement as "start-up opportunities." For such start-up opportunities, the Company provides Harvest with exclusive rights of first-look and first negotiation. For any opportunities it decides to pursue, Harvest establishes new collaboration entities which enter into an ECC with the Company in a designated field. The terms of such ECCs are negotiated between the Company and Harvest. In addition, the agreement provides the Company the right to present to Harvest the opportunity to invest in other ventures, including investment opportunities with respect to the Company's existing collaborations. Any such opportunities are presented at the Company's discretion on a non-exclusive basis. The agreement with Harvest does not limit the Company's ability to execute other collaborations and joint ventures with third parties. As consideration for providing exclusive rights of first-look and first negotiation for start-up opportunities, the Company receives a portion of the management fee collected by the fund sponsor of Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled $613 and $1,871 for the three and nine months ended September 30, 2016, respectively, and totaled $697 for the three and nine months ended September 30, 2015.

19. Net Loss per Share

The following table presents the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2016 and 2015:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Historical net loss per share:
Numerator:
Net loss attributable to Intrexon	$	(28,982	)	$	(38,213	)	$	(142,475	)	$	(51,779	)
Denominator:
Weighted average shares outstanding, basic and diluted	118,346,782			112,244,129			117,785,160			109,244,641
Net loss attributable to Intrexon per share, basic and diluted	$	(0.24	)	$	(0.34	)	$	(1.21	)	$	(0.47	)

The following potentially dilutive securities as of September 30, 2016 and 2015, have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months then ended, as they would have been anti-dilutive:



	September 30,
	2016	2015
Options	12,103,407	10,660,040
Warrants	30,191	194,719
Total	12,133,598	10,854,759

Table of Contents

20. Subsequent Events

In November 2016, the Company entered into a stock purchase agreement with AquaBounty pursuant to which the Company will purchase 72,632,190 shares of AquaBounty's common stock for $25,000 subject to AquaBounty's common stock being approved for listing on the NASDAQ Capital Market ("NASDAQ") and other closing conditions as defined in the agreement. In November 2016, AquaBounty filed a Form 10 registration statement with the Securities and Exchange Commission as an initial step towards the listing of its common stock. The Company anticipates converting up to $10,000 of convertible promissory notes, plus accrued interest thereon, into shares of AquaBounty common stock in conjunction with these transactions. The Company also announced its intent to distribute a portion of its previously held shares of AquaBounty common stock to shareholders of Intrexon as a special stock dividend once AquaBounty shares are available to trade on NASDAQ. The number of shares to be distributed by the Company is subject to final determination and approval by the Board of Directors of the Company. After consideration of all transactions contemplated herein, the Company expects to continue to be the majority owner of AquaBounty.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following "Management's Discussion and Analysis of Financial Condition and Results of Operations" should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K.

The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements and you are cautioned not to place undue reliance on forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in "Special Note Regarding Forward-Looking Statements" and "Risk Factors." The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof.

Overview

We believe we are a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems to enable rational, design-based control of cellular function for a specific purpose. Using our suite of proprietary and complementary technologies, we design, build and regulate gene programs, which are DNA sequences that consist of key genetic components. A single gene program or a complex, multi-genic program are fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information. DNA vectors can, in turn, be introduced into cells in order to generate a simple or complex cellular system, which are the basic and complex cellular activities that take place within a cell and the interaction of those systems in the greater cellular environment. It is these genetically modified cell systems that can be used to produce biological effector molecules, or be employed directly to enable the development of new and improved products and manufacturing processes across a variety of end markets, including health, food, energy, environment, and consumer. Our synthetic biology capabilities include the ability to precisely control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

We believe that because synthetic biology has applicability across many diverse end markets, we cannot take full advantage of synthetic biology with internal development programs alone. To address this, we have devised our business model to allow us to focus on our core expertise in synthetic biology while bringing many different commercial products to market via collaborations in a broad range of industries or end markets, thus minimizing and leveraging the use of our own capital.

Our business model is built primarily around the formation of exclusive channel collaborations, or ECCs. An ECC is an agreement with a collaborator to develop products based on technologies in a specifically defined field. We seek collaborators that have expertise within a specific industry sector and the commitment to provide resources for the commercialization of products within that industry sector. In our ECCs, we provide expertise in the engineering of gene programs and cellular systems, and our collaborators are responsible for providing market and product development expertise, as well as sales and marketing capabilities.

This business model allows us to leverage our capabilities and capital across numerous product development programs and a broader landscape of end markets than we would be capable of addressing on our own. Our ECC business model also allows us to participate in the potential upside from products that are enabled by our technologies across an extensive range of industries, without the need for us to invest considerable resources in bringing individual products to market. Additionally, the flexibility of the business model allows us to collaborate with a range of counterparts, from small innovative companies to global multinational conglomerates.

Alternatively, we may execute a research collaboration to develop an early-stage program pursuant to which we receive reimbursement for our development costs but the exclusive commercial rights, and related access fees, are deferred until completion of an initial research program.

In certain strategic circumstances, we may enter into a joint venture, or JV, with a third party collaborator whereby we may contribute access to our technology, cash or both into the joint venture which we will jointly control with our collaborator. Pursuant to a joint venture agreement, we may be required to contribute additional capital to the joint venture, and we may be able to receive a higher financial return than we would normally receive from an ECC to the extent that we and our collaborator are successful in developing one or more products. For a discussion of our joint ventures, see the "Notes to the Consolidated Financial Statements (Unaudited) - Note 4" appearing elsewhere in this Quarterly Report on Form 10-Q.

Table of Contents

As we consider the broad potential applications of our synthetic biology technologies, we have identified a number of ventures that are already enabling products that benefit from the application of such technology. We believe that the strategic acquisition of certain such companies will allow us to develop and commercialize innovative products and create significant value for us. Our business model therefore includes the acquisition of certain product-focused companies that may leverage our technologies and expertise in order to expand their respective product applications.

As a means to further the development of our business model, in June 2015, we entered into an agreement with Harvest Intrexon Enterprise Fund I, LP, or Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security, LLC, or Third Security. Harvest was established to invest in life science research and development opportunities that we offer to Harvest. These are investment proposals that are suitable for pursuit by a start-up venture, characterized by the agreement as "start-up opportunities." For such start-up opportunities, we provide Harvest with exclusive rights of first-look and first negotiation. For any opportunities it decides to pursue, Harvest establishes new collaboration entities which enter into an ECC with us in a designated field. The terms of such ECCs are negotiated between us and Harvest. In addition, the agreement provides us the right to present to Harvest the opportunity to invest in other ventures, including investment opportunities with respect to our existing collaborations. Any such opportunities are presented at our discretion on a non-exclusive basis. The agreement with Harvest does not limit our ability to execute other collaborations and joint ventures with third parties. As consideration for providing exclusive rights of first-look and first negotiation for start-up opportunities, we receive a portion of the management fee collected by the fund sponsor of Harvest.

Pursuant to our business model, we may receive equity in lieu of cash for technology access fees and milestones and also may participate in capital raises to allow earlier-stage collaborators to focus their resources on product development. However, when such a collaborator develops greater operational or financial resources, its shares become a financial asset within Intrexon that is independent of our operational or collaborative purposes. In June 2015, we provided our shareholders the opportunity to participate directly in the value generated by our ECC with ZIOPHARM Oncology, Inc., or ZIOPHARM, by distributing all of our common shares in ZIOPHARM to our shareholders as a special stock dividend.

Mergers, acquisitions, and technology in-licensing

We may augment our suite of proprietary technologies through mergers or acquisitions of technologies which then become available to new or existing collaborators. Among other things, we pursue technologies that we believe will be generally complementary to our existing technologies and also meet our desired return on investment and other economic criteria. In certain cases, such technologies may already be applied in the production of products or services, and in these cases, we may seek to expand the breadth or efficacy of such products or services through the use of our technologies. Other than our acquisition of all of the assets of Old EnviroFlight, as described in Note 4 to our consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, there have been no mergers, acquisitions or significant technology in-licensing activities completed in 2016. For a discussion of our 2015 mergers, acquisitions and significant technology in-licensing activities, see the "Notes to the Consolidated Financial Statements (Unaudited)" appearing elsewhere in this Quarterly Report on Form 10-Q.

Financial overview

We have incurred significant losses since our inception. We anticipate that we may continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability. We have never generated any royalty revenues from sales of products by our collaborators and may never be profitable. Certain of our consolidated subsidiaries require regulatory approval and/or commercial scale-up before they may commence significant product sales and operating profits.

We expect our future capital requirements will be substantial, particularly as we continue to develop our business and expand our synthetic biology technology platform. We believe that our existing cash and cash equivalents, short-term and long-term investments, and cash expected to be received through our current collaborators and for sales of products and services provided by our consolidated subsidiaries will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.

Sources of revenue

We derive our revenues through the execution of ECCs and license and collaboration agreements for the development and commercialization of products enabled by our technologies. Generally, the terms of our collaborations provide that we receive some or all of the following: (i) technology access fees upon signing; (ii) reimbursements of costs incurred by us for our research and development and/or manufacturing efforts related to the specific application provided for in the collaboration;

Table of Contents

(iii) milestone payments upon the achievement of specified development, regulatory and commercial activities; and (iv) royalties on sales of products arising from the collaboration.

Our technology access fees and milestone payments may be in the form of cash or securities of the collaborator. Our collaborations contain multiple arrangements and we typically defer revenues from the technology access fees and milestone payments received and recognize such revenues over the expected life of our technology platform using a straight-line approach. We are also entitled to sublicensing revenues in those situations where our collaborators choose to license our technologies to other parties.

From time to time, we and certain collaborators may cancel the agreements, relieving us of any further performance obligations under the agreement. When no further performance obligations are required of us under an agreement, we recognize any remaining deferred revenue.

We also generate products and services revenue through sales of advanced reproductive technologies, including bovine embryos derived from our embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.

In future periods, our revenues will depend on the number of collaborations to which we are party, the advancement and creation of programs within our collaborations and the extent to which our collaborators bring products enabled by our technologies to market. Our revenues will also depend upon our ability to maintain or improve the volume and pricing of our current product and service offerings and to develop new offerings, including those arising from our acquisitions. Our future revenues may also include additional revenue streams we may acquire through mergers and acquisitions. In light of our limited operating history and experience in consummating new collaborations and also the limited experience with our consolidated subsidiaries, there can be no assurance as to the timing, magnitude and predictability of revenues to which we might be entitled.

Cost of products and services revenues

Cost of products and services revenues includes primarily labor and related costs, drugs and supplies used primarily in the embryo transfer and in vitro fertilization processes, livestock and feed used in production, and facility charges, including rent and depreciation. Fluctuations in the price of livestock and feed have not had a significant impact on our operating margins and we typically do not use derivative financial instruments to mitigate the price risk.

Research and development expenses

We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:


•	salaries and benefits, including stock-based compensation expense, for personnel in research and development functions;


•	fees paid to consultants and contract research organizations who perform research on our behalf and under our direction;


•	costs related to laboratory supplies used in our research and development efforts;


•	costs related to certain in-licensed technology rights;


•	depreciation of leasehold improvements and laboratory equipment;


•	amortization of patents and related technologies acquired in mergers and acquisitions; and


•	rent and utility costs for our research and development facilities.

We have no individually significant research and development projects and our research and development expenses primarily relate to either the costs incurred to expand or otherwise improve our multiple platform technologies, the costs incurred to develop a specific application of our technologies in support of current or prospective collaborators, or costs incurred to expand

Table of Contents

or otherwise improve our products and services. Research and development expenses, including costs for preclinical or clinical development, incurred for programs we support pursuant to an ECC agreement are typically reimbursed by the collaborator at cost and all other research and development programs may be terminated or otherwise deferred at our discretion. The amount of our research and development expenses may be impacted by, among other things, the number of ECCs and the number and size of programs we may support on behalf of an ECC.

The table below summarizes our research and development expenses incurred to expand or otherwise improve our multiple platform technologies, the costs incurred to develop a specific application of our technologies in support of current or prospective collaborators and licensees, or costs incurred to expand or otherwise improve our products and services for the three and nine months ended September 30, 2016 and 2015. Other research and development expenses for these periods include indirect salaries and overhead expenses that are not allocated to either expanding or improving our multiple platform technologies, specific applications of our technologies in support of current or prospective collaborators and licensees, or expanding or improving our product and services offerings. Research and development expenses for the nine months ended September 30, 2015 include a $59.6 million payment in our common stock for an exclusive license to certain technologies owned by the University of Texas MD Anderson Cancer Center, or MD Anderson, to be used in the expansion and improvement of our platform technologies.



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
	(In thousands)
Expansion or improvement of our platform technologies	$	3,014	$	3,641	$	8,881	$	72,168
Specific applications of our technologies in support of current and prospective collaborators and licensees	17,004		10,608		47,171		28,686
Expansion or improvement of our product and service offerings	4,245		2,595		13,012		6,410
Other	4,772		4,754		14,202		14,022
Total research and development expenses	$	29,035	$	21,598	$	83,266	$	121,286

We expect that our research and development expenses will increase as we continue to enter into collaborations and as we expand our offerings across additional market sectors. We believe these increases will likely include increased costs related to the hiring of additional personnel in research and development functions, increased costs paid to consultants and contract research organizations and increased costs related to laboratory supplies. Research and development expenses may also increase as a result of ongoing research and development operations which we might assume through mergers and acquisitions.

Selling, general and administrative expenses

Selling, general and administrative, or SG&A, expenses consist primarily of salaries and related costs, including stock-based compensation expense, for employees in executive, operational, finance, sales and marketing, information technology, legal and corporate communications functions. Other significant SG&A expenses include rent and utilities, insurance, accounting and legal services and expenses associated with obtaining and maintaining our intellectual property.

We expect that our SG&A expenses will increase as we continue to operate as a public company and expand our operations. We believe that these increases will likely include costs related to the hiring of additional personnel and increased fees for business development functions, outside consultants, lawyers and accountants, including costs to comply with corporate governance, internal controls and similar requirements applicable to public companies. Selling, general and administrative expenses may also increase as a result of ongoing operations which we might assume through mergers and acquisitions.

Other income (expense), net

We hold equity securities received and/or purchased from certain collaborators, as well as preferred stock received from another of our collaborators, ZIOPHARM, which may be converted to common stock in the future. Other than investments accounted for using the equity method discussed below, we elected the fair value option to account for our equity securities and investment in preferred stock held in these collaborators. These equity securities and preferred stock are recorded at fair value at each reporting date. Unrealized appreciation (depreciation) resulting from fair value adjustments are reported as other income (expense) in the consolidated statements of operations. As such, we bear the risk that fluctuations in the securities' share

Table of Contents

prices may significantly impact our results of operations. In June 2015, we recorded a realized gain related to the distribution of all of our common shares of ZIOPHARM to our shareholders as a special stock dividend.

Interest income consists of interest earned on our cash and cash equivalents and short-term and long-term investments. Dividend income consists of the monthly preferred stock dividend received from ZIOPHARM.

Interest expense pertains to deferred consideration payable to the former members of Trans Ova Genetics, L.C., or Trans Ova, and long term debt.

As consideration for providing exclusive rights of first-look and first negotiation, we receive a portion of the management fee collected by the fund sponsor of Harvest for our obligation to provide Harvest with investment proposals that are suitable for pursuit by a startup. These fees are included in other income.

Equity in net income (loss) of affiliates

Equity in net income or loss of affiliates is our pro-rata share of our equity method investments' operating results, adjusted for accretion of basis difference. We account for investments in our joint ventures and startup entities backed by Harvest using the equity method of accounting since we have the ability to exercise significant influence, but not control, over the operating activities of these entities.

Results of operations

Comparison of the three months ended September 30, 2016 and the three months ended September 30, 2015

The following table summarizes our results of operations for the three months ended September 30, 2016 and 2015, together with the changes in those items in dollars and as a percentage:



	Three Months Ended September 30,						Dollar Change			Percent Change
	2016			2015			Dollar Change			Percent Change
	(In thousands)
Revenues
Collaboration and licensing revenues	$	30,590		$	34,726		$	(4,136	)	(11.9	)%
Product revenues	9,260			9,446			(186		)	(2.0	)%
Service revenues	8,706			8,945			(239		)	(2.7	)%
Other revenues	429			250			179			71.6	%
Total revenues	48,985			53,367			(4,382		)	(8.2	)%
Operating expenses
Cost of products	9,156			11,215			(2,059		)	(18.4	)%
Cost of services	5,803			5,451			352			6.5	%
Research and development	29,035			21,598			7,437			34.4	%
Selling, general and administrative	33,812			23,019			10,793			46.9	%
Total operating expenses	77,806			61,283			16,523			27.0	%
Operating loss	(28,821		)	(7,916		)	(20,905		)	>200%
Total other income (expense), net	4,647			(29,607		)	34,254			115.7	%
Equity in loss of affiliates	(6,255		)	(2,429		)	(3,826		)	157.5	%
Loss before income taxes	(30,429		)	(39,952		)	9,523			(23.8	)%
Income tax benefit	418			923			(505		)	(54.7	)%
Net loss	(30,011		)	(39,029		)	9,018			(23.1	)%
Net loss attributable to noncontrolling interests	1,029			816			213			26.1	%
Net loss attributable to Intrexon	$	(28,982	)	$	(38,213	)	$	9,231		(24.2	)%

Table of Contents

Collaboration and licensing revenues

The following table shows the collaboration and licensing revenue for the three months ended September 30, 2016 and 2015, together with the changes in those items. See Note 5 to our consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for further discussion of our collaboration and licensing revenues.



	Three Months Ended September 30,				Dollar Change
	2016		2015		Dollar Change
	(In thousands)
ZIOPHARM Oncology, Inc.	$	10,429	$	4,651	$	5,778
Oragenics, Inc.	556		5,200		(4,644		)
Fibrocell Science, Inc.	1,167		6,140		(4,973		)
Genopaver, LLC	1,693		1,061		632
S & I Ophthalmic, LLC	2,782		1,193		1,589
OvaXon, LLC	709		549		160
Intrexon Energy Partners, LLC	4,855		3,810		1,045
Persea Bio, LLC	333		422		(89		)
Ares Trading S.A.	2,316		1,857		459
Thrive Agrobiotics, Inc.	425		—		425
Intrexon Energy Partners II, LLC	872		—		872
Exotech Bio, Inc.	221		—		221
Relieve Genetics, Inc.	462		—		462
Intrexon T1D Partners, LLC	787		—		787
AD Skincare, Inc.	185		—		185
Other	2,798		9,843		(7,045		)
Total	$	30,590	$	34,726	$	(4,136	)

Collaboration and licensing revenues decreased $4.1 million from the three months ended September 30, 2015 due to the recognition in 2015 of previously deferred revenue related to collaboration agreements for which we satisfied all of our obligations or which were terminated during the three months ended September 30, 2015. This decrease is offset by (i) the recognition of deferred revenue for upfront payments received from collaborations signed by us between October 1, 2015 and September 30, 2016 and the recognition of the payment received in June 2016 from ZIOPHARM to amend our collaborations; and (ii) increased research and development services for these collaborations and for the progression of programs or the addition of new programs with previously existing collaborators, including ZIOPHARM and our joint ventures with S & I Ophthalmic, LLC, or S & I Ophthalmic, and Intrexon Energy Partners, LLC, or Intrexon Energy Partners.

Product revenues and gross margin

Product revenues were $9.3 million for the three months ended September 30, 2016 compared to $9.4 million for the three months ended September 30, 2015, a decrease of $0.1 million, or 2 percent. Gross margin on products improved in the current period primarily due to a decline in the average cost of cows.

Service revenues and gross margin

Service revenues were $8.7 million for the three months ended September 30, 2016 compared to $8.9 million for the three months ended September 30, 2015, a decrease of $0.2 million, or 3 percent. Gross margin on services decreased in the current period primarily due to an increase in service related costs in the current period driven by increased headcount to support future revenue growth.

Research and development expenses

Research and development expenses increased $7.4 million, or 34 percent, due primarily to increases in (i) salaries, benefits and other personnel costs for research and development employees, (ii) lab supplies and consulting expenses, and (iii)

Table of Contents

depreciation and amortization. Salaries, benefits and other personnel costs increased $2.1 million due to (i) an increase in research and development headcount to support new and expanded collaborations and (ii) a full period of costs for research and development employees assumed in our acquisition of Oxitec Limited, or Oxitec, in September 2015. Lab supplies and consulting expenses increased $3.9 million as a result of (i) the progression into the preclinical phase with certain of our collaborators, (ii) the increased level of research and development services provided to our collaborators, and (iii) a full period of costs incurred as a result of our September 2015 acquisition of Oxitec. Depreciation and amortization increased $0.9 million primarily as a result of (i) the inclusion of a full period of depreciation and amortization on property, equipment and intangible assets acquired in our 2015 acquisitions, (ii) amortization of developed technology acquired from Old EnviroFlight in February 2016; and (iii) amortization related to the intangible assets of AquaBounty Technologies, Inc., or AquaBounty, upon regulatory approval in November 2015.

Selling, general and administrative expenses

SG&A expenses increased $10.8 million, or 47 percent, over the three months ended September 30, 2015. Legal and professional expenses increased $4.5 million due to (i) consulting expenses payable in shares of our common stock pursuant to our services agreement with Third Security which we entered into in November 2015; (ii) expenses incurred to support domestic and international government affairs for regulatory and other approvals necessary to commercialize our products and services; (iii) increased legal fees to defend ongoing litigation; and (iv) incremental costs incurred to support the ongoing operations of our 2015 acquisitions. Salaries, benefits and other personnel costs increased $5.3 million due to increased headcount, including the hiring of two new executive officers and additional business development professionals, to support our expanding operations, as well as our acquisition of Oxitec in September 2015.

Total other income (expense), net

Total other income (expense), net, was $4.6 million for the three months ended September 30, 2016 compared to $(29.6) million for the three months ended September 30, 2015, an increase of $34.2 million or 116 percent. This increase was primarily attributable to changes in the value of our equity securities portfolio and dividend income from our investment in preferred stock.

Equity in net loss of affiliates

Equity in net loss of affiliates for the three months ended September 30, 2016 and 2015 includes our pro-rata share of the net losses of our investments we account for using the equity method of accounting. The $3.8 million increase is due to the addition of our new joint ventures entered into subsequent to October 1, 2015, including our investments in start-up entities backed by Harvest, as well as additional expenses incurred by our other joint ventures as their programs continue to progress.

Table of Contents

Comparison of the nine months ended September 30, 2016 and the nine months ended September 30, 2015

The following table summarizes our results of operations for the nine months ended September 30, 2016 and 2015, together with the changes in those items in dollars and as a percentage:



	Nine Months Ended September 30,						Dollar Change			Percent Change
	2016			2015			Dollar Change			Percent Change
	(In thousands)
Revenues
Collaboration and licensing revenues	$	82,144		$	66,690		$	15,454		23.2	%
Product revenues	28,699			32,645			(3,946		)	(12.1	)%
Service revenues	33,298			32,157			1,141			3.5	%
Other revenues	783			615			168			27.3	%
Total revenues	144,924			132,107			12,817			9.7	%
Operating expenses
Cost of products	29,471			31,654			(2,183		)	(6.9	)%
Cost of services	17,807			17,316			491			2.8	%
Research and development	83,266			121,286			(38,020		)	(31.3	)%
Selling, general and administrative	106,956			74,320			32,636			43.9	%
Total operating expenses	237,500			244,576			(7,076		)	(2.9	)%
Operating loss	(92,576		)	(112,469		)	19,893			(17.7	)%
Total other income (expense), net	(39,125		)	65,121			(104,246		)	(160.1	)%
Equity in loss of affiliates	(16,951		)	(6,565		)	(10,386		)	158.2	%
Loss before income taxes	(148,652		)	(53,913		)	(94,739		)	175.7	%
Income tax benefit (expense)	3,290			(806		)	4,096			>200%
Net loss	(145,362		)	(54,719		)	(90,643		)	165.7	%
Net loss attributable to noncontrolling interests	2,887			2,940			(53		)	(1.8	)%
Net loss attributable to Intrexon	$	(142,475	)	$	(51,779	)	$	(90,696	)	175.2	%

Table of Contents

Collaboration and licensing revenues

The following table shows the collaboration and licensing revenue for the nine months ended September 30, 2016 and 2015, together with the changes in those items. See Note 5 to our consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for further discussion of our collaboration and licensing revenues.



	Nine Months Ended September 30,				Dollar Change
	2016		2015		Dollar Change
	(In thousands)
ZIOPHARM Oncology, Inc.	$	24,380	$	13,702	$	10,678
Oragenics, Inc.	1,869		5,845		(3,976		)
Fibrocell Science, Inc.	4,418		10,219		(5,801		)
Genopaver, LLC	4,908		2,665		2,243
S & I Ophthalmic, LLC	6,326		2,838		3,488
OvaXon, LLC	2,211		1,855		356
Intrexon Energy Partners, LLC	13,055		9,976		3,079
Persea Bio, LLC	988		928		60
Ares Trading S.A.	6,939		2,596		4,343
Thrive Agrobiotics, Inc.	1,309		—		1,309
Intrexon Energy Partners II, LLC	2,316		—		2,316
Exotech Bio, Inc.	360		—		360
Relieve Genetics, Inc.	812		—		812
Intrexon T1D Partners, LLC	1,097		—		1,097
AD Skincare, Inc.	185		—		185
Other	10,971		16,066		(5,095		)
Total	$	82,144	$	66,690	$	15,454

Collaboration and licensing revenues increased $15.5 million over the nine months ended September 30, 2015 primarily due to (i) the recognition of deferred revenue for upfront payments received from collaborations signed by us between October 1, 2015 and September 30, 2016, including the payment received in June 2016 from ZIOPHARM to amend the collaborations between us; and (ii) increased research and development services for these collaborations and for the progression of programs or the addition of new programs with previously existing collaborators, including ZIOPHARM, Genopaver, LLC, ARES Trading S.A., and our joint ventures with S & I Ophthalmic and Intrexon Energy Partners. This increase is partially offset by the recognition in 2015 of previously deferred revenue related to collaboration agreements for which we satisfied all of our obligations or which were terminated during 2015.

Product revenues and gross margin

Product revenues were $28.7 million for the nine months ended September 30, 2016 compared to $32.6 million for the nine months ended September 30, 2015, a decrease of $3.9 million, or 12 percent. The decrease in product revenues primarily relates to a decrease in quantities sold of livestock previously used in production and live calves sold due to lower customer demand. These decreases were partially offset by an increase in the quantity of weaned calves sold due to higher customer demand. Gross margin on products decreased due to a decline in the average sales prices of livestock previously used in production and also of live calves, and is partially offset by an increase in gross margin on sales of pregnant cows due to a decline in the average cost of cows.

Service revenues and gross margin

Service revenues were $33.3 million for the nine months ended September 30, 2016 compared to $32.2 million for the nine months ended September 30, 2015, an increase of $1.1 million, or 4 percent. The increase relates to an increase in the number of in vitro fertilization cycles performed due to higher customer demand. Gross margin on services was consistent period over period.

Table of Contents

Research and development expenses

Research and development expenses declined $38.0 million, or 31 percent, due primarily to the inclusion in 2015 of a $59.6 million payment in common stock for an exclusive license to certain technologies owned by MD Anderson. This decrease was partially offset by increases in (i) salaries, benefits and other personnel costs for research and development employees, (ii) lab supplies and consulting expenses, and (iii) depreciation and amortization. Salaries, benefits and other personnel costs increased $6.7 million due to (i) an increase in research and development headcount to support new and expanded collaborations and (ii) costs for research and development employees assumed in our acquisition of Oxitec in September 2015. Lab supplies and consulting expenses increased $10.1 million as a result of (i) the progression into the preclinical phase with certain of our collaborators, (ii) the increased level of research and development services provided to our collaborators, and (iii) costs incurred as a result of our September 2015 acquisition of Oxitec. Depreciation and amortization increased $4.7 million primarily as a result of (i) inclusion of a full period of depreciation and amortization on property, equipment and intangible assets acquired in our 2015 acquisitions and (ii) amortization related to AquaBounty's intangible assets which commenced upon regulatory approval in November 2015.

Selling, general and administrative expenses

SG&A expenses increased $32.6 million, or 44 percent, over the nine months ended September 30, 2015. Salaries, benefits and other personnel costs for SG&A employees increased $9.2 million due to (i) increased headcount, including the hiring of two new executive officers and additional business development professionals, to support our expanding operations; (ii) non-cash compensation paid to our Chief Executive Officer, or CEO, pursuant to the compensation agreement entered into in November 2015; (iii) a full period of stock compensation expense for officers hired in 2015; and (iv) salaries, benefits and other personnel costs for employees assumed in our acquisition of Oxitec in September 2015. These increases were partially offset by a decrease in stock compensation and other compensation expenses resulting primarily from the departure of certain officers of the Company in 2016. Legal and professional expenses increased $13.9 million primarily due to (i) consulting expenses payable in shares of our common stock pursuant to our services agreement with Third Security which we entered into in November 2015; (ii) expenses incurred to support domestic and international government affairs for regulatory and other approvals necessary to commercialize our products and services; (iii) increased legal fees for trial and post-trial activities for our litigation with XY, LLC, or XY, and to defend ongoing litigation; and (iv) incremental costs incurred to support the ongoing operations of our 2015 acquisitions and other business development activities. In 2016, we also recorded $4.2 million in litigation expenses arising from the entrance of a court order in our trial with XY.

Total other income (expense), net

Total other income (expense), net, was $(39.1) million for the nine months ended September 30, 2016 compared to $65.1 million for the nine months ended September 30, 2015, a decrease of $104.2 million or 160 percent. This decrease was attributable to the $81.4 million realized gain recognized upon the special stock dividend of all of our shares of ZIOPHARM to our shareholders in June 2015 and the decrease in fair value of our equity securities portfolio.

Equity in net loss of affiliates

Equity in net loss of affiliates for the nine months ended September 30, 2016 and 2015 includes our pro-rata share of the net losses of our investments we account for using the equity method of accounting. The $10.4 million increase is due to the addition of our new joint ventures entered into subsequent to October 1, 2015, including our investments in start-up entities backed by Harvest, as well as additional expenses incurred by our other joint ventures as their programs continue to progress.

Liquidity and capital resources

Sources of liquidity

We have incurred losses from operations since our inception and as of September 30, 2016, we had an accumulated deficit of $685.2 million. From our inception through September 30, 2016, we have funded our operations principally with proceeds received from private and public offerings, cash received from our collaborators and through product and service sales made directly to customers. As of September 30, 2016, we had cash and cash equivalents of $69.7 million and short-term and long-term investments of $211.0 million. Cash in excess of immediate requirements is invested primarily in money market funds and U.S. government debt securities in order to maintain liquidity and preserve capital.

Table of Contents

Cash flows

The following table sets forth the significant sources and uses of cash for the periods set forth below:



	Nine Months Ended September 30,
	2016			2015
	(In thousands)
Net cash provided by (used in):
Operating activities	$	(31,780	)	$	23,337
Investing activities	(45,144		)	(257,318		)
Financing activities	11,162			331,441
Effect of exchange rate changes on cash and cash equivalents	(313		)	507
Net increase (decrease) in cash and cash equivalents	$	(66,075	)	$	97,967

Cash flows from operating activities:

Net cash used in operating activities was $31.8 million for the nine months ended September 30, 2016 compared to net cash provided by operations of $23.3 million for the nine months ended September 30, 2015. During the nine months ended September 30, 2016, we received a $10.0 million technology access fee pursuant to a new collaboration. Our net loss of $145.4 million, after deduction of significant noncash items of (i) $45.4 million of noncash unrealized losses on our equity securities, (ii) $30.6 million of stock-based compensation expense, (iii) $17.7 million of depreciation and amortization expense, (iv) $8.3 million of shares issued as payment for services, and (v) $17.0 million of equity in net loss of affiliates, was $26.4 million. Net cash provided by operating activities was $23.3 million for the nine months ended September 30, 2015. During the nine months ended September 30, 2015, we received a $115.0 million technology access fee, of which $57.5 million was paid to ZIOPHARM, from our license and collaboration agreement with Ares Trading. Our net loss of $54.7 million, after deduction of significant noncash items of (i) $64.4 million of unrealized appreciation and realized gains on our equity securities, (ii) $59.6 million of common stock issued to MD Anderson recorded as research and development expense, (iii) $26.5 million of stock-based compensation expense, and (iv) $12.2 million of depreciation and amortization expense, was $20.8 million.

Cash flows from investing activities:

Net cash used in investing activities was $45.1 million for the nine months ended September 30, 2016 compared to $257.3 million for the nine months ended September 30, 2015. During the nine months ended September 30, 2016, we purchased $20.2 million of property, plant and equipment, advanced $9.4 million to our joint ventures, paid $7.2 million to acquire the assets of Old EnviroFlight, and purchased $3.3 million of net short-term and long-term investments. During the nine months ended September 30, 2015, we paid $114.5 million, net of cash received, for the acquisitions of ActoGeniX NV, Okanagan Specialty Fruits, Inc., and Oxitec, $111.6 million for net short-term and long-term investments, $17.1 million for the purchase of equity securities and warrants of certain of our collaborators, and $9.8 million for purchases of property, plant and equipment.

Cash flows from financing activities:

Net cash provided by financing activities was $11.2 million for the nine months ended September 30, 2016 compared to $331.4 million for the nine months ended September 30, 2015. During the nine months ended September 30, 2016, we received $18.2 million from stock option exercises and paid $6.7 million of deferred consideration to former shareholders of an acquired business. During the nine months ended September 30, 2015, we received $328.2 million of net proceeds from our public offerings in January and August.

Future capital requirements

We established our current strategy and business model of commercializing our technologies through collaborators with development expertise in 2010 and we consummated our first collaboration in January 2011. We believe that we will continue to consummate collaborations with new companies across our various market sectors, which will result in additional upfront, milestone and cost recovery payments in the future.

Table of Contents

We believe that our existing cash and cash equivalents, short-term and long-term investments, and cash expected to be received from our current collaborators and for sales of products and services provided by our consolidated subsidiaries will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.

We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:


•	progress in our research and development programs, as well as the magnitude of these programs;


•	the timing, receipt and amount of upfront, milestone and other payments, if any, from present and future collaborators, if any;


•	the timing, receipt and amount of sales and royalties, if any, from our potential products;


•	our ability to maintain or improve the volume and pricing of our current product offerings and to develop new offerings, including those which may incorporate new technologies;


•	the timing, receipt and amount of funding under future government contracts, if any;


•	our ability to maintain and establish additional collaborative arrangements and/or new business initiatives;


•	the timing of regulatory approval of products of our collaborations and operations;


•	the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims;


•	investments we may make in current and future collaborators, including joint ventures;


•	strategic mergers and acquisitions, including both the upfront acquisition cost as well as the cost to integrate, maintain, and expand the strategic target; and


•	the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes.

Until such time, if ever, as we can regularly generate positive operating cash flows, we may finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.

Table of Contents

Contractual obligations and commitments

The following table summarizes our significant contractual obligations and commercial commitments at September 30, 2016 and the effects such obligations are expected to have on our liquidity and cash flows in future periods:



	Total		Less Than 1 Year		1 - 3 Years		3 - 5 Years		More Than 5 Years
	(In thousands)
Operating leases	$	48,750	$	5,261	$	11,591	$	10,708	$	21,190
Deferred consideration	8,723		8,723		—		—		—
Long term debt	6,418		471		925		1,120		3,902
Contingent consideration	3,839		1,583		2,256		—		—
	$	67,730	$	16,038	$	14,772	$	11,828	$	25,092

In addition to the obligations in the table above, as of September 30, 2016 we also have the significant contractual obligations described below.

In conjunction with the formation of our joint ventures, we committed to making future capital contributions of at least $45.0 million to the joint ventures, subject to certain conditions and limitations, of which $31.0 million is remaining as of September 30, 2016. These future capital contributions are not included in the table above due to the uncertainty of the timing and amounts of such contributions.

We are also party to in-licensed research and development agreements with various academic and commercial institutions where we could be required to make future payments for annual maintenance fees as well as for milestones and royalties we might receive upon commercial sales of products which incorporate their technologies. These agreements are generally subject to termination by us and therefore no amounts are included in the tables above. At September 30, 2016, we had research and development commitments with third parties totaling $8.5 million that had not yet been incurred.

In January 2015, we and ZIOPHARM jointly entered into a license agreement with MD Anderson whereby we received an exclusive license to certain technologies owned by MD Anderson. ZIOPHARM will receive access to these technologies pursuant to the terms of our ECC. We and ZIOPHARM are obligated to reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies. These reimbursements are not included in the table above due to the uncertainty of the timing and amounts of such reimbursements.

As part of our August 2014 acquisition of Trans Ova, we agreed to pay a portion of certain cash proceeds received from the litigation with XY. These amounts are not included in the table above due to the uncertainty of whether and when any amounts may be due.

In conjunction with a prior transaction associated with Trans Ova's subsidiary, ViaGen, L.C., or ViaGen, in September 2012, we may be obligated to make certain future contingent payments to the former equity holders of ViaGen, up to a total of $5.0 million if certain revenue targets, as defined in the share purchase agreement, are met. This amount is not included in the table above due to the uncertainty of when we will make any of these future payments, if ever.

In January 2009, AquaBounty was awarded a grant to provide funding of a research and development project from the Atlantic Canada Opportunities Agency, a Canadian government agency. Amounts claimed by AquaBounty must be repaid in the form of a 10 percent royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to additional regulatory considerations, the timing of repayment is uncertain. AquaBounty has claimed all amounts available under the grant, resulting in total long-term debt of $2.0 million on our consolidated financial statements as of September 30, 2016. This amount is not included in the table above due to the uncertainty of the timing of repayment.

Net operating losses

As of September 30, 2016, we had net operating loss carryforwards of approximately $257.7 million for U.S. federal income tax purposes available to offset future taxable income and U.S. federal and state research and development tax credits of $7.1 million, prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of

Table of Contents

1986, as amended, or Section 382. These carryforwards begin to expire in 2022. Our direct foreign subsidiaries have foreign loss carryforwards of approximately $120.6 million, most of which do not expire.

Our past issuances of stock and mergers and acquisitions have resulted in ownership changes within the meaning of Section 382. As a result, the utilization of portions of our net operating losses may be subject to annual limitations. As of September 30, 2016, approximately $15.1 million of our net operating losses generated prior to 2008 are limited by Section 382 to annual usage limits of approximately $1.5 million. As of September 30, 2016, approximately $18.6 million of domestic net operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction. Future changes in stock ownership may also trigger an ownership change and, consequently, a Section 382 limitation.

Off-balance sheet arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, other than operating leases as mentioned above, as defined under Securities and Exchange Commission, or SEC, rules.

Critical accounting policies and estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies from those described in "Management's discussion and analysis of financial condition and results of operations" included in our Annual report on Form 10-K for the year ended December 31, 2015, except for the addition of a new critical accounting policy as disclosed below.

Investment in Preferred Stock

We hold preferred stock received from one of our collaborators, ZIOPHARM, which may be converted to common stock upon the occurrence of certain events in the future. We elected the fair value option to account for our investment in preferred stock whereby the value of preferred stock is adjusted to fair value as of each reporting date and unrealized gains and losses are reported in the consolidated statement of operations. This investment is subject to fluctuation in the future due to, among other things, the likelihood and timing of conversion of the preferred stock into common stock, the volatility of ZIOPHARM's common stock, and changes in general economic and financial conditions of ZIOPHARM. The investment is classified as noncurrent in the consolidated balance sheet since we do not intend to sell the investment nor expect it to be converted into shares of common stock within one year.

Until such time as we convert the instrument into common stock, we are entitled to a monthly dividend payable in additional shares of preferred stock and record dividend income based on the fair value of the preferred shares.

Recent accounting pronouncements

For information with respect to recent accounting pronouncements and the impact of these pronouncements on our consolidated financial statements, see Note 2 – "Summary of Significant Accounting Policies" in the notes to the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The following sections provide quantitative information on our exposure to interest rate risk, stock price risk, and foreign currency exchange risk. We make use of sensitivity analyses which are inherently limited in estimating actual losses in fair value that can occur from changes in market conditions.

Interest rate risk

We had cash, cash equivalents and short-term and long-term investments of $280.7 million and $343.8 million at September 30, 2016 and December 31, 2015, respectively. Our cash and cash equivalents and short-term and long-term investments consist of cash, money market funds, U.S. government debt securities and certificates of deposit. The primary objective of our investment activities is to preserve principal, maintain liquidity and maximize income without significantly increasing risk. Our investments consist of U.S. government debt securities and certificates of deposit which may be subject to market risk due to changes in prevailing interest rates that may cause the fair values of our investments to fluctuate. We believe that a hypothetical 100 basis point increase in interest rates would not materially affect the fair value of our interest-sensitive financial instruments and any such losses would only be realized if we sold the investments prior to maturity.

Investments in publicly traded companies' common stock

We have common stock investments in several publicly traded companies that are subject to market price volatility. We have adopted the fair value method of accounting for these investments, except for our investment in AquaBounty as further described below, and therefore, have recorded them at fair value at the end of each reporting period with the unrealized gain or loss recorded as a separate component of other income (expense), net for the period. As of September 30, 2016 and December 31, 2015, the original aggregate cost basis of these investments was $108.3 million and $107.2 million, respectively, and the market value was $39.4 million and $83.7 million, respectively. The fair value of these investments is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these companies. The fair value of these investments as of September 30, 2016 would be approximately $43.3 million and $31.5 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the value of the investments. The fair value of these investments as of December 31, 2015 would be approximately $92.1 million and $67.0 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the value of the investments.

The common stock of AquaBounty is traded on the London Stock Exchange and as of September 30, 2016, we owned 99,114,668 shares or approximately 63 percent. The fair value of our investment in AquaBounty as of September 30, 2016 and December 31, 2015 was $39.2 million and $36.7 million, respectively. The fair value of our investment in AquaBounty as of September 30, 2016 would be approximately $43.1 million and $31.4 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the share price of AquaBounty. The fair value of our investment in AquaBounty as of December 31, 2015 would be approximately $40.4 million and $29.4 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the share price of AquaBounty.

Investment in publicly traded company's preferred stock

We have a preferred stock investment in ZIOPHARM, a publicly traded company, which may be converted to common stock upon the occurrence of certain events in the future. We have adopted the fair value method of accounting for this investment whereby the value of preferred stock is adjusted to fair value as of each reporting date. As of September 30, 2016, the original cost basis of this investment, including shares received as dividends, approximated the fair value, which was $123.7 million. The fair value of this investment is subject to fluctuation in the future due to, among other things, the likelihood and timing of conversion of the preferred stock into common stock, the volatility of ZIOPHARM's common stock, and changes in general economic and financial conditions of ZIOPHARM. The fair value of this investment as of September 30, 2016 would be approximately $136.1 million and $99.0 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the value of the investment.

Foreign currency exchange risk

We have international subsidiaries with operations in Belgium, Brazil, Canada, England, and Hungary. These subsidiaries' assets, liabilities, and current revenues and expenses are denominated in their respective foreign currencies. We do not hedge our foreign currency exchange rate risk. The effect of a hypothetical 10 percent change in foreign currency exchange rates applicable to our business would not have a material impact on our consolidated financial statements.

Item 4. Controls and Procedures

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we carried out an evaluation, under supervision and with the participation of our management, including our Chief Executive Officer ("CEO"), who is our principal executive officer, and our Chief Financial Officer ("CFO"), who is our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined under Rule 13a-15(e) and 15(d)-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, as of the end

of the period covered by this report, our CEO and CFO concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

There has been no change in our internal control over financial reporting during the three months ended September 30, 2016, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are involved in litigation or legal matters incidental to our business activities. While the outcome of these matters cannot be predicted with certainty, we are vigorously defending them and do not currently expect that any of them will have a material adverse effect on our business or financial position. However, should one or more of these matters be resolved in a manner adverse to our current expectation, the effect on our results of operations for a particular fiscal reporting period could be material.

In May 2016, two purported shareholder class action lawsuits, captioned Hoffman v. Intrexon Corporation et al. and Gibrall v. Intrexon Corporation et al., were filed in the U.S. District Court for the Northern District of California on behalf of purchasers of our common stock between May 12, 2015 and April 20, 2016 (the "Class Period"). In July 2016, the court consolidated the lawsuits and appointed a lead plaintiff. The consolidated amended complaint names as defendants us and certain of our current and former officers (the "Defendants"). It alleges, among other things, that the Defendants made materially false and/or misleading statements during the Class Period with respect to our business, operations, and prospects in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended. The plaintiffs' claims are based upon allegations in a report published in April 2016 on the Seeking Alpha financial blog. The plaintiffs seek compensatory damages, interest and an award of reasonable attorneys' fees and costs. We intend to defend the lawsuit vigorously; however, there can be no assurance regarding the ultimate outcome of this case.

In July 2016, a purported shareholder derivative action captioned Basile v. Kirk et al. was filed in the Circuit Court of Fairfax County, Virginia, against certain of our directors, our CEO, and Third Security, and naming us as a nominal defendant. The complaint alleges causes of action for breaches of fiduciary duty and unjust enrichment relating to the entry by us into the Services Agreement with Third Security. The plaintiff seeks, among other things, damages in an unspecified amount, disgorgement of improper benefits, appropriate equitable relief, and an award of attorney fees and other costs and expenses. Our Board of Directors appointed a Special Litigation Committee consisting of independent directors to investigate the claims and allegations made in the derivative action and to decide on our behalf whether the claims and allegations should be pursued. The action has been stayed pending the report of the Special Litigation Committee.

Item 1A. Risk Factors

As disclosed in "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There are no additional material updates or changes to our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2015, except as follows:

We own equity interests in several of our collaborators and have exposure to the volatility and liquidity risks inherent in holding their equity.

Our collaborators may have limited capital in which case we may allow them to pay technology access fees, milestone payments or other contractual payments in shares of their common stock or other equity. As a result, we own equity interests in several of our collaborators. Owning equity in our collaborators further increases our exposure to the risks of our collaborators' businesses beyond our dependence on these collaborators to provide market and product development expertise, as well as sales, marketing and regulatory capabilities. Our equity ownership in our collaborators exposes us to volatility and the potential for negative returns. We may have restrictions on resale and/or limited markets to sell our equity ownership. In many cases, our equity position is a minority position which exposes us to further risk as we are not able to exert control over the companies in which we hold securities.

We evaluate prospective collaborators based on a variety of factors such as their capabilities, capacity and expertise in a defined field. The process by which we obtain equity interests in our collaborators and the factors we consider in deciding whether to acquire, hold or dispose of these equity positions may differ significantly from those that an independent investor would consider when purchasing equity interests in the collaborator. One significant factor would include our own expectation as to the success of our efforts to assist the collaborator in developing products enabled by our technologies.

We own common stock of several publicly traded companies and the values of those equity interests are subject to market price volatility. We own preferred stock of a publicly traded company that may be converted into shares of common stock in the future and the value of this equity interest is subject to fluctuation due to the uncertainties of the timing and occurrence of the

defined conversion events, the volatility of the underlying common stock, and changes in general economic and financial conditions of the collaborator. For each collaborator where we own equity securities, we make an accounting policy election to present them at either the fair value at the end of each reporting period or using the cost or equity method depending on our level of influence. We have adopted the fair value method of accounting for certain of these securities, and therefore, have recorded them at fair value at the end of each reporting period with the unrealized gain or loss recorded as a separate component of other income or expense, net for the period. As of September 30, 2016 and December 31, 2015, the aggregate original cost basis of these securities was $232.0 million and $107.2 million, respectively, and the market value was $163.1 million and $83.7 million, respectively. The fair value of these securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial and operational conditions of one or more collaborators.

The equity of our collaborators may not be publicly traded, and if it is traded publicly, the trading market could be limited or have low trading volume. In some cases, we could hold unregistered shares and we may not have demand registration rights with respect to those shares. We own preferred stock of a publicly traded company that may be converted into shares of common stock, but the timing of that conversion is uncertain and may never occur. If the conversion does not occur, there is a risk that we may not be able to sell the preferred stock. We evaluate whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the ECC or JV. In the event we conclude that a discount should be applied, the fair value of the securities is adjusted at inception of the ECC or JV and re-evaluated at each reporting period thereafter. In all of these instances, we have substantial liquidity risk related to these holdings, and we may not be able to sell, or sell quickly, all or part of these equity interests.

In connection with future ECCs or JVs, we may, from time to time, receive from collaborators, both public and private, warrants, rights and/or options, all of which involve special risks. To the extent we receive warrants or options in connection with future ECCs or JVs, we would be exposed to risks involving pricing differences between the market value of underlying securities and our exercise price for the warrants or options, a possible lack of liquidity and the related inability to close a warrant or options position, all of which could ultimately have an adverse effect on our financial position.

We use estimates in determining the fair value of certain assets and liabilities. If our estimates prove to be incorrect, we may be required to write down the value of these assets or write up the value of these liabilities, which could adversely affect our financial position.

Our ability to measure and report our financial position and operating results is influenced by the need to estimate the impact or outcome of future events on the basis of information available at the time of the financial statements. An accounting estimate is considered critical if it requires that management make assumptions about matters that were highly uncertain at the time the accounting estimate was made. If actual results differ from management's judgments and assumptions, then they may have an adverse impact on our results of operations and cash flows.

Fair value is estimated based on a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy prioritizes the inputs to valuation techniques into three broad levels whereby the highest priority is given to Level 1 inputs and the lowest to Level 3 inputs.

As a result of our ongoing and potential future business activities, the number and complexity of estimates we use in determining fair value has increased. As of September 30, 2016 and December 31, 2015, 37 percent and 30 percent of our consolidated total assets, respectively, were measured at fair value on a recurring basis, including 12 percent as of September 30, 2016 which were considered Level 3 valuations. Our largest Level 3 asset carried at fair value is our investment in preferred stock of ZIOPHARM. As of September 30, 2016 and December 31, 2015, liabilities measured at fair value on a recurring basis were not a significant portion of our total liabilities. We estimate the fair value of our assets and liabilities using assumptions that we believe are appropriate and are used by market participants. The methodology used to estimate these values is complex and uses asset- and liability-specific data and market inputs for assumptions including interest and discount rates and expected future performance and liquidity dates.

Valuations are highly dependent upon the reasonableness of management's assumptions and the predictability of the relationships that drive the results of our valuation methodologies. Because of the inherent unpredictability in the future performance of the investments requiring Level 3 valuations, we may be required to adjust the value of certain assets, which could adversely affect our financial position.

In evaluating our risks, readers should carefully consider these risk factors and the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2015, which could materially affect our business, financial condition or operating results, in addition to the other information set forth in this report and in our other filings with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a) Sales of Unregistered Securities

From July 1, 2016 through September 30, 2016, we consummated the following transactions involving the issuance of unregistered securities:


•	the issuance of 89,326 unregistered shares of our common stock in July, August, and September 2016, as payment under the Services Agreement entered into and effective as of November 1, 2015, by and between us and Third Security as previously discussed in our Current Report on Form 8-K filed on October 30, 2015.

•

On September 22, 2016, pursuant to New York Stock Exchange Rule 303A.08 and in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, we granted Geno J. Germano an employment inducement award in connection with Mr. Germano's appointment as President. The inducement award was a stock option award of 1,000,000 shares at an exercise price of $29.94. The award vests in four equal annual installments beginning on June 1, 2017. The award is subject to accelerated vesting in certain situations and expires on May 31, 2026. The award will generally be subject to the same terms and conditions as apply to awards granted under the 2013 Omnibus Incentive Plan. No commissions or other remuneration was paid in connection with the grant of the award.

(b) Use of Proceeds

On August 7, 2013, our registration statement on Form S-1 (File No. 333-189853) was declared effective by the SEC for our initial public offering pursuant to which we sold an aggregate of 11,499,998 shares of our common stock (inclusive of 1,499,999 shares of common stock sold by us pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering) at a price to the public of $16.00 per share for aggregate gross offering proceeds of approximately $184.0 million. J.P. Morgan Securities LLC and Barclays Capital Inc. acted as joint book-running managers. On August 13, 2013, we closed the sale of such shares, resulting in net proceeds to us of approximately $168.3 million after deducting underwriting discounts and commissions of approximately $12.9 million and other offering expenses of approximately $2.8 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates. We invested the funds received in cash equivalents and other short-term and long-term investments in accordance with our investment policy. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus, dated August 7, 2013, and filed with the SEC on August 8, 2013 pursuant to Rule 424(b).

On January 27, 2015, we closed a public offering of 4,312,500 shares of our common stock (inclusive of 562,500 shares of common stock sold by us pursuant to the full exercise of an option granted to the underwriters in connection with the offering) at a public offering price of $27.00 per share for aggregate gross offering proceeds of approximately $116.4 million. J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as joint book-running managers. Net proceeds to us were approximately $110.0 million after deducting underwriting discounts and commissions of approximately $6.1 million and other offering expenses of approximately $0.3 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates. We invested the funds received in cash equivalents and other short-term and long-term investments in accordance with our investment policy. There has been no material change in the planned use of proceeds from this offering as described in our final prospectus, dated January 21, 2015, and filed with the SEC on January 22, 2015 pursuant to Rule 424(b).

On August 26, 2015, we closed a public offering of 5,609,756 shares of our common stock (inclusive of 731,707 shares of common stock sold by us pursuant to the full exercise of an option granted to the underwriters in connection with the offering) at a public offering price of $41.00 per share for aggregate gross offering proceeds of approximately $230.0 million. JMP Securities LLC acted as sole book-running manager. Stifel, Nicolaus & Company, Incorporated acted as lead manager. Griffin Securities, Inc. and Wunderlich Securities, Inc. acted as co-managers. Net proceeds to us were approximately $218.2 million after deducting underwriting discounts and commissions of approximately $11.5 million and other offering expenses of approximately $0.3 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates. We invested the funds received in cash equivalents and other short-term and long-term investments in accordance with our investment policy. There has been no material change in the planned

use of proceeds from this offering as described in our final prospectus, dated August 21, 2015, and filed with the SEC on August 25, 2015 pursuant to Rule 424(b).

Not applicable.

Item 6. Exhibits



Exhibit No.		Description
10.1*		Amended and Restated Certificate of Designation (incorporated by reference to Exhibit 3.1 to ZIOPHARM Oncology, Inc.'s Current Report on Form 8-K/A, filed on July 1, 2016 with the Securities and Exchange Commission).

10.2*†		Offer Letter for Andrew Last, Ph.D., dated as of August 5, 2016 (incorporated by reference to Exhibit 10.1 to Intrexon Corporation's Current Report on Form 8-K, filed on August 8, 2016 with the Securities and Exchange Commission).

31.1		Certification of Randal J. Kirk, Chairman and Chief Executive Officer (Principal Executive Officer) of Intrexon Corporation, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Rick L. Sterling, Chief Financial Officer (Principal Financial Officer) of Intrexon Corporation, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of Randal J. Kirk, Chairman and Chief Executive Officer (Principal Executive Officer) of Intrexon Corporation, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of Rick L. Sterling, Chief Financial Officer (Principal Financial Officer) of Intrexon Corporation, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.0**		Interactive Data File (Quarterly Report on Form 10-Q, for the quarterly period ended September 30, 2016, formatted in XBRL (eXtensible Business Reporting Language)). Attached as Exhibit 101.0 to this Quarterly Report on Form 10-Q are the following documents formatted in XBRL: (i) the Consolidated Balance Sheets at September 30, 2016 and December 31, 2015, (ii) the Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015, (iii) the Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2016 and 2015, (iv) the Consolidated Statements of Shareholders' and Total Equity for the nine months ended September 30, 2016, (v) the Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015, and (vi) the Notes to Consolidated Financial Statements.

* Previously filed.


**	Furnished herewith.


†	Indicates management contract or compensatory plan.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	Intrexon Corporation
	(Registrant)

Date: November 9, 2016	By:	/s/ Rick L. Sterling
		Rick L. Sterling
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 xon-20160930xexx311.htm EX 31.1 Exhibit

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Randal J. Kirk, certify that:


1.	I have reviewed this quarterly report on Form 10-Q of Intrexon Corporation;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2016

/s/ RANDAL J. KIRK

Randal J. Kirk

Chairman and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 xon-20160930xexx312.htm EX 31.2 Exhibit

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Rick L. Sterling, certify that:


1.	I have reviewed this quarterly report on Form 10-Q of Intrexon Corporation;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2016

/s/ RICK L. STERLING

Rick L. Sterling

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 xon-20160930xexx321.htm EX 32.1 Exhibit

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

I, Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon Corporation (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:


•	the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2016 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


•	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2016

/s/ RANDAL J. KIRK

Randal J. Kirk

Chairman and Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-32.2 5 xon-20160930xexx322.htm EX 32.2 Exhibit

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

I, Rick L. Sterling, Chief Financial Officer of Intrexon Corporation (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:


•	the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2016 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


•	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2016

/s/ RICK L. STERLING

Rick L. Sterling

Chief Financial Officer

(Principal Financial Officer)

EX-101.INS 6 xon-20160930.xml XBRL INSTANCE DOCUMENT 0001356090 2016-01-01 2016-09-30 0001356090 xon:OkanaganSpecialtyFruitsIncMember 2016-01-01 2016-09-30 0001356090 xon:OxitecLimitedMember 2016-01-01 2016-09-30 0001356090 xon:ActoGeniXNVMember 2016-01-01 2016-09-30 0001356090 xon:A2015BusinessAcquisitionsMember 2016-01-01 2016-09-30 0001356090 2016-10-31 0001356090 2015-12-31 0001356090 2016-09-30 0001356090 2016-07-01 2016-09-30 0001356090 2015-07-01 2015-09-30 0001356090 2015-01-01 2015-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001356090 us-gaap:CommonStockMember 2016-09-30 0001356090 us-gaap:ParentMember 2016-01-01 2016-09-30 0001356090 us-gaap:RetainedEarningsMember 2016-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-09-30 0001356090 us-gaap:NoncontrollingInterestMember 2016-09-30 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001356090 us-gaap:NoncontrollingInterestMember 2015-12-31 0001356090 us-gaap:CommonStockMember 2015-12-31 0001356090 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-09-30 0001356090 us-gaap:RetainedEarningsMember 2015-12-31 0001356090 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001356090 us-gaap:ParentMember 2016-09-30 0001356090 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001356090 us-gaap:ParentMember 2015-12-31 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0001356090 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001356090 2015-09-30 0001356090 2014-12-31 0001356090 xon:BioPopMember 2016-09-30 0001356090 xon:AquaBountyMember 2016-09-30 0001356090 us-gaap:NonUsMember 2015-12-31 0001356090 xon:OragenicsMember 2015-12-31 0001356090 us-gaap:NonUsMember 2016-01-01 2016-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2016-07-01 2016-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2016-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2016-01-01 2016-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2015-07-01 2015-09-30 0001356090 us-gaap:NonUsMember 2016-09-30 0001356090 xon:OragenicsMember 2016-09-30 0001356090 us-gaap:NonUsMember 2015-01-01 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2015-01-01 2015-09-30 0001356090 us-gaap:NonUsMember 2016-07-01 2016-09-30 0001356090 us-gaap:NonUsMember 2015-07-01 2015-09-30 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2015-12-31 0001356090 us-gaap:EquityMethodInvestmentsMember 2015-12-31 0001356090 us-gaap:EquityMethodInvestmentsMember 2016-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2015-07-01 2015-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2016-07-01 2016-09-30 0001356090 us-gaap:EquityMethodInvestmentsMember 2015-01-01 2015-09-30 0001356090 xon:OxitecLimitedMember 2015-09-01 2015-09-30 0001356090 xon:OkanaganSpecialtyFruitsIncMember 2015-04-30 0001356090 xon:OxitecLimitedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-09-30 0001356090 xon:ActoGeniXNVMember 2015-02-01 2015-02-28 0001356090 xon:OkanaganSpecialtyFruitsIncMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001356090 xon:OxitecLimitedMember 2015-09-30 0001356090 xon:ActoGeniXNVMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001356090 xon:OkanaganSpecialtyFruitsIncMember 2015-04-01 2015-04-30 0001356090 xon:ActoGeniXNVMember 2015-08-01 2015-08-31 0001356090 xon:ActoGeniXNVMember 2015-02-28 0001356090 xon:A2015BusinessAcquisitionsMember us-gaap:ProFormaMember 2015-07-01 2015-09-30 0001356090 xon:A2015BusinessAcquisitionsMember us-gaap:ProFormaMember 2015-01-01 2015-09-30 0001356090 xon:OxitecLimitedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001356090 xon:EnviroFlightLLCMember 2016-02-01 2016-02-29 0001356090 xon:SIOphthalmicMember 2015-01-01 2015-12-31 0001356090 xon:EnviroFlightLLCMember us-gaap:SubsequentEventMember 2016-10-01 2016-10-31 0001356090 xon:SIOphthalmicMember 2013-10-01 2013-10-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2016-09-30 0001356090 us-gaap:IntellectualPropertyMember xon:EnviroFlightLLCMember 2016-02-01 2016-02-29 0001356090 xon:OtherAccruedLiabilitiesMember xon:IntrexonEnergyPartnersMember 2015-12-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:IntrexonT1DPartnersLLCMember 2016-03-01 2016-03-31 0001356090 xon:InvestmentsInAffiliatesMember xon:SIOphthalmicMember 2016-09-30 0001356090 xon:SIOphthalmicMember 2016-09-30 0001356090 xon:InvestmentsInAffiliatesMember xon:IntrexonEnergyPartnersIILLCMember 2016-09-30 0001356090 xon:OtherAccruedLiabilitiesMember xon:IntrexonEnergyPartnersMember 2016-09-30 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-31 0001356090 xon:IntrexonT1DPartnersLLCMember 2016-03-31 0001356090 xon:EnviroFlightLLCMember 2016-02-29 0001356090 xon:IntrexonEnergyPartnersMember 2016-09-30 0001356090 xon:OtherAccruedLiabilitiesMember xon:OvaXonMember 2015-12-31 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersMember 2014-03-31 0001356090 xon:InvestmentsInAffiliatesMember xon:IntrexonT1DPartnersLLCMember 2016-09-30 0001356090 us-gaap:InvestorMember xon:IntrexonT1DPartnersLLCMember 2016-03-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2015-12-31 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-01 2015-12-31 0001356090 xon:IntrexonEnergyPartnersMember 2014-03-31 0001356090 xon:InvestmentsInAffiliatesMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-31 0001356090 xon:OvaXonMember 2014-01-01 2014-01-31 0001356090 xon:InvestmentsInAffiliatesMember xon:SIOphthalmicMember 2015-12-31 0001356090 us-gaap:InvestorMember xon:EnviroFlightLLCMember 2016-02-29 0001356090 xon:AllInvestorsMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-01 2015-12-31 0001356090 xon:IntrexonT1DPartnersLLCMember 2016-09-30 0001356090 xon:SIOphthalmicMember 2013-10-31 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersMember 2014-03-01 2014-03-31 0001356090 us-gaap:InvestorMember xon:IntrexonT1DPartnersLLCMember 2016-03-01 2016-03-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-01 2015-12-31 0001356090 us-gaap:FairValueInputsLevel3Member xon:EnviroFlightLLCMember 2016-09-30 0001356090 xon:InvestmentsInAffiliatesMember xon:OvaXonMember 2016-09-30 0001356090 xon:OvaXonMember 2016-09-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2014-03-01 2014-03-31 0001356090 xon:OvaXonMember 2014-01-31 0001356090 xon:InvestmentsInAffiliatesMember xon:EnviroFlightLLCMember 2016-09-30 0001356090 us-gaap:InvestorMember xon:SIOphthalmicMember 2015-01-01 2015-12-31 0001356090 us-gaap:InvestorMember xon:SIOphthalmicMember 2013-10-01 2013-10-31 0001356090 us-gaap:InvestorMember xon:SIOphthalmicMember 2013-10-31 0001356090 us-gaap:InvestorMember xon:OvaXonMember 2014-01-01 2014-01-31 0001356090 us-gaap:InvestorMember xon:OvaXonMember 2014-01-31 0001356090 xon:SIOphthalmicMember 2016-07-01 2016-09-30 0001356090 xon:ThriveAgrobioticsInc.Member 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ExotechBioInc.Member 2016-07-01 2016-09-30 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ZiopharmMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2016-07-01 2016-09-30 0001356090 xon:ZiopharmMember 2016-07-01 2016-09-30 0001356090 xon:RelieveGeneticsInc.Member 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OvaXonMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:SIOphthalmicMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2016-07-01 2016-09-30 0001356090 xon:OtherCollaborationsMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OtherCollaborationsMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OvaXonMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:FibrocellMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:RelieveGeneticsInc.Member 2016-07-01 2016-09-30 0001356090 xon:FibrocellMember 2016-07-01 2016-09-30 0001356090 xon:ADSkincareInc.Member 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2016-07-01 2016-09-30 0001356090 xon:ExotechBioInc.Member 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OragenicsMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersIILLCMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:RelieveGeneticsInc.Member 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:SIOphthalmicMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2016-07-01 2016-09-30 0001356090 xon:OvaXonMember 2016-07-01 2016-09-30 0001356090 xon:PerseaBioLLCMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:AresTradingS.A.Member 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:PerseaBioLLCMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersMember 2016-07-01 2016-09-30 0001356090 xon:OragenicsMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ThriveAgrobioticsInc.Member 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonT1DPartnersLLCMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:GenopaverLLCMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersIILLCMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ExotechBioInc.Member 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ADSkincareInc.Member 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ThriveAgrobioticsInc.Member 2016-07-01 2016-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2016-07-01 2016-09-30 0001356090 xon:GenopaverLLCMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverLLCMember 2016-07-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonT1DPartnersLLCMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ADSkincareInc.Member 2016-07-01 2016-09-30 0001356090 xon:AresTradingS.A.Member 2016-07-01 2016-09-30 0001356090 xon:IntrexonT1DPartnersLLCMember 2016-07-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OragenicsMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:PerseaBioLLCMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2015-01-01 2015-09-30 0001356090 xon:FibrocellMember 2015-01-01 2015-09-30 0001356090 xon:SIOphthalmicMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverLLCMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:FibrocellMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OvaXonMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OtherCollaborationsMember 2015-01-01 2015-09-30 0001356090 xon:OragenicsMember 2015-01-01 2015-09-30 0001356090 xon:OtherCollaborationsMember 2015-01-01 2015-09-30 0001356090 xon:AresTradingS.A.Member 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OvaXonMember 2015-01-01 2015-09-30 0001356090 xon:OvaXonMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ZiopharmMember 2015-01-01 2015-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:AresTradingS.A.Member 2015-01-01 2015-09-30 0001356090 xon:PerseaBioLLCMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:SIOphthalmicMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:SIOphthalmicMember 2015-01-01 2015-09-30 0001356090 xon:GenopaverLLCMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:GenopaverLLCMember 2015-01-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersMember 2015-01-01 2015-09-30 0001356090 xon:ZiopharmMember 2015-01-01 2015-09-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:GentenTherapeuticsInc.Member 2016-09-01 2016-09-30 0001356090 xon:RelieveGeneticsInc.Member 2016-03-01 2016-03-31 0001356090 xon:CRSBioInc.Member 2016-09-01 2016-09-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:ExotechBioInc.Member 2016-03-01 2016-03-31 0001356090 xon:OtherContractualPaymentsMember xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2016-06-01 2016-06-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:RelieveGeneticsInc.Member 2016-03-01 2016-03-31 0001356090 us-gaap:MaximumMember xon:ExotechBioInc.Member 2016-03-01 2016-03-31 0001356090 xon:ZiopharmMember 2016-01-01 2016-05-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:ADSkincareInc.Member 2016-06-01 2016-06-30 0001356090 xon:ZiopharmMember 2016-06-01 2016-06-30 0001356090 xon:ADSkincareInc.Member 2016-06-01 2016-06-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:IntrexonT1DPartnersLLCMember 2016-03-01 2016-03-31 0001356090 us-gaap:MaximumMember xon:ADSkincareInc.Member 2016-06-01 2016-06-30 0001356090 xon:ExotechBioInc.Member 2016-03-01 2016-03-31 0001356090 us-gaap:MaximumMember xon:RelieveGeneticsInc.Member 2016-03-01 2016-03-31 0001356090 us-gaap:MaximumMember xon:CRSBioInc.Member 2016-09-01 2016-09-30 0001356090 us-gaap:MaximumMember xon:GentenTherapeuticsInc.Member 2016-09-01 2016-09-30 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:CRSBioInc.Member 2016-09-01 2016-09-30 0001356090 xon:GentenTherapeuticsInc.Member 2016-09-01 2016-09-30 0001356090 xon:IntrexonT1DPartnersLLCMember 2016-03-01 2016-03-31 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ZiopharmMember 2015-07-01 2015-09-30 0001356090 xon:ZiopharmMember 2015-07-01 2015-09-30 0001356090 xon:FibrocellMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:SIOphthalmicMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OvaXonMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:AresTradingS.A.Member 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverLLCMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:GenopaverLLCMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:SIOphthalmicMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:PerseaBioLLCMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2015-07-01 2015-09-30 0001356090 xon:AresTradingS.A.Member 2015-07-01 2015-09-30 0001356090 xon:PerseaBioLLCMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember 2015-07-01 2015-09-30 0001356090 xon:GenopaverLLCMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OvaXonMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2015-07-01 2015-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2015-07-01 2015-09-30 0001356090 xon:OvaXonMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OragenicsMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OtherCollaborationsMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:FibrocellMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2015-07-01 2015-09-30 0001356090 xon:SIOphthalmicMember 2015-07-01 2015-09-30 0001356090 xon:OragenicsMember 2015-07-01 2015-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersMember 2015-07-01 2015-09-30 0001356090 xon:OtherCollaborationsMember 2015-07-01 2015-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2016-09-30 0001356090 xon:PrepaidProductAndServiceRevenuesMember 2015-12-31 0001356090 xon:DeferredRevenueOtherMember 2015-12-31 0001356090 xon:DeferredRevenueOtherMember 2016-09-30 0001356090 xon:PrepaidProductAndServiceRevenuesMember 2016-09-30 0001356090 xon:PrepaidResearchAndDevelopmentServicesMember 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2015-12-31 0001356090 xon:PrepaidResearchAndDevelopmentServicesMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GentenTherapeuticsInc.Member 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonT1DPartnersLLCMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverLLCMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:CRSBioInc.Member 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ADSkincareInc.Member 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GentenTherapeuticsInc.Member 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ThriveAgrobioticsInc.Member 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:CRSBioInc.Member 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ExotechBioInc.Member 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersIILLCMember 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ExotechBioInc.Member 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:RelieveGeneticsInc.Member 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ThriveAgrobioticsInc.Member 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ADSkincareInc.Member 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverLLCMember 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonT1DPartnersLLCMember 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:RelieveGeneticsInc.Member 2015-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2016-09-30 0001356090 xon:RelieveGeneticsInc.Member 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ADSkincareInc.Member 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ExotechBioInc.Member 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OragenicsMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersIILLCMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ADSkincareInc.Member 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ThriveAgrobioticsInc.Member 2016-01-01 2016-09-30 0001356090 xon:ThriveAgrobioticsInc.Member 2016-01-01 2016-09-30 0001356090 xon:ExotechBioInc.Member 2016-01-01 2016-09-30 0001356090 xon:FibrocellMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:SIOphthalmicMember 2016-01-01 2016-09-30 0001356090 xon:OtherCollaborationsMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2016-01-01 2016-09-30 0001356090 xon:IntrexonT1DPartnersLLCMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:AresTradingS.A.Member 2016-01-01 2016-09-30 0001356090 xon:PerseaBioLLCMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OvaXonMember 2016-01-01 2016-09-30 0001356090 xon:OvaXonMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonEnergyPartnersMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:SIOphthalmicMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:IntrexonT1DPartnersLLCMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ExotechBioInc.Member 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OvaXonMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersIILLCMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:RelieveGeneticsInc.Member 2016-01-01 2016-09-30 0001356090 xon:OragenicsMember 2016-01-01 2016-09-30 0001356090 xon:SIOphthalmicMember 2016-01-01 2016-09-30 0001356090 xon:GenopaverLLCMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:FibrocellMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverLLCMember 2016-01-01 2016-09-30 0001356090 xon:ZiopharmMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ZiopharmMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:OtherCollaborationsMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2016-01-01 2016-09-30 0001356090 xon:ADSkincareInc.Member 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:GenopaverLLCMember 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonT1DPartnersLLCMember 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:ThriveAgrobioticsInc.Member 2016-01-01 2016-09-30 0001356090 xon:IntrexonEnergyPartnersMember 2016-01-01 2016-09-30 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2016-01-01 2016-09-30 0001356090 xon:AresTradingS.A.Member 2016-01-01 2016-09-30 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:RelieveGeneticsInc.Member 2016-01-01 2016-09-30 0001356090 xon:ResearchAndDevelopmentServicesMember xon:PerseaBioLLCMember 2016-01-01 2016-09-30 0001356090 us-gaap:CertificatesOfDepositMember 2016-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2016-09-30 0001356090 us-gaap:CertificatesOfDepositMember 2015-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2015-12-31 0001356090 us-gaap:PreferredStockMember 2016-09-30 0001356090 xon:ZiopharmMember 2016-01-01 2016-09-30 0001356090 xon:ZiopharmMember 2016-07-01 2016-09-30 0001356090 xon:ZiopharmMember 2016-06-30 0001356090 xon:ZiopharmMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001356090 xon:ZiopharmMember 2016-01-01 2016-09-30 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2015-12-31 0001356090 us-gaap:FairValueInputsLevel2Member 2015-12-31 0001356090 us-gaap:FairValueInputsLevel1Member 2015-12-31 0001356090 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001356090 us-gaap:EquitySecuritiesMember 2015-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001356090 xon:OtherFinancialAssetsMember 2015-12-31 0001356090 us-gaap:FairValueInputsLevel3Member 2016-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001356090 us-gaap:PreferredStockMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001356090 us-gaap:PreferredStockMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001356090 xon:OtherFinancialAssetsMember 2016-09-30 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2016-09-30 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001356090 us-gaap:FairValueInputsLevel1Member 2016-09-30 0001356090 us-gaap:EquitySecuritiesMember 2016-09-30 0001356090 us-gaap:FairValueInputsLevel2Member 2016-09-30 0001356090 us-gaap:PreferredStockMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001356090 xon:LivestockMember 2016-09-30 0001356090 xon:SuppliesSemenAndEmbryosMember 2016-09-30 0001356090 xon:WorkInProcessMember 2015-12-31 0001356090 xon:FeedMember 2015-12-31 0001356090 xon:FeedMember 2016-09-30 0001356090 xon:SuppliesSemenAndEmbryosMember 2015-12-31 0001356090 xon:LivestockMember 2015-12-31 0001356090 xon:WorkInProcessMember 2016-09-30 0001356090 us-gaap:TrademarksMember 2015-12-31 0001356090 us-gaap:CustomerRelationshipsMember 2015-12-31 0001356090 us-gaap:IntellectualPropertyMember 2015-12-31 0001356090 xon:CovenantNotToCompeteMember 2015-12-31 0001356090 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001356090 xon:CovenantNotToCompeteMember 2016-09-30 0001356090 us-gaap:IntellectualPropertyMember us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0001356090 us-gaap:TrademarksMember 2016-09-30 0001356090 xon:CovenantNotToCompeteMember us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0001356090 us-gaap:IntellectualPropertyMember 2016-09-30 0001356090 us-gaap:InProcessResearchAndDevelopmentMember 2016-09-30 0001356090 us-gaap:TrademarksMember us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0001356090 us-gaap:CustomerRelationshipsMember us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0001356090 us-gaap:CustomerRelationshipsMember 2016-09-30 0001356090 xon:AquaBountyMember xon:FinancePEIMember xon:OtherLongTermDebtMember 2016-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember 2016-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001356090 xon:TransOvaGeneticsLcMember xon:AmericanStateBankMember us-gaap:NotesPayableToBanksMember 2016-09-30 0001356090 xon:AquaBountyMember xon:AtlanticCanadaOpportunitiesAgencyMember xon:RoyaltybasedFinancingMember 2016-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember 2016-09-30 0001356090 xon:AquaBountyMember xon:AtlanticCanadaOpportunitiesAgencyMember xon:RoyaltybasedFinancingMember 2016-01-01 2016-09-30 0001356090 xon:TransOvaGeneticsLcMember xon:AmericanStateBankMember us-gaap:NotesPayableToBanksMember 2016-01-01 2016-09-30 0001356090 xon:AquaBountyMember xon:AtlanticCanadaOpportunitiesAgencyMember xon:RoyaltybasedFinancingMember 2013-03-31 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember us-gaap:MaximumMember 2016-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:RevolvingCreditFacilityMember xon:AmericanStateBankMember 2016-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember us-gaap:MinimumMember 2016-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember us-gaap:MinimumMember 2016-09-30 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-01-01 2016-09-30 0001356090 xon:AquaBountyMember xon:FinancePEIMember xon:OtherLongTermDebtMember 2016-01-01 2016-09-30 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:NotesPayableOtherPayablesMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001356090 us-gaap:NotesPayableOtherPayablesMember 2015-12-31 0001356090 xon:OtherLongTermDebtMember 2016-09-30 0001356090 xon:OtherLongTermDebtMember 2015-12-31 0001356090 xon:RoyaltybasedFinancingMember 2015-12-31 0001356090 xon:RoyaltybasedFinancingMember 2016-09-30 0001356090 us-gaap:NotesPayableOtherPayablesMember 2016-09-30 0001356090 us-gaap:DomesticCountryMember 2015-01-01 2015-09-30 0001356090 us-gaap:ForeignCountryMember 2016-01-01 2016-09-30 0001356090 us-gaap:DomesticCountryMember 2016-09-30 0001356090 us-gaap:ForeignCountryMember 2015-07-01 2015-09-30 0001356090 us-gaap:ForeignCountryMember 2016-07-01 2016-09-30 0001356090 us-gaap:DomesticCountryMember 2016-07-01 2016-09-30 0001356090 us-gaap:DomesticCountryMember 2016-01-01 2016-09-30 0001356090 us-gaap:ForeignCountryMember 2016-09-30 0001356090 us-gaap:DomesticCountryMember 2015-07-01 2015-09-30 0001356090 us-gaap:ForeignCountryMember 2015-01-01 2015-09-30 0001356090 xon:IntrexonStockOptionPlanMember 2015-06-01 2015-06-30 0001356090 xon:ZiopharmMember 2015-06-01 2015-06-30 0001356090 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0001356090 us-gaap:AccumulatedTranslationAdjustmentMember 2016-09-30 0001356090 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0001356090 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-09-30 0001356090 xon:IntrexonStockOptionPlanMember 2016-01-01 2016-09-30 0001356090 xon:IntrexonStockOptionPlanMember 2016-09-30 0001356090 xon:IntrexonStockOptionPlanMember 2015-12-31 0001356090 xon:IntrexonStockOptionPlanMember 2015-01-01 2015-12-31 0001356090 xon:AquaBounty2006StockOptionPlanMember 2015-12-31 0001356090 us-gaap:ChiefExecutiveOfficerMember 2015-11-01 2015-11-30 0001356090 xon:AquaBounty2016StockOptionPlanMember 2016-09-30 0001356090 xon:IntrexonStockOptionPlan2013PlanMember 2016-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:ChiefExecutiveOfficerMember 2016-01-01 2016-09-30 0001356090 xon:AquaBounty2006StockOptionPlanMember 2016-04-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:ChiefExecutiveOfficerMember 2016-07-01 2016-09-30 0001356090 xon:IntrexonStockOptionPlan2008PlanMember 2016-09-30 0001356090 xon:IntrexonStockOptionPlanOtherPlanMember 2016-09-30 0001356090 xon:AquaBounty2006StockOptionPlanMember 2016-09-30 0001356090 xon:IntrexonStockOptionPlan2008PlanMember 2013-08-31 0001356090 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2016-10-01 2016-10-31 0001356090 xon:CostOfServicesMember 2015-01-01 2015-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001356090 xon:CostOfProductsMember 2016-07-01 2016-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001356090 xon:CostOfServicesMember 2016-07-01 2016-09-30 0001356090 xon:CostOfServicesMember 2015-07-01 2015-09-30 0001356090 xon:CostOfProductsMember 2015-01-01 2015-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0001356090 xon:CostOfProductsMember 2015-07-01 2015-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001356090 xon:CostOfProductsMember 2016-01-01 2016-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0001356090 xon:CostOfServicesMember 2016-01-01 2016-09-30 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-01-31 0001356090 us-gaap:MinimumMember xon:ZiopharmMember 2015-01-31 0001356090 us-gaap:MaximumMember xon:ZiopharmMember 2015-01-31 0001356090 xon:ZiopharmMember 2015-01-01 2015-01-31 0001356090 2015-01-01 2015-01-31 0001356090 xon:LicensingAndPatentInfringementSuitMember 2016-04-01 2016-04-30 0001356090 xon:XYLLCMember xon:LicensingAndPatentInfringementSuitMember 2016-04-01 2016-04-30 0001356090 xon:ShareholderClassActionLawsuitsMember 2016-05-01 2016-05-31 0001356090 xon:LicensingAndPatentInfringementSuitMember 2012-03-01 2016-04-30 0001356090 xon:LicensingAndPatentInfringementSuitMember 2016-09-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember xon:LicensingAndPatentInfringementSuitMember 2016-01-01 2016-09-30 0001356090 us-gaap:OtherNonoperatingIncomeExpenseMember xon:HarvestIntrexonEnterpriseFundILPMember 2016-01-01 2016-09-30 0001356090 us-gaap:OtherNoncurrentAssetsMember xon:ConvertibleNoteandWarrantsMember xon:FibrocellMember 2016-09-30 0001356090 xon:ThirdSecurityMember 2016-01-01 2016-09-30 0001356090 xon:ThirdSecurityMember 2015-07-01 2015-09-30 0001356090 xon:FibrocellMember 2016-09-01 2016-09-30 0001356090 xon:ThirdSecurityMember 2015-01-01 2015-09-30 0001356090 xon:ThirdSecurityMember 2016-07-01 2016-09-30 0001356090 xon:OragenicsMember 2016-06-01 2016-06-30 0001356090 us-gaap:OtherNonoperatingIncomeExpenseMember xon:HarvestIntrexonEnterpriseFundILPMember 2016-07-01 2016-09-30 0001356090 us-gaap:OtherNonoperatingIncomeExpenseMember xon:HarvestIntrexonEnterpriseFundILPMember 2015-07-01 2015-09-30 0001356090 xon:RelatedPartiesAggregatedMember 2016-07-01 2016-09-30 0001356090 xon:ThirdSecurityMember 2015-11-01 2015-11-30 0001356090 xon:RelatedPartiesAggregatedMember 2015-01-01 2015-09-30 0001356090 us-gaap:MaximumMember xon:OragenicsMember 2016-09-30 0001356090 xon:RelatedPartiesAggregatedMember 2016-01-01 2016-09-30 0001356090 xon:ThirdSecurityMember us-gaap:CommonStockMember 2015-11-01 2015-11-30 0001356090 xon:OragenicsMember 2016-06-30 0001356090 xon:RelatedPartiesAggregatedMember 2015-07-01 2015-09-30 0001356090 us-gaap:OtherNonoperatingIncomeExpenseMember xon:HarvestIntrexonEnterpriseFundILPMember 2015-01-01 2015-09-30 0001356090 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001356090 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001356090 us-gaap:StockOptionMember 2016-01-01 2016-09-30 0001356090 us-gaap:StockOptionMember 2015-01-01 2015-09-30 0001356090 us-gaap:WarrantMember 2015-07-01 2015-09-30 0001356090 us-gaap:StockOptionMember 2015-07-01 2015-09-30 0001356090 us-gaap:StockOptionMember 2016-07-01 2016-09-30 0001356090 us-gaap:WarrantMember 2016-07-01 2016-09-30 0001356090 xon:AquaBountyMember us-gaap:SubsequentEventMember 2016-11-01 2016-11-09 0001356090 us-gaap:MaximumMember xon:AquaBountyMember us-gaap:SubsequentEventMember 2016-11-01 2016-11-09 xbrli:shares iso4217:USD xon:segment xon:board_seat iso4217:USD xbrli:shares xbrli:pure xon:claim false --12-31 Q3 2016 2016-09-30 10-Q 0001356090 118575964 Large Accelerated Filer INTREXON CORP XON

2995000

2521000

4967000

7866000

25101000

22034000

-298000

-862000

26240000

32303000

-12752000

-25302000

1249559000

1310979000

30610000

30555000

55000

30555000

8385000

2234000

6032000

21000

98000

26524000

6141000

20006000

76000

301000

10792000

2236000

8467000

21000

68000

30631000

6979000

23385000

61000

206000

2857000

6434000

3651000

10888000

10854759

10660040

194719

10854759

10660040

194719

12133598

12103407

30191

12133598

12103407

30191

982046000

1005588000

323801000

316223000

291762000

83653000

65850000

17803000

16601000

207704000

405000

65850000

225912000

376093000

1990000

39432000

31245000

8187000

6171000

123676000

210689000

2296000

31245000

221172000

123676000

21000

79000

540000

10000

208494000

271000

208223000

210892000

272000

210620000

44122000

166839000

207975000

271000

207704000

210961000

272000

210689000

105447000

44122000

7520000

7965000

707853

965377

1359343

-42241000

-63379000

53754000

133060000

341000

418000

1675000

1644000

381000

267000

1644000

40933000

72474000

146394000

30933000

39735000

56195000

11440000

109473000

71848000

36655000

3780000

3180000

58000

121000

31000

125000

16000

1187000

230000

181000

210000

253000

12584000

612000

8847000

96854000

68100000

36500000

14347000

2023000

9209000

95126000

69825000

27446000

1107000

23000

1198000

209000

32000

146394000

72474000

40933000

533000

926000

27466000

125433000

135782000

69707000

97967000

-66075000

17830305

200000000

116658886

118446717

116658886

118446717

-41123000

-56970000

-32633000

-155025000

-778000

-2874000

-1024000

-2916000

-41901000

-59844000

-33657000

-157941000

2193000

7523000

11215000

31654000

9156000

29471000

5451000

17316000

5803000

17807000

-318000

-27000

459000

-27000

-110000

-323000

0.0295

0.04

0.045

0.03

0.0395

4000

1000

39000

-578000

374000

-308000

-2967000

197729000

701000

4759000

10938000

181331000

53567000

21445000

2250000

17833000

20625000

8813000

20339000

4500000

1621000

30338000

322397000

620000

5594000

7057000

309126000

4213000

48776000

2111000

4722000

19631000

2045000

4523000

16333000

18750000

9383000

8027000

17260000

4125000

4093000

1483000

143651000

35366000

54937000

162363000

267460000

7060000

18060000

21802000

18060000

1987000

5768000

2332000

6769000

12202000

17657000

172419000

23597000

16159000

150000

611000

-0.34

-0.47

-0.24

-1.21

507000

-313000

19050000

11011000

P3Y

113655000

106649000

0.5

0.307

0.5

0.295

0.5

29662000

92041000

28123000

81049000

6274000

8325000

-8391000

-116731000

-18223000

-48510000

1539000

10992000

330000

1480000

65000

394000

9977000

2000000

6379000

-1270000

-144000

25847000

4611000

1591000

1078000

435000

3737000

-627000

P14Y

P18Y

P21Y

P6Y6M

P15Y3M18D

P9Y3M18D

P2Y

21692000

2739000

17775000

1018000

160000

32695000

4189000

26596000

1598000

312000

269227000

10700000

93932000

157411000

6800000

384000

271276000

10700000

82861000

170520000

6800000

395000

247535000

7961000

93932000

139636000

5782000

224000

238581000

6511000

82861000

143924000

5202000

83000

9880000

1283000

1234000

-519000

-297000

51268000

165169000

159793000

2649000

13487000

-5376000

-39952000

-43979000

-53913000

-66686000

-30429000

-148652000

-2429000

-6565000

-6255000

-16951000

-923000

806000

-418000

-3290000

1165000

-3560000

2901000

12014000

-2118000

52400000

-14099000

11182000

-7438000

-67000

479000

5895000

-8001000

-3451000

-4683000

-1000

42000

1323000

7771000

168000

126000

3817000

-2134000

-6390000

-381000

4005000

985000

6987000

247535000

238581000

310000

1012000

227000

759000

1119000

875000

26563000

1964000

16907000

1402000

6290000

21880000

2183000

12588000

1278000

5831000

567000

1211000

4494000

5817000

5425000

9119000

11276000

2167000

6548000

2075000

6410000

6888000

10479000

277160000

397168000

982046000

1005588000

75904000

100521000

179000

3839000

549000

0.0348

700000

6000000

561000

549000

-6066000

528000

4228000

8528000

6477000

244000

1807000

8421000

2003000

543000

431000

5338000

5769000

649000

2003000

930000

471000

335000

364000

549000

404000

168000

7598000

7950000

36016000

41343000

697000

613000

1871000

10808000

7947000

0.63

0.51

331441000

11162000

-257318000

-45144000

23337000

-31780000

-38213000

-51779000

-28982000

-142475000

-816000

-2940000

-1029000

-2887000

-29607000

-34000

65121000

-31000

4647000

75000

-39125000

1502000

601000

1505000

61283000

8687000

244576000

118180000

77806000

18363000

237500000

50406000

-7916000

-8357000

-112469000

-116700000

-28821000

-18298000

-92576000

-50012000

48750000

5487000

5434000

5695000

6362000

20179000

36000

9000

705000

334000

1153000

184000

854000

257700000

120600000

7949000

16353000

3725000

3485000

230000

249000

-151000

588000

-3102000

-5374000

-3495000

-13167000

-12579000

-12550000

-29000

-12550000

795000

3177000

83653000

39432000

-305000

-1259000

589000

530000

-32000

1205000

250000

615000

429000

783000

5000000

4244000

7244000

3170000

1566000

10000000

32739000

90199000

114480000

5000000

1500000

25000000

18000000

4000000

3000000

10000000

5000000

4699000

9415000

181572000

75246000

2964000

17080000

2308000

9841000

20197000

12.00

3063

1200

6634000

8591000

1500000

328234000

81000

547000

13719000

2308000

70000000

71987000

420000

243000

12208000

18180000

800000

142000

294000

156000

301000

-39029000

-43057000

-54719000

-66319000

-30011000

-145362000

-2887000

-142475000

68979000

86732000

42739000

3877000

54429000

11331000

1562000

1609000

81401000

15517000

2320000

1032000

848000

21598000

121286000

29035000

83266000

6987000

463000

1397000

-542729000

-685204000

53367000

1183000

132107000

3446000

48985000

3502000

144924000

8678000

9446000

32645000

9260000

28699000

8945000

32157000

8706000

33298000

23019000

74320000

33812000

106956000

26524000

30631000

16000000

3982064

34804

2127334

4384860

312795

5382000

11043528

5567000

570977

10532430

12103407

1000000

0.26

32.66

0.26

31.24

4320333

5321598

3369252

27.99

10177058

30.99

15.63

35.76

43.29

29.42

25.40

P8Y5M27D

P8Y6M0D

P7Y2M30D

P8Y4M12D

102528000

166839000

89326

254496

328648

59337

136340

1162843

1322843

126863000

2132000

8284000

6542000

8284000

1583000

4401000

18180000

694078000

-519000

-12752000

-12233000

600473000

69000

-25302000

-25371000

704886000

-12752000

1249559000

10808000

694078000

-542729000

608420000

-25302000

1310979000

7947000

600473000

-685204000

2404000

6283000

-455000

-11597000

3598000

145786000

112244129

109244641

118346782

117785160

845000 2185000 1952000 20000000 15000000 P3Y 4000000 3660000 0 3660000 9449000 480422 1991000 P18M 246000 196000 7395000 305000 49000 120000 732000 181000 P90D P90D P90D P90D P90D P90D 34726000 14134000 260000 1317000 993000 3185000 332000 2002000 549000 297000 1193000 4006000 20592000 1597000 4823000 68000 625000 4868000 7841000 0 125000 0 645000 31740000 1857000 6140000 1061000 3810000 5200000 9843000 549000 422000 1193000 4651000 66690000 39364000 260000 4500000 2460000 8101000 408000 6620000 1855000 553000 2838000 11769000 27326000 2336000 5719000 205000 1875000 5437000 9446000 0 375000 0 1933000 59775000 2596000 10219000 2665000 9976000 5845000 16066000 1855000 928000 2838000 13702000 30590000 20370000 65000 719000 82000 563000 1625000 372000 4230000 511000 294000 1903000 709000 208000 342000 2782000 379000 5586000 10220000 120000 1597000 139000 604000 68000 500000 625000 276000 262000 895000 0 125000 120000 0 46000 4843000 26688000 185000 2316000 221000 1167000 1693000 872000 4855000 787000 556000 2798000 709000 333000 462000 2782000 425000 10429000 82144000 58097000 65000 2148000 82000 2604000 4703000 816000 11180000 543000 1083000 6287000 2211000 613000 572000 6326000 1171000 17693000 24047000 120000 4791000 278000 1814000 205000 1500000 1875000 554000 786000 4684000 0 375000 240000 0 138000 6687000 70299000 185000 6939000 360000 4418000 4908000 2316000 13055000 1097000 1869000 10971000 2211000 988000 812000 6326000 1309000 24380000 1500000 100000 25000000 18000000 10000000 5000000 10000000 4333000 120000000 4333000 2100000 3000000 0.5 0.2 P12M P2M 200000 5960000 6912000 P20D 6931000 8723000 8698000 0 23388000 83716000 -30453000 64392000 412000 -45388000 P5Y -943000 -630000 0 123676000 25000000 25000000 10000000 10000000 5000000 5000000 5000000 5000000 12367000 3650000 P3Y 3824000 774000 6418000 17000000 52500000 52500000 2000000 75000000 82000000 0 3676000 3676000 3676000 5 5 5 4 4 4888000 54400000 59579000 6252000 6705000 2604000 0.30 1.00 24.00 0 120000000 25000000 72632190 0.1 10000000 2759000 P1Y 59579000 0 480000 8284000 2261419 0.52 2100085 9412000 0 4667000 18766000 -15865000 22935000 8334000 -9346000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,892</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(540</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and results of operations and cash flows for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited condensed pro forma financial information for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> is presented as if the acquisitions had been consummated on January 1, 2014:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro Forma</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,686</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to the noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">816</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,940</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and Licensing Revenue</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue through contractual agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensees obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Upfront and milestone payments are typically deferred and recognized over the expected life of the Company's technology platform using a straight-line approach. The Company recognizes the reimbursement payments received for research and development services in the period in which the services are performed and collection is reasonably assured. The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">556</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,693</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S & I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thrive Agrobiotics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">372</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exotech Bio, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relieve Genetics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AD Skincare, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,903</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,798</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S & I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S & I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">988</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thrive Agrobiotics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,171</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exotech Bio, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relieve Genetics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,097</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AD Skincare, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,287</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,097</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S & I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">928</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,066</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except for the agreements discussed below, there have been no significant changes to arrangements with our collaborators and licensees in the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. See Note 5 in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;"> for additional details of the Company's existing collaboration and licensing agreements. </font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exotech Bio Collaboration</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Company entered into an ECC with Exotech Bio, Inc. ("Exotech Bio"), an affiliate of Harvest and a related party. Exotech Bio was formed for the purpose of entering into the ECC and developing and commercializing products using exosomes carrying a RNA payload designed to kill, suppress, or render immune-visible a cancer cell. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Exotech Bio valued at </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. The Company is also entitled to up to </font><font style="font-family:inherit;font-size:10pt;">$52,500</font><font style="font-family:inherit;font-size:10pt;"> of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. Exotech Bio will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. Exotech Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Exotech Bio upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Relieve Genetics Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Company entered into an ECC with Relieve Genetics, Inc. ("Relieve Genetics"), an affiliate of Harvest and a related party. Relieve Genetics was formed for the purpose of entering into the ECC and developing and commercializing products using a viral vector expressing interleukin-10 for the treatment of chronic neuropathic pain resultant from cancer in humans. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Relieve Genetics valued at </font><font style="font-family:inherit;font-size:10pt;">$4,333</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. The Company is also entitled to up to </font><font style="font-family:inherit;font-size:10pt;">$52,500</font><font style="font-family:inherit;font-size:10pt;"> of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. Relieve Genetics will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. Relieve Genetics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Relieve Genetics upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intrexon T1D Partners Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Company entered into an ECC with Intrexon T1D Partners, a related party. Pursuant to the ECC, Intrexon T1D Partners received an exclusive license to the Company's technology platform to develop and commercialize products to treat type 1 diabetes. Upon execution of the ECC, the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2016 and continues until March 2036; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated Intrexon T1D Partners upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AD Skincare Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company entered into an ECC with AD Skincare, Inc. ("AD Skincare"), an affiliate of Harvest and a related party. AD Skincare was formed for the purpose of entering into the ECC and developing an advanced topical delivery system to improve the efficacy of biologically active ingredients aimed at improving signs of aging human skin. Upon execution of the ECC, the Company received a technology access fee in the form of equity in AD Skincare valued at </font><font style="font-family:inherit;font-size:10pt;">$4,333</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. The Company is also entitled to up to </font><font style="font-family:inherit;font-size:10pt;">$2,000</font><font style="font-family:inherit;font-size:10pt;"> of potential payments for substantive and non-substantive development milestones for each product developed under the ECC, as well as up to </font><font style="font-family:inherit;font-size:10pt;">$17,000</font><font style="font-family:inherit;font-size:10pt;"> in one-time commercial milestones. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. AD Skincare will pay the Company royalties as a percentage in the low double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. AD Skincare is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in June 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by AD Skincare upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ZIOPHARM Collaborations</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company amended each of its two existing collaboration agreements with ZIOPHARM and as a result the rate of the royalty which the Company is entitled to receive on certain products commercialized pursuant to the agreements was reduced from </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">. As consideration for execution of the amendments, ZIOPHARM issued the Company </font><font style="font-family:inherit;font-size:10pt;">100,000</font><font style="font-family:inherit;font-size:10pt;"> shares of ZIOPHARM's Series 1 Preferred Stock valued at </font><font style="font-family:inherit;font-size:10pt;">$120,000</font><font style="font-family:inherit;font-size:10pt;">. The Company allocated the consideration received to each ECC based on the cumulative value of upfront and milestone payments previously received pursuant to that ECC. Because the Company has remaining performance obligations under each of the ZIOPHARM ECCs, the Company recorded the initial fair value received as deferred revenue and will recognize this amount straight-line over the remaining performance period for each ZIOPHARM ECC. No other financially significant terms of the ZIOPHARM ECCs were changed as a result of the amendments. See Note </font><font style="font-family:inherit;font-size:10pt;">7</font><font style="font-family:inherit;font-size:10pt;"> for additional discussion of the terms of the preferred stock and the accounting treatment.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Genten Therapeutics Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2016, the Company entered into an ECC with Genten Therapeutics, Inc. ("Genten Therapeutics"), an affiliate of Harvest and a related party. Genten Therapeutics was formed for the purpose of entering into the ECC and developing and commercializing products using the Company's technology for expression of gluten peptides, alone or in combination with immunomodulatory cytokines, to reestablish immune tolerance for patients with celiac disease. Upon execution of the ECC, the Company received a technology access fee in the form of a </font><font style="font-family:inherit;font-size:10pt;">$1,500</font><font style="font-family:inherit;font-size:10pt;"> cash payment and equity in Genten Therapeutics valued at </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;"> as upfront consideration. The Company is entitled to receive additional equity interests in Genten Therapeutics upon the first instance of the achievement of a certain non-substantive development milestone. The Company is also entitled to up to </font><font style="font-family:inherit;font-size:10pt;">$82,000</font><font style="font-family:inherit;font-size:10pt;"> of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. Genten Therapeutics will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. Genten Therapeutics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Genten Therapeutics upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">CRS Bio Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2016, the Company entered into an ECC with CRS Bio, Inc. ("CRS Bio"), an affiliate of Harvest and a related party. CRS Bio was formed for the purpose of entering into the ECC and developing and commercializing products through targeted delivery of antibodies for treatment of chronic rhinosinusitis with and without nasal polyps, by utilizing the Company's technology to block inflammatory mediators in the nasal passage, leading to improved breathing and, importantly, patients' quality of life. Upon execution of the ECC, the Company received a technology access fee in the form of equity in CRS Bio valued at </font><font style="font-family:inherit;font-size:10pt;">$2,100</font><font style="font-family:inherit;font-size:10pt;">. The Company is entitled to receive additional equity interests in CRS Bio upon the first instance of the achievement of a certain non-substantive development milestone. The Company is also entitled to up to </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;"> of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. CRS Bio will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. CRS Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by CRS Bio upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> written notice to the Company.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenue</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue primarily consists of consideration received for upfront and milestone payments in connection with the Company's collaborations and licensing agreements, prepayments for research and development services performed for collaborators and licensees, and prepayments for product and service revenues. Deferred revenue consists of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront and milestone payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid product and service revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">701</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,937</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,366</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,460</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,027</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,045</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thrive Agrobiotics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exotech Bio, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,722</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relieve Genetics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AD Skincare, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genten Therapeutics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,523</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CRS Bio, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,331</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consists of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront and milestone payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid product and service revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">701</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,937</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,366</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,460</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized unaudited financial data as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, for the Company's equity method investments are shown in the following tables. Summarized unaudited financial data for ZIOPHARM has been included through June 30, 2015 for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> as the Company determined it had significant influence over ZIOPHARM until the Company distributed its investment in ZIOPHARM to shareholders in June 2015.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,049</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,992</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,662</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,325</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,716</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended <br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,406</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,180</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(116,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,510</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(116,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,689</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,689</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,676</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,676</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,676</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets<br clear="none"/>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs<br clear="none"/>(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of available-for-sale investments classified by their contractual maturities as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> was:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due within one year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After one year through two years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment consist of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land and land improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and building improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,965</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,016</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,960</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction and other assets in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,732</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,979</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,429</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,233</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$72,474</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred is presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt consists of the following:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty-based financing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,003</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,807</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,421</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,528</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">930</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt, less current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,950</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the computation of basic and diluted net loss per share for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended <br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historical net loss per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,982</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(142,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,346,782</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,244,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,785,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,244,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.47</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation costs included in the consolidated statements of operations are presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended <br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended <br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,467</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,006</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,792</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,385</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,631</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,524</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Useful Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, related technologies and know-how</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,189</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,511</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covenant not to compete</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(312</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,861</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,861</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,276</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,695</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, related technologies and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,739</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,961</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covenant not to compete</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,932</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,932</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,692</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,362</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,434</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the carrying amount of goodwill for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,793</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consists of the following:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies, semen and embryos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,290</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Livestock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,563</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future maturities of long term debt are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">404</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,655</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,487</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,854</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity was as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,043,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.49</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,384,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,162,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,127,334</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43.29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,804</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,103,407</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.50</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,369,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.25</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vested and Expected to Vest at September 30, 2016(1)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,177,058</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.37</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of stock options expected to vest takes into account an estimate of expected forfeitures.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">556</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,693</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S & I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thrive Agrobiotics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">372</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exotech Bio, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relieve Genetics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AD Skincare, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,903</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,798</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S & I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S & I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">988</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thrive Agrobiotics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,171</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exotech Bio, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relieve Genetics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,097</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AD Skincare, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,287</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,097</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognized From</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Upfront and Milestone Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S & I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">928</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,066</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,027</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,045</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thrive Agrobiotics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exotech Bio, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,722</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relieve Genetics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AD Skincare, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genten Therapeutics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,523</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CRS Bio, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,331</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investment in Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company received </font><font style="font-family:inherit;font-size:10pt;">100,000</font><font style="font-family:inherit;font-size:10pt;"> shares of ZIOPHARM's Series 1 Preferred Stock (the "Preferred Shares"), with a per share stated value of </font><font style="font-family:inherit;font-size:10pt;">$1,200</font><font style="font-family:inherit;font-size:10pt;">, as consideration for amending their two previously existing ECC agreements (Note </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">). A summary of the terms of the Preferred Shares are as follows.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion. </font><font style="font-family:inherit;font-size:10pt;">The Preferred Shares shall automatically convert into shares of ZIOPHARM common stock upon the date the first approval in the United States of (i) a ZIOPHARM product, as defined in and developed under one of the ECC agreements, or (ii) a product, as defined and developed under the License and Collaboration Agreement with Ares Trading S.A., a subsidiary of the biopharmaceutical business of Merck KGaA, and ZIOPHARM, is publicly announced (the "Conversion Event Date"). The Preferred Shares shall convert into a number of shares of ZIOPHARM common stock equal to the stated value of such Preferred Share, divided by the greater of: (i) the volume weighted average closing price of ZIOPHARM's common stock over the </font><font style="font-family:inherit;font-size:10pt;">twenty</font><font style="font-family:inherit;font-size:10pt;"> trading days ending on the Conversion Event Date or (ii) </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;">. The number of converted shares is subject to certain limitations defined in the amended and restated Certificate of Designation, Preferences, and Rights of Series 1 Preferred Stock (the "A&R Certificate of Designation").</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividend Rights.</font><font style="font-family:inherit;font-size:10pt;"> The Company shall receive a monthly dividend, payable in additional Preferred Shares, equal to </font><font style="font-family:inherit;font-size:10pt;">$12.00</font><font style="font-family:inherit;font-size:10pt;"> per Preferred Share held per month divided by the stated value of the Preferred Shares, which is referred to as the PIK Dividend. For any Preferred Shares that are not converted on the Conversion Event Date, the rate of PIK Dividend on these unconverted Preferred Shares will automatically increase from </font><font style="font-family:inherit;font-size:10pt;">$12.00</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$24.00</font><font style="font-family:inherit;font-size:10pt;"> per Preferred Share per month.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Voting Rights</font><font style="font-family:inherit;font-size:10pt;">. The Preferred Shares do not have any voting rights except for certain protective voting rights defined in the A&R Certificate of Designation.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidation Rights. </font><font style="font-family:inherit;font-size:10pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of ZIOPHARM or a deemed liquidation event, as defined in the A&R Certificate of Designation, including a change of control or the sale, lease transfer or exclusive license of all or substantially all of ZIOPHARM's assets, the holders of the Preferred Shares shall be entitled to receive a portion of all funds to be distributed in proportion to the holders' proportionate share of ZIOPHARM's common stock on an as-converted to common stock basis (the "Series 1 Liquidation Amount"). For purposes of calculating the Series 1 Liquidation Amount, if such liquidation event occurs prior to the Conversion Event Date, each Preferred Share shall be deemed to be convertible into the number of shares of ZIOPHARM's common stock equal to (i) the stated value of each Preferred Share, divided by (ii) the volume weighted average price of ZIOPHARM's common stock for the </font><font style="font-family:inherit;font-size:10pt;">twenty</font><font style="font-family:inherit;font-size:10pt;"> day period ending on the date of the public announcement of the liquidation event. In addition, ZIOPHARM may elect to redeem the Preferred Shares in connection with or following a deemed liquidation event at a price per share equal to the Series 1 Liquidation Amount.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company elected the fair value option to account for its investment in ZIOPHARM preferred stock (the "investment in preferred stock"). The investment in preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Preferred Shares are not traded on a public exchange. The fair value of the investment in preferred stock was estimated using a probability-weighted expected return ("PWERM") model. The key inputs used in the PWERM model were (i) estimating the future returns for conversion of the Preferred Shares for both product approval and a change in control of ZIOPHARM (the "conversion events") using market data of the change in value for guideline companies as a result of these conversion events; (ii) estimating the expected date and likelihood of each conversion event; and (iii) discounting these estimated future returns using a discount rate for the Preferred Shares considering industry debt issuances originated by public funds and venture capital rates of return. There have been no significant changes in the fair value of the Preferred Shares during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. A significant change in unobservable inputs discussed above could result in a significant impact to the fair value of the Company's investment in preferred stock. The fair value of the Company's investment in preferred stock, including additional Preferred Shares received as dividends, is </font><font style="font-family:inherit;font-size:10pt;">$123,676</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company received </font><font style="font-family:inherit;font-size:10pt;">3,063</font><font style="font-family:inherit;font-size:10pt;"> shares of additional Preferred Shares and recognized </font><font style="font-family:inherit;font-size:10pt;">$3,676</font><font style="font-family:inherit;font-size:10pt;"> of dividend income in the accompanying consolidated statements of operations. The only change in the Level 3 investment during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> was this receipt of additional Preferred Shares arising from the dividend.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investment in Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company holds preferred stock received from one of its collaborators, ZIOPHARM Oncology, Inc. ("ZIOPHARM"), which may be converted to common stock upon the occurrence of certain events in the future (Note </font><font style="font-family:inherit;font-size:10pt;">7</font><font style="font-family:inherit;font-size:10pt;">). The Company elected the fair value option to account for its investment in preferred stock whereby the value of preferred stock is adjusted to fair value as of each reporting date and unrealized gains and losses are reported in the consolidated statement of operations. This investment is subject to fluctuation in the future due to, among other things, the likelihood and timing of conversion of the preferred stock into common stock, the volatility of ZIOPHARM's common stock, and changes in general economic and financial conditions of ZIOPHARM. The investment is classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell the investment nor expect it to be converted into shares of common stock within one year.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Until such time as the Company converts the instrument into common stock, the Company is entitled to a monthly dividend payable in additional shares of preferred stock and records dividend income based on the fair value of the preferred shares.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company and ZIOPHARM jointly entered into a license agreement with the University of Texas System Board of Regents on behalf of the University of Texas MD Anderson Cancer Center ("MD Anderson") whereby the Company received an exclusive license to certain research and development technologies owned and licensed by MD Anderson, including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies, as well as co-licenses and non-exclusive licenses to certain other related technologies. ZIOPHARM received access to these technologies pursuant to the terms of the Company's ECC with ZIOPHARM. The Company issued </font><font style="font-family:inherit;font-size:10pt;">2,100,085</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$59,579</font><font style="font-family:inherit;font-size:10pt;"> to MD Anderson as consideration, which is included in research and development expenses in the accompanying consolidated statement of operations for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Subject to certain exceptions, the license agreement expires on the last to occur of (i) the expiration of all patents licensed thereunder, or (ii) the twentieth anniversary of the date of the license agreement.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the license agreement, the Company, ZIOPHARM, and MD Anderson entered into a research and development agreement which governs certain operational activities between the parties and pursuant to which ZIOPHARM provides funding for certain research and development activities of MD Anderson for a period of </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">, in an amount between </font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> per year. The Company and ZIOPHARM reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies.</font></div></div>

EX-101.SCH 7 xon-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2112100 - Disclosure - Collaboration and Licensing Revenue link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Collaboration and Licensing Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Collaboration and Licensing Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2126100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2426404 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2426402 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2426403 - Disclosure - Commitments and Contingencies - Operating Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2326301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Shareholders' and Total Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Goodwill and Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2420404 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Goodwill and Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Investment in Preferred Stock link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Investment in Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Investments in Joint Ventures link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Investments in Joint Ventures - EnviroFlight - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Investments in Joint Ventures - OvaXon - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Investments in Joint Ventures - S & I Ophthalmic - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 2425401 - Disclosure - License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Lines of Credit and Long Term Debt link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2421404 - Disclosure - Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2421405 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2421403 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Long Term Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - Lines of Credit and Long Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Mergers and Acquisitions link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - Mergers and Acquisitions - 2015 Acquisitions - Pro Forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Mergers and Acquisitions - ActoGeniX - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Mergers and Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Mergers and Acquisitions - Fair Value of Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Mergers and Acquisitions - Okanagan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Mergers and Acquisitions - Oxitec - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Mergers and Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2428403 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Property, Plant and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Property, Plant and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2427401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - Share-Based Payments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2424404 - Disclosure - Share-Based Payments - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Shareholders' Equity - Dividend to Shareholders (Details) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Short-term and Long-term Investments link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term and Long-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Short-term and Long-term Investments - Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Short-term and Long-term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2429401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2129100 - Disclosure - Subsequent Events Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies - Summarized Unaudited Financial Information for the Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies - Summarized Unaudited Financial Information for the Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 xon-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 xon-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 xon-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Financial Position [Abstract] Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] ActoGeniX NV ActoGeniX NV [Member] ActoGeniX NV [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, general and administrative Selling, General and Administrative Expenses [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Percentage of outstanding common stock acquired Business Acquisition, Percentage of Voting Interests Acquired Consideration transferred, shares issued or issuable Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Cash Payments to Acquire Businesses, Gross Consideration transferred Business Combination, Consideration Transferred Expected useful life of intangible asset Finite-Lived Intangible Asset, Useful Life Acquisition related costs Business Combination, Acquisition Related Costs Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] U.S. government debt securities US Government Debt Securities [Member] Equity securities Equity Securities [Member] Preferred stock Preferred Stock [Member] Other Other Financial Assets [Member] Other Financial Assets [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets Assets, Fair Value Disclosure [Abstract] Fair value of financial assets measured at fair value on a recurring basis Assets, Fair Value Disclosure Mergers and Acquisitions Mergers, Acquisitions and Dispositions Disclosures [Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Total Intrexon Shareholders' Equity Parent [Member] Noncontrolling Interests Noncontrolling Interest [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balances (in shares) Balances Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Exercises of stock options and warrants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercises of stock options and warrants Stock Issued During Period, Value, Stock Options Exercised Shares issued as payment for services (in shares) Stock Issued During Period, Shares, Issued for Services Shares issued as payment for services Stock Issued During Period, Value, Issued for Services Shares issued in asset acquisition (in shares) Stock Issued During Period, Shares, Purchase of Assets Shares issued in asset acquisition Stock Issued During Period, Value, Purchase of Assets Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Balances (in shares) Balances Accounting Policies [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Oragenics Oragenics [Member] Oragenics, Inc. Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Company's ownership percentage Equity Method Investment, Ownership Percentage Unrealized appreciation (depreciation) in fair value of equity securities Unrealized Gain (Loss) on Investments Debt Disclosure [Abstract] Lines of Credit and Long Term Debt Debt Disclosure [Text Block] Schedule of Long Term Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Future Maturities of Long Term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Investment in Preferred Stock [Abstract] Investment in Preferred Stock [Abstract] Schedule of Investments [Table] Schedule of Investments [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] ZIOPHARM Oncology, Inc. Ziopharm [Member] ZIOPHARM Oncology, Inc. Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Other Contractual Payments Other Contractual Payments [Member] Other Contractual Payments [Member] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Upfront and Milestone Payments Upfront And Milestone Payments [Member] Upfront and milestone payments received as collaboration for the entity's collaborations Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Collaborative arrangement consideration received, number of preferred shares (in shares) Collaborative Arrangement Consideration Received Preferred Shares Number of shares of preferred stock of a collaborator received by the entity as consideration. Preferred shares, stated value (in usd per share) Preferred Stock, Par or Stated Value Per Share Threshold consecutive trading days, conversion of shares Convertible Stock, Threshold Consecutive Trading Days Convertible Stock, Threshold Consecutive Trading Days Preferred shares, conversion calculation, divisor (in usd per share) Preferred Stock Conversion Rate Divisor Divisor of calculation used to convert preferred shares into common stock. Preferred shares, dividend rate (in usd per share) Preferred Stock, Dividend Rate, Per-Dollar-Amount Preferred shares, dividend rate, for unconverted shares after conversion event (in usd per share) Preferred Stock, Dividend Rate, Per-Dollar-Amount, Unconverted Shares The amount per share used to calculate dividend payments on preferred stock for unconverted shares after a conversion event. Dividend income, number of preferred shares received (in shares) Preferred Stock Dividends, Shares Noncash dividend income on preferred shares Noncash Dividend Income Amount of dividend income included in net income that results in no cash flow. Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Foreign Countries Non-US [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Number of segments Number of Operating Segments Property, plant and equipment, net Property, Plant and Equipment, Net Revenues Revenues Commitments and Contingencies Disclosure [Abstract] Future Minimum Lease Payments Under Noncancelable Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill accumulated impairment losses Goodwill, Impaired, Accumulated Impairment Loss Amortization expense Amortization of Intangible Assets Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Licensing and patent infringement suit Licensing And Patent Infringement Suit [Member] Licensing And Patent Infringement Suit [Member] Hoffman v. Intrexon Corporation et al. and Gibrall v. Intrexon Corporation et al. Shareholder Class Action Lawsuits [Member] Shareholder Class Action Lawsuits [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] XY, LLC XY, LLC [Member] XY, LLC [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Damages awarded to (against) Trans Ova Litigation Settlement, Amount Cumulative payments for royalties and licenses Payments for Royalties Royalty payments not yet deposited Royalty Payments Undeposited The amount of cash paid for royalties that have not been deposited as of the reporting date. Litigation settlement expense Litigation Settlement, Expense Number of lawsuits Loss Contingency, New Claims Filed, Number Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Stock-Based Compensation Costs Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Stock Option Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Convertible Note and Warrants Convertible Note and Warrants [Member] Notes which are convertible into another security, usually common shares of the issuer with warrants attached. Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Assets Other Noncurrent Assets [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Third Security, LLC Third Security [Member] Third Security, LLC Fibrocell Science, Inc. Fibrocell [Member] Fibrocell Science, Inc. Oragenics, Inc. Related Parties, Aggregated Related Parties, Aggregated [Member] Related Parties, Aggregated [Member] Harvest Intrexon Enterprise Fund I, LP Harvest Intrexon Enterprise Fund I, LP [Member] Harvest Intrexon Enterprise Fund I, LP [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Maximum Maximum [Member] Other nonoperating income Other Nonoperating Income (Expense) [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Expense for services Professional and Contract Services Expense Initial term of services agreement Services Agreement Term Initial term of a services agreement. Payments to acquire convertible notes and warrants Payments to Acquire Convertible Notes and Warrants Amount of cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money and/or common stock at a future date as well as warrants to purchase additional common shares of the maker of the note. Maximum percentage of shares of future securities offerings of collaborative partners to which the entity is entitled to purchase Percentage Of Shares Entitled To Purchase Percentage of shares that the entity is entitled to purchase in securities offerings conducted by collaborator Common stock purchased from collaborative partners, shares Shares Purchased From Collaborative Partners Number of shares of common stock purchased from collaborator Price per share of common shares (usd per share) Shares Purchased Price Per Share Price per share of collaborator's common stock purchased Collaboration and licensing revenues Collaboration And Licensing Revenue Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use as well as revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration and licensing agreements. Management fees revenue Management Fees Revenue Goodwill Goodwill [Roll Forward] Beginning balance Goodwill Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Ending balance Investment [Axis] Investment [Axis] Investment [Domain] Investment [Domain] Equity Method Investments Equity Method Investments [Member] Current assets Equity Method Investment, Summarized Financial Information, Current Assets Non-current assets Equity Method Investment, Summarized Financial Information, Noncurrent Assets Total assets Equity Method Investment, Summarized Financial Information, Assets Current liabilities Equity Method Investment, Summarized Financial Information, Current Liabilities Net assets Equity Method Investment Summarized Financial Information Assets Liabilities Net Equity Method Investment Summarized Financial Information Assets Liabilities Net Revenues Equity Method Investment, Summarized Financial Information, Revenue Operating expenses Operating Expenses Operating loss Operating Income (Loss) Other Nonoperating Income (Expense) Net loss Equity Method Investment, Summarized Financial Information, Net Income (Loss) Organization, Consolidation and Presentation of Financial Statements [Abstract] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Genopaver, LLC Genopaver, LLC [Member] Genopaver, LLC [Member] Intrexon Energy Partners, LLC Intrexon Energy Partners [Member] Intrexon Energy Partners, LLC Persea Bio, LLC Persea Bio, LLC [Member] Persea Bio, LLC Ares Trading S.A. Ares Trading S.A. [Member] Ares Trading S.A., a subsidiary of Merck Serono S.A. [Member] Thrive Agrobiotics, Inc. Thrive Agrobiotics, Inc. [Member] Thrive Agrobiotics, Inc. [Member] Intrexon Energy Partners II Intrexon Energy Partners II, LLC [Member] Intrexon Energy Partners II, LLC [Member] Exotech Bio, Inc. Exotech Bio, Inc. [Member] Exotech Bio, Inc. [Member] Relieve Genetics, Inc. Relieve Genetics, Inc. [Member] Relieve Genetics, Inc. [Member] Intrexon T1D Partners, LLC Intrexon T1D Partners, LLC [Member] Intrexon T1D Partners, LLC [Member] AD Skincare, Inc. AD Skincare, Inc. [Member] AD Skincare, Inc. [Member] Genten Therapeutics, Inc. Genten Therapeutics, Inc. [Member] Genten Therapeutics, Inc. [Member] CRS Bio, Inc. CRS Bio, Inc. [Member] CRS Bio, Inc. [Member] Other Other Collaborations [Member] Aggregate of other collaborations not separately disclosed Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Deferred revenue Deferred Revenue Investments, Debt and Equity Securities [Abstract] Short-term and Long-term Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] EX-101.PRE 11 xon-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Oct. 31, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	XON
Entity Registrant Name	INTREXON CORP
Entity Central Index Key	0001356090
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		118,575,964

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 69,707	$ 135,782
Restricted cash	6,987	0
Short-term investments	166,839	102,528
Receivables
Trade, net	22,034	25,101
Related parties	16,159	23,597
Notes, net	1,505	601
Other	2,521	2,995
Inventory	21,880	26,563
Prepaid expenses and other	8,591	6,634
Total current assets	316,223	323,801
Long-term investments	44,122	105,447
Equity securities	39,432	83,653
Investment in preferred stock	123,676	0
Property, plant and equipment, net	54,429	42,739
Intangible assets, net	238,581	247,535
Goodwill	159,793	165,169
Investments in affiliates	25,847	9,977
Other assets	3,485	3,725
Total assets	1,005,588	982,046
Current liabilities
Accounts payable	7,866	4,967
Accrued compensation and benefits	11,011	19,050
Other accrued liabilities	16,353	7,949
Deferred revenue	54,937	35,366
Lines of credit	549	561
Current portion of long term debt	471	930
Current portion of deferred consideration	8,723	6,931
Related party payables	611	150
Total current liabilities	100,521	75,904
Long term debt, net of current portion	7,950	7,598
Deferred consideration, net of current portion	0	8,698
Deferred revenue, net of current portion	267,460	162,363
Deferred tax liabilities	18,060	21,802
Other long term liabilities	3,177	795
Total liabilities	397,168	277,160
Commitments and contingencies (Note 17)
Total equity
Common stock, no par value, 200,000,000 shares authorized as of September 30, 2016 and December 31, 2015; 118,446,717 and 116,658,886 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	0	0
Additional paid-in capital	1,310,979	1,249,559
Accumulated deficit	(685,204)	(542,729)
Accumulated other comprehensive loss	(25,302)	(12,752)
Total Intrexon shareholders' equity	600,473	694,078
Noncontrolling interests	7,947	10,808
Total equity	608,420	704,886
Total liabilities and total equity	$ 1,005,588	$ 982,046

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - shares	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	118,446,717	116,658,886
Common stock, shares outstanding	118,446,717	116,658,886

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues
Collaboration and licensing revenues	$ 30,590	$ 34,726	$ 82,144	$ 66,690
Product revenues	9,260	9,446	28,699	32,645
Service revenues	8,706	8,945	33,298	32,157
Other revenues	429	250	783	615
Total revenues	48,985	53,367	144,924	132,107
Operating Expenses
Cost of products	9,156	11,215	29,471	31,654
Cost of services	5,803	5,451	17,807	17,316
Research and development	29,035	21,598	83,266	121,286
Selling, general and administrative	33,812	23,019	106,956	74,320
Total operating expenses	77,806	61,283	237,500	244,576
Operating loss	(28,821)	(7,916)	(92,576)	(112,469)
Other Income (Expense), Net
Unrealized and realized appreciation (depreciation) in fair value of equity securities	412	(30,453)	(45,388)	64,392
Interest expense	(227)	(310)	(759)	(1,012)
Interest and dividend income	4,494	567	5,817	1,211
Other income (expense), net	(32)	589	1,205	530
Total other income (expense), net	4,647	(29,607)	(39,125)	65,121
Equity in net loss of affiliates	(6,255)	(2,429)	(16,951)	(6,565)
Loss before income taxes	(30,429)	(39,952)	(148,652)	(53,913)
Income tax benefit (expense)	418	923	3,290	(806)
Net loss	(30,011)	(39,029)	(145,362)	(54,719)
Net loss attributable to the noncontrolling interests	1,029	816	2,887	2,940
Net loss attributable to Intrexon	$ (28,982)	$ (38,213)	$ (142,475)	$ (51,779)
Net loss attributable to Intrexon per share, basic and diluted (in usd per share)	$ (0.24)	$ (0.34)	$ (1.21)	$ (0.47)
Weighted average shares outstanding, basic and diluted	118,346,782	112,244,129	117,785,160	109,244,641

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (30,011)	$ (39,029)	$ (145,362)	$ (54,719)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	(151)	230	588	249
Foreign currency translation adjustments	(3,495)	(3,102)	(13,167)	(5,374)
Comprehensive loss	(33,657)	(41,901)	(157,941)	(59,844)
Comprehensive loss attributable to the noncontrolling interests	1,024	778	2,916	2,874
Comprehensive loss attributable to Intrexon	$ (32,633)	$ (41,123)	$ (155,025)	$ (56,970)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Shareholders' and Total Equity - 9 months ended Sep. 30, 2016 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total Intrexon Shareholders' Equity	Noncontrolling Interests
Balances (in shares) at Dec. 31, 2015	116,658,886	116,658,886
Balances at Dec. 31, 2015	$ 704,886	$ 0	$ 1,249,559	$ (12,752)	$ (542,729)	$ 694,078	$ 10,808
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	30,610		30,555			30,555	55
Exercises of stock options and warrants (in shares)		1,322,843
Exercises of stock options and warrants	18,180		18,180			18,180
Shares issued as payment for services (in shares)		328,648
Shares issued as payment for services	8,284		8,284			8,284
Shares issued in asset acquisition (in shares)		136,340
Shares issued in asset acquisition	4,401		4,401			4,401
Net loss	(145,362)				(142,475)	(142,475)	(2,887)
Other comprehensive loss	$ (12,579)			(12,550)		(12,550)	(29)
Balances (in shares) at Sep. 30, 2016	118,446,717	118,446,717
Balances at Sep. 30, 2016	$ 608,420	$ 0	$ 1,310,979	$ (25,302)	$ (685,204)	$ 600,473	$ 7,947

XML 18 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities
Net loss	$ (145,362)	$ (54,719)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	17,657	12,202
Loss on disposal of property, plant and equipment	297	519
Unrealized and realized (appreciation) depreciation on equity securities	45,388	(64,392)
Noncash dividend income	(3,676)	0
Amortization of discount/premium on investments	862	298
Equity in net loss of affiliates	16,951	6,565
Stock-based compensation expense	30,631	26,524
Shares issued as payment for services	8,284	480
Shares issued as consideration for license agreement	0	59,579
Provision for bad debts	1,609	1,562
Deferred income taxes	(2,967)	374
Other noncash items	1,259	305
Changes in operating assets and liabilities:
Restricted cash	(6,987)	0
Receivables:
Trade	2,118	(12,014)
Related parties	7,438	(11,182)
Notes	(42)	1
Other	381	6,390
Inventory	4,683	3,451
Prepaid expenses and other	(985)	(4,005)
Other assets	2,134	(3,817)
Accounts payable	2,901	(3,560)
Accrued compensation and benefits	(8,001)	5,895
Other accrued liabilities	7,771	1,323
Deferred revenue	(14,099)	52,400
Deferred consideration	(630)	(943)
Related party payables	479	(67)
Other long term liabilities	126	168
Net cash provided by (used in) operating activities	(31,780)	23,337
Cash flows from investing activities
Purchases of investments	(75,246)	(181,572)
Maturities of investments	71,987	70,000
Purchases of equity securities and warrants	(2,308)	(17,080)
Acquisitions of businesses, net of cash received	0	(114,480)
Acquisition of noncontrolling interest	0	(1,566)
Investments in affiliates	(9,415)	(4,699)
Cash paid in asset acquisition	(7,244)	0
Purchases of property, plant and equipment	(20,197)	(9,841)
Proceeds from sale of property, plant and equipment	243	420
Issuances of notes receivable	(2,964)	0
Proceeds from notes receivable	0	1,500
Net cash used in investing activities	(45,144)	(257,318)
Cash flows from financing activities
Proceeds from issuance of shares in public offerings, net of issuance costs	0	328,234
Advances from lines of credit	2,308	13,719
Repayments of advances from lines of credit	(2,320)	(15,517)
Proceeds from long term debt	547	81
Payments of long term debt	(848)	(1,032)
Payments of deferred consideration	(6,705)	(6,252)
Proceeds from stock option exercises	18,180	12,208
Net cash provided by financing activities	11,162	331,441
Effect of exchange rate changes on cash and cash equivalents	(313)	507
Net increase (decrease) in cash and cash equivalents	(66,075)	97,967
Cash and cash equivalents
Beginning of period	135,782	27,466
End of period	69,707	125,433
Supplemental disclosure of cash flow information
Cash paid during the period for interest	875	1,119
Cash paid during the period for income taxes	0	1,165
Significant noncash financing and investing activities
Note receivable as consideration for collaboration agreement	0	5,000
Stock received as consideration for collaboration agreements	18,766	4,667
Preferred stock received as consideration for collaboration amendments	120,000	0
Stock issued in business combinations	0	126,863
Stock issued to acquire noncontrolling interest	0	9,412
Stock issued in asset acquisition	4,401	0
Contingent consideration assumed in asset acquisition	3,660	0
Noncash dividend to shareholders	0	172,419
Deferred consideration payable related to acquisition	0	11,440
Purchases of equipment included in accounts payable and other accrued liabilities	$ 926	$ 533

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization	9 Months Ended
Organization	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Intrexon Corporation ("Intrexon"), a Virginia corporation, forms collaborations to create biologically based products and processes using synthetic biology. Intrexon's primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. There have been no commercialized products derived from Intrexon's collaborations to date. Trans Ova Genetics, L.C. ("Trans Ova"), a provider of bovine reproductive technologies and other genetic processes to cattle breeders and producers, is a wholly owned subsidiary of Intrexon with primary operations in Iowa, Maryland, Missouri, Oklahoma, and Texas. Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil. Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, is a wholly owned subsidiary of IPHI with primary operations in Canada. Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington. ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, and Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, are wholly owned subsidiaries with primary operations in Texas and Iowa, respectively. As of September 30, 2016, Intrexon owned approximately 63% of AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture, and approximately 51% of Biological & Popular Culture, Inc. ("BioPop"), a company developing artwork, children's toys and novelty goods that are derived from living organisms or enabled by synthetic biology. Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company."

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.

Restricted Cash

Restricted cash represents funds deposited with the U.S. Treasury, as required by a court decision resulting from litigation against Trans Ova (Note 17).

Investment in Preferred Stock

Equity Method Investments



	September 30, 2016		December 31, 2015
Current assets	$	81,049	$	28,123
Non-current assets	10,992		1,539
Total assets	92,041		29,662
Current liabilities	8,325		6,274
Net assets	$	83,716	$	23,388



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Revenues	$	65		$	330		$	394		$	1,480
Operating expenses	18,363			8,687			50,406			118,180
Operating loss	(18,298		)	(8,357		)	(50,012		)	(116,700		)
Other	75			(34		)	1,502			(31		)
Net loss	$	(18,223	)	$	(8,391	)	$	(48,510	)	$	(116,731	)

Variable Interest Entities

Net Loss per Share

Segment Information

Use of Estimates

Recently Issued Accounting Pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

Mergers and Acquisitions

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Mergers and Acquisitions

Oxitec Acquisition

The fair value of the total consideration transferred was $146,394. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:



Cash	$	90,199
Common shares	56,195
	$	146,394



Cash	$	3,780
Trade receivables	125
Other receivables	7,395
Prepaid expenses and other	121
Property, plant, and equipment	1,198
Intangible assets	96,854
Total assets acquired	109,473
Accounts payable	1,187
Accrued compensation and benefits	246
Other accrued liabilities	210
Deferred revenue	120
Deferred tax liabilities	12,584
Total liabilities assumed	14,347
Net assets acquired	95,126
Goodwill	51,268
Total consideration	$	146,394

Okanagan Acquisition

The fair value of the total consideration transferred was $40,933. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	10,000
Common shares	30,933
	$	40,933



Cash	$	58
Trade receivables	16
Other receivables	49
Property, plant, and equipment	32
Intangible assets	36,500
Total assets acquired	36,655
Accounts payable	181
Deferred revenue	181
Deferred tax liabilities	8,847
Total liabilities assumed	9,209
Net assets acquired	27,446
Goodwill	13,487
Total consideration	$	40,933

ActoGeniX Acquisition

The fair value of the total consideration transferred was $72,474. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	32,739
Common shares	39,735
	$	72,474



Cash	$	3,180
Other receivables	305
Prepaid expenses and other	31
Property, plant and equipment	209
Intangible assets	68,100
Other non-current assets	23
Total assets acquired	71,848
Accounts payable	230
Accrued compensation and benefits	196
Other accrued liabilities	253
Deferred revenue	732
Deferred tax liabilities	612
Total liabilities assumed	2,023
Net assets acquired	69,825
Goodwill	2,649
Total consideration	$	72,474

Unaudited Condensed Pro Forma Financial Information



	Three Months Ended September 30, 2015			Nine Months Ended September 30, 2015
	Pro Forma
Revenues	$	53,754		$	133,060
Loss before income taxes	(43,979		)	(66,686		)
Net loss	(43,057		)	(66,319		)
Net loss attributable to the noncontrolling interests	816			2,940
Net loss attributable to Intrexon	(42,241		)	(63,379		)

XML 22 R11.htm IDEA: XBRL DOCUMENT

Investments in Joint Ventures	9 Months Ended
Investments in Joint Ventures	Sep. 30, 2016
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures Intrexon T1D Partners In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a joint venture formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners which provides the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50%. Intrexon has committed to make capital contributions of up to $5,000, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, have committed to make additional capital contributions of up to $5,000, at the request of Intrexon T1D Partners' board of managers (the "Intrexon T1D Partners Board") and subject to certain limitations. As of September 30, 2016, the Company's remaining commitment was $3,650. Intrexon T1D Partners is governed by the Intrexon T1D Partners Board, which has five members. Two members of the Intrexon T1D Partners Board are designated by the Company and three members are designated by a majority of the T1D Investors. The Company and the T1D Investors have the right, but not the obligation, to make additional capital contributions above these limits when and if solicited by the Intrexon T1D Partners Board. The Company's investment in Intrexon T1D Partners was $1,078 as of September 30, 2016 and is included in investments in affiliates in the accompanying consolidated balance sheet. EnviroFlight In February 2016, the Company entered into a series of transactions involving EnviroFlight, LLC ("Old EnviroFlight"), Darling Ingredients Inc. ("Darling") and a newly formed venture between the Company and Darling ("New EnviroFlight"). The Company determined that the series of integrated transactions to acquire substantially all of the assets of Old EnviroFlight for cash, common stock, and contingent consideration should be accounted for as a single transaction, which constituted a business, and considered New EnviroFlight to be the accounting acquirer pursuant to Accounting Standards Codification ("ASC") 805, Business Combinations. Consideration paid to Old EnviroFlight was $4,244 in cash, 136,340 shares of the Company's common stock valued at $4,401 and contingent consideration estimated at $3,660. Contemporaneously, all the assets acquired from Old EnviroFlight, with the exception of certain developed technology, and $3,000 of cash were contributed to New EnviroFlight in exchange for a non-controlling, 50% membership interest in New EnviroFlight. The Company's contributions to New EnviroFlight included an exclusive license to the developed technology that was retained by the Company. Darling received the remaining 50% membership interest in New EnviroFlight as consideration for terminating rights previously held in the developed technology with Old EnviroFlight. New EnviroFlight was formed to generate high-nutrition, low environmental impact animal and fish feed, as well as fertilizer products. The Company and Darling as members have each agreed to make additional capital contributions of up to $5,000 to fund ongoing operations of New EnviroFlight. All of the employees of Old EnviroFlight became employees of New EnviroFlight. The Company determined that its investment in New EnviroFlight should be accounted for using the equity method of accounting. The Company recorded an estimated fair value of $5,425 for its investment in New EnviroFlight and $9,880 for the retained developed technology intangible asset. The developed technology will be amortized over a period of twenty-one years. The contingent consideration liability payable to the members of Old EnviroFlight is considered a freestanding financial instrument in accordance with ASC 480, Distinguishing Liabilities and Equity, and will be recorded at fair value each reporting period. The value of this liability was estimated at $3,839 as of September 30, 2016. New EnviroFlight met a regulatory milestone, as defined in the asset purchase agreement, and the members of Old EnviroFlight received a portion of the contingent consideration consisting of 59,337 shares of the Company's common stock valued at $1,583 in October 2016. The members of Old EnviroFlight may receive up to $4,000 of additional shares of the Company's common stock if certain commercial milestones are met prior to February 2019. The Company's investment in New EnviroFlight was $4,611 as of September 30, 2016 and is included in investments in affiliates in the accompanying consolidated balance sheet. Intrexon Energy Partners II In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a joint venture formed to utilize the Company's natural gas bioconversion platform for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II which provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Intrexon has committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $1,591 and $2,000 as of September 30, 2016 and December 31, 2015, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets. Intrexon Energy Partners In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's gas-to-liquid bioconversion platform for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Intrexon has committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of September 30, 2016, the Company's remaining commitment was $12,367. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(627) and $(1,270) as of September 30, 2016 and December 31, 2015, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets. OvaXon In December 2013, the Company and OvaScience, Inc. ("OvaScience"), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, entered into a Limited Liability Company Agreement ("OvaXon LLC Agreement") to form OvaXon, LLC ("OvaXon"), a joint venture to create new applications for improving human and animal health. Both the Company and OvaScience made an initial capital contribution of $1,500 in January 2014 for a 50% membership interest in OvaXon. OvaXon is governed by the OvaXon board of managers ("OvaXon Board") which has four members, two each from the Company and OvaScience. In cases in which the OvaXon Board determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations, each of the Company and OvaScience has the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement. The Company's investment in OvaXon was $435 and $(144) as of September 30, 2016 and December 31, 2015, respectively, and is included in investments in affiliates and other accrued liabilities, respectively, in the accompanying consolidated balance sheets. S & I Ophthalmic In September 2013, the Company entered into a Limited Liability Company Agreement ("Sun LLC Agreement") with Caraco Pharmaceutical Laboratories, Ltd. ("Sun Pharmaceutical Subsidiary"), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceutical"), an international specialty pharmaceutical company focused on chronic diseases, to form S & I Ophthalmic, LLC ("S & I Ophthalmic"). The Sun LLC Agreement governs the affairs and the conduct of business of S & I Ophthalmic. S & I Ophthalmic leverages experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of $5,000 in October 2013 for a 50% membership interest in S & I Ophthalmic. S & I Ophthalmic is governed by a board of managers ("S & I Ophthalmic Board") which has four members, two each from the Company and Sun Pharmaceutical Subsidiary. In cases in which the S & I Ophthalmic Board determines that additional capital contributions are necessary in order for S & I Ophthalmic to conduct business and comply with its obligations, each of the Company and Sun Pharmaceutical Subsidiary has committed to making additional capital contributions to S & I Ophthalmic subject to certain limits defined in the agreement. Each has the right, but not the obligation, to make additional capital contributions above the defined limits when and if solicited by the S & I Ophthalmic Board. In 2015, both the Company and Sun Pharmaceutical Subsidiary made subsequent capital contributions of $5,000. Beginning on the seventh anniversary of the effective date of the Sun LLC Agreement, and upon the second anniversary thereafter, the Company, as well as Sun Pharmaceutical Subsidiary, may make a cash offer to purchase all of the other party's interest in S & I Ophthalmic. Upon receipt of such an offer, the other party must either agree to tender its interests at the offered price or submit a counteroffer at a price higher than the original offer. Such offer and counteroffer may continue until one party agrees to the other's price. The Company's investment in S & I Ophthalmic was $3,737 and $6,379 as of September 30, 2016 and December 31, 2015, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Revenue

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration and Licensing Revenue



	Three Months Ended September 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	4,843	$	5,586	$	10,429
Oragenics, Inc.	262		294		556
Fibrocell Science, Inc.	604		563		1,167
Genopaver, LLC	68		1,625		1,693
S & I Ophthalmic, LLC	—		2,782		2,782
OvaXon, LLC	—		709		709
Intrexon Energy Partners, LLC	625		4,230		4,855
Persea Bio, LLC	125		208		333
Ares Trading S.A.	1,597		719		2,316
Thrive Agrobiotics, Inc.	46		379		425
Intrexon Energy Partners II, LLC	500		372		872
Exotech Bio, Inc.	139		82		221
Relieve Genetics, Inc.	120		342		462
Intrexon T1D Partners, LLC	276		511		787
AD Skincare, Inc.	120		65		185
Other	895		1,903		2,798
Total	$	10,220	$	20,370	$	30,590



	Three Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	645	$	4,006	$	4,651
Oragenics, Inc.	4,868		332		5,200
Fibrocell Science, Inc.	4,823		1,317		6,140
Genopaver, LLC	68		993		1,061
S & I Ophthalmic, LLC	—		1,193		1,193
OvaXon, LLC	—		549		549
Intrexon Energy Partners, LLC	625		3,185		3,810
Persea Bio, LLC	125		297		422
Ares Trading S.A.	1,597		260		1,857
Other	7,841		2,002		9,843
Total	$	20,592	$	14,134	$	34,726



	Nine Months Ended September 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	6,687	$	17,693	$	24,380
Oragenics, Inc.	786		1,083		1,869
Fibrocell Science, Inc.	1,814		2,604		4,418
Genopaver, LLC	205		4,703		4,908
S & I Ophthalmic, LLC	—		6,326		6,326
OvaXon, LLC	—		2,211		2,211
Intrexon Energy Partners, LLC	1,875		11,180		13,055
Persea Bio, LLC	375		613		988
Ares Trading S.A.	4,791		2,148		6,939
Thrive Agrobiotics, Inc.	138		1,171		1,309
Intrexon Energy Partners II, LLC	1,500		816		2,316
Exotech Bio, Inc.	278		82		360
Relieve Genetics, Inc.	240		572		812
Intrexon T1D Partners, LLC	554		543		1,097
AD Skincare, Inc.	120		65		185
Other	4,684		6,287		10,971
Total	$	24,047	$	58,097	$	82,144



	Nine Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	1,933	$	11,769	$	13,702
Oragenics, Inc.	5,437		408		5,845
Fibrocell Science, Inc.	5,719		4,500		10,219
Genopaver, LLC	205		2,460		2,665
S & I Ophthalmic, LLC	—		2,838		2,838
OvaXon, LLC	—		1,855		1,855
Intrexon Energy Partners, LLC	1,875		8,101		9,976
Persea Bio, LLC	375		553		928
Ares Trading S.A.	2,336		260		2,596
Other	9,446		6,620		16,066
Total	$	27,326	$	39,364	$	66,690

Exotech Bio Collaboration

In March 2016, the Company entered into an ECC with Exotech Bio, Inc. ("Exotech Bio"), an affiliate of Harvest and a related party. Exotech Bio was formed for the purpose of entering into the ECC and developing and commercializing products using exosomes carrying a RNA payload designed to kill, suppress, or render immune-visible a cancer cell. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Exotech Bio valued at $5,000 as upfront consideration. The Company is also entitled to up to $52,500 of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. Exotech Bio will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. Exotech Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Exotech Bio upon 90 days written notice to the Company.

Relieve Genetics Collaboration

Intrexon T1D Partners Collaboration

AD Skincare Collaboration

ZIOPHARM Collaborations

Genten Therapeutics Collaboration

CRS Bio Collaboration

Deferred Revenue



	September 30, 2016		December 31, 2015
Upfront and milestone payments	$	309,126	$	181,331
Prepaid research and development services	7,057		10,938
Prepaid product and service revenues	5,594		4,759
Other	620		701
Total	$	322,397	$	197,729
Current portion of deferred revenue	$	54,937	$	35,366
Long-term portion of deferred revenue	267,460		162,363
Total	$	322,397	$	197,729

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement:



	September 30, 2016		December 31, 2015
ZIOPHARM Oncology, Inc.	$	143,651	$	30,338
Oragenics, Inc.	8,027		8,813
Fibrocell Science, Inc.	19,631		21,445
Genopaver, LLC	2,045		2,250
Intrexon Energy Partners, LLC	18,750		20,625
Persea Bio, LLC	4,125		4,500
Ares Trading S.A.	48,776		53,567
Thrive Agrobiotics, Inc.	1,483		1,621
Intrexon Energy Partners II, LLC	16,333		17,833
Exotech Bio, Inc.	4,722		—
Relieve Genetics, Inc.	4,093		—
Intrexon T1D Partners, LLC	9,383		—
AD Skincare, Inc.	4,213		—
Genten Therapeutics, Inc.	4,523		—
CRS Bio, Inc.	2,111		—
Other	17,260		20,339
Total	$	309,126	$	181,331

XML 24 R13.htm IDEA: XBRL DOCUMENT

Short-term and Long-term Investments

9 Months Ended

Sep. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Short-term and Long-term Investments



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	210,620	$	79	$	(10	)	$	210,689
Certificates of deposit	272		—		—			272
Total	$	210,892	$	79	$	(10	)	$	210,961

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2015:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	208,223	$	21	$	(540	)	$	207,704
Certificates of deposit	271		—		—			271
Total	$	208,494	$	21	$	(540	)	$	207,975

The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2016 was:



Due within one year	$	166,839
After one year through two years	44,122
Total	$	210,961

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

Investment in Preferred Stock	9 Months Ended
Investment in Preferred Stock	Sep. 30, 2016
Investment in Preferred Stock [Abstract]
Investment In Preferred Stock	Investment in Preferred Stock In June 2016, the Company received 100,000 shares of ZIOPHARM's Series 1 Preferred Stock (the "Preferred Shares"), with a per share stated value of $1,200, as consideration for amending their two previously existing ECC agreements (Note 5). A summary of the terms of the Preferred Shares are as follows. Conversion. The Preferred Shares shall automatically convert into shares of ZIOPHARM common stock upon the date the first approval in the United States of (i) a ZIOPHARM product, as defined in and developed under one of the ECC agreements, or (ii) a product, as defined and developed under the License and Collaboration Agreement with Ares Trading S.A., a subsidiary of the biopharmaceutical business of Merck KGaA, and ZIOPHARM, is publicly announced (the "Conversion Event Date"). The Preferred Shares shall convert into a number of shares of ZIOPHARM common stock equal to the stated value of such Preferred Share, divided by the greater of: (i) the volume weighted average closing price of ZIOPHARM's common stock over the twenty trading days ending on the Conversion Event Date or (ii) $1.00. The number of converted shares is subject to certain limitations defined in the amended and restated Certificate of Designation, Preferences, and Rights of Series 1 Preferred Stock (the "A&R Certificate of Designation"). Dividend Rights. The Company shall receive a monthly dividend, payable in additional Preferred Shares, equal to $12.00 per Preferred Share held per month divided by the stated value of the Preferred Shares, which is referred to as the PIK Dividend. For any Preferred Shares that are not converted on the Conversion Event Date, the rate of PIK Dividend on these unconverted Preferred Shares will automatically increase from $12.00 to $24.00 per Preferred Share per month. Voting Rights. The Preferred Shares do not have any voting rights except for certain protective voting rights defined in the A&R Certificate of Designation. Liquidation Rights. In the event of any voluntary or involuntary liquidation, dissolution or winding up of ZIOPHARM or a deemed liquidation event, as defined in the A&R Certificate of Designation, including a change of control or the sale, lease transfer or exclusive license of all or substantially all of ZIOPHARM's assets, the holders of the Preferred Shares shall be entitled to receive a portion of all funds to be distributed in proportion to the holders' proportionate share of ZIOPHARM's common stock on an as-converted to common stock basis (the "Series 1 Liquidation Amount"). For purposes of calculating the Series 1 Liquidation Amount, if such liquidation event occurs prior to the Conversion Event Date, each Preferred Share shall be deemed to be convertible into the number of shares of ZIOPHARM's common stock equal to (i) the stated value of each Preferred Share, divided by (ii) the volume weighted average price of ZIOPHARM's common stock for the twenty day period ending on the date of the public announcement of the liquidation event. In addition, ZIOPHARM may elect to redeem the Preferred Shares in connection with or following a deemed liquidation event at a price per share equal to the Series 1 Liquidation Amount. The Company elected the fair value option to account for its investment in ZIOPHARM preferred stock (the "investment in preferred stock"). The investment in preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Preferred Shares are not traded on a public exchange. The fair value of the investment in preferred stock was estimated using a probability-weighted expected return ("PWERM") model. The key inputs used in the PWERM model were (i) estimating the future returns for conversion of the Preferred Shares for both product approval and a change in control of ZIOPHARM (the "conversion events") using market data of the change in value for guideline companies as a result of these conversion events; (ii) estimating the expected date and likelihood of each conversion event; and (iii) discounting these estimated future returns using a discount rate for the Preferred Shares considering industry debt issuances originated by public funds and venture capital rates of return. There have been no significant changes in the fair value of the Preferred Shares during the three months ended September 30, 2016. A significant change in unobservable inputs discussed above could result in a significant impact to the fair value of the Company's investment in preferred stock. The fair value of the Company's investment in preferred stock, including additional Preferred Shares received as dividends, is $123,676 as of September 30, 2016. During the three and nine months ended September 30, 2016, the Company received 3,063 shares of additional Preferred Shares and recognized $3,676 of dividend income in the accompanying consolidated statements of operations. The only change in the Level 3 investment during the three months ended September 30, 2016 was this receipt of additional Preferred Shares arising from the dividend.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		September 30, 2016
Assets
U.S. government debt securities	$	—	$	210,689	$	—	$	210,689
Equity securities	31,245		8,187		—		39,432
Preferred stock	—		—		123,676		123,676
Other	—		2,296		—		2,296
Total	$	31,245	$	221,172	$	123,676	$	376,093



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2015
Assets
U.S. government debt securities	$	—	$	207,704	$	—	$	207,704
Equity securities	65,850		17,803		—		83,653
Other	—		405		—		405
Total	$	65,850	$	225,912	$	—	$	291,762

There were no transfers between levels of the fair value hierarchy in the nine months ended September 30, 2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Inventory

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Inventory

Inventory consists of the following:



	September 30, 2016		December 31, 2015
Supplies, semen and embryos	$	1,278	$	1,402
Work in process	5,831		6,290
Livestock	12,588		16,907
Feed	2,183		1,964
Total inventory	$	21,880	$	26,563

XML 28 R17.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net

9 Months Ended

Sep. 30, 2016

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, Net

Property, plant and equipment consist of the following:



	September 30, 2016			December 31, 2015
Land and land improvements	$	11,276		$	9,119
Buildings and building improvements	7,965			7,520
Furniture and fixtures	1,234			1,283
Equipment	41,343			36,016
Leasehold improvements	10,479			6,888
Computer hardware and software	6,912			5,960
Construction and other assets in progress	7,523			2,193
	86,732			68,979
Less: Accumulated depreciation and amortization	(32,303		)	(26,240		)
Property, plant and equipment, net	$	54,429		$	42,739

XML 29 R18.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets, Net

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, Net

The changes in the carrying amount of goodwill for the nine months ended September 30, 2016 are as follows:



Balance at December 31, 2015	$	165,169
Foreign currency translation adjustments	(5,376		)
Balance at September 30, 2016	$	159,793

No goodwill or accumulated impairment losses existed as of September 30, 2016 and December 31, 2015.

Intangible assets consist of the following at September 30, 2016:



	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Patents, related technologies and know-how	15.3	$	170,520	$	(26,596	)	$	143,924
Customer relationships	6.5	10,700		(4,189		)	6,511
Trademarks	9.3	6,800		(1,598		)	5,202
Covenant not to compete	2.0	395		(312		)	83
In-process research and development		82,861		—			82,861
Total		$	271,276	$	(32,695	)	$	238,581

Intangible assets consist of the following at December 31, 2015:



	Gross Carrying Amount		Accumulated Amortization			Net
Patents, related technologies and know-how	$	157,411	$	(17,775	)	$	139,636
Customer relationships	10,700		(2,739		)	7,961
Trademarks	6,800		(1,018		)	5,782
Covenant not to compete	384		(160		)	224
In-process research and development	93,932		—			93,932
Total	$	269,227	$	(21,692	)	$	247,535

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Lines of Credit and Long Term Debt

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Lines of Credit and Long Term Debt

Lines of Credit

Long Term Debt

Long term debt consists of the following:



	September 30, 2016		December 31, 2015
Notes payable	$	5,769	$	6,477
Royalty-based financing	2,003		1,807
Other	649		244
Long term debt	8,421		8,528
Less current portion	471		930
Long term debt, less current portion	$	7,950	$	7,598

Future maturities of long term debt are as follows:



2016	$	168
2017	404
2018	549
2019	364
2020	335
2021	774
Thereafter	3,824
Total	$	6,418

The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the three and nine months ended September 30, 2016, the Company had U.S. taxable income of approximately $8,334 and U.S. taxable loss of approximately $9,346, respectively, for which no income tax benefit was recognized. For the three and nine months ended September 30, 2016, the Company recognized $110 and $323 of current foreign income tax benefit, respectively. For the three months ended September 30, 2015, the Company had U.S. taxable loss of approximately $15,865, which resulted in an income tax benefit of $318. For the nine months ended September 30, 2015, the Company had U.S. taxable income of approximately $22,935, which resulted in $459 of current income tax expense due to the corporate alternative minimum tax. For the three and nine months ended September 30, 2015, the Company recognized $27 of current foreign income tax benefit. For the three and nine months ended September 30, 2016, the Company recorded deferred tax benefit of $308 and $2,967, respectively. For the three and nine months ended September 30, 2015, the Company recorded deferred tax benefit of $578 and deferred tax expense of $374, respectively. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $18,060, are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. At September 30, 2016, the Company has loss carryforwards for U.S. federal income tax purposes of approximately $257,700 available to offset future taxable income and federal and state research and development tax credits of approximately $7,060, prior to consideration of annual limitations that may be imposed under Section 382. These carryforwards will begin to expire in 2022. Of these loss carryforwards, approximately $54,400 relates to benefits from stock compensation deductions that will be recorded as a component of paid-in capital when realized. The Company's direct foreign subsidiaries have foreign loss carryforwards of approximately $120,600, most of which do not expire.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Shareholders' Equity

Dividend to Shareholders

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	September 30, 2016			December 31, 2015
Unrealized gain (loss) on investments	$	69		$	(519	)
Foreign currency translation adjustments	(25,371		)	(12,233		)
Total accumulated other comprehensive loss	$	(25,302	)	$	(12,752	)

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Share-Based Payments

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Payments



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Cost of products	$	21	$	21	$	61	$	76
Cost of services	68		98		206		301
Research and development	2,236		2,234		6,979		6,141
Selling, general and administrative	8,467		6,032		23,385		20,006
Total	$	10,792	$	8,385	$	30,631	$	26,524

Intrexon Stock Option Plans

Stock option activity was as follows:



	Number of Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2015	11,043,528		$	32.66		8.49
Granted	4,384,860		29.42
Exercised	(1,162,843	)	(15.63		)
Forfeited	(2,127,334	)	(43.29		)
Expired	(34,804	)	(35.76		)
Balances at September 30, 2016	12,103,407		31.24			8.50
Exercisable at September 30, 2016	3,369,252		27.99			7.25
Vested and Expected to Vest at September 30, 2016(1)	10,177,058		30.99			8.37


(1)	The number of stock options expected to vest takes into account an estimate of expected forfeitures.

Intrexon currently uses authorized and unissued shares to satisfy share award exercises.

Other Plans

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 34 R23.htm IDEA: XBRL DOCUMENT

License Agreement	9 Months Ended
License Agreement	Sep. 30, 2016
License Agreement [Abstract]
License Agreement	License Agreement In January 2015, the Company and ZIOPHARM jointly entered into a license agreement with the University of Texas System Board of Regents on behalf of the University of Texas MD Anderson Cancer Center ("MD Anderson") whereby the Company received an exclusive license to certain research and development technologies owned and licensed by MD Anderson, including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies, as well as co-licenses and non-exclusive licenses to certain other related technologies. ZIOPHARM received access to these technologies pursuant to the terms of the Company's ECC with ZIOPHARM. The Company issued 2,100,085 shares of its common stock valued at $59,579 to MD Anderson as consideration, which is included in research and development expenses in the accompanying consolidated statement of operations for the nine months ended September 30, 2015. Subject to certain exceptions, the license agreement expires on the last to occur of (i) the expiration of all patents licensed thereunder, or (ii) the twentieth anniversary of the date of the license agreement. In connection with the license agreement, the Company, ZIOPHARM, and MD Anderson entered into a research and development agreement which governs certain operational activities between the parties and pursuant to which ZIOPHARM provides funding for certain research and development activities of MD Anderson for a period of three years, in an amount between $15,000 and $20,000 per year. The Company and ZIOPHARM reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies.

XML 35 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Operating Leases



2016	$	705
2017	6,362
2018	5,695
2019	5,434
2020	5,487
2021	4,888
Thereafter	20,179
Total	$	48,750

Contingencies

XML 36 R25.htm IDEA: XBRL DOCUMENT

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's CEO and Chairman of the Board of Directors of the Company is also the manager of Third Security. In November 2015, the independent members of Intrexon's Board of Directors, with the recommendation of the Audit Committee of the Board of Directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provides the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its CEO. As consideration for providing these services, Third Security is entitled to a fee of $800 per month to be paid in the form of fully vested shares of the Company's common stock. The number of shares of common stock is calculated based on the closing price of the Company's common stock on the 15th day of each month. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan (Note 15). The Services Agreement had a term of one year, can be terminated by the Company at any time, and may be extended only by agreement of the parties, including approval of a majority of the independent members of Intrexon's Board of Directors. In October 2016, the independent members of Intrexon's Board of Directors, with the recommendation of the Audit Committee of the Board of Directors, approved the extension of the Services Agreement through December 2016. For the three and nine months ended September 30, 2016, the Company issued 89,326 shares and 254,496 shares, respectively, with values of $2,132 and $6,542, respectively, to Third Security as payment for services pursuant to the Services Agreement. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf and the total expenses incurred by the Company under this arrangement was $156 and $142 for the three months ended September 30, 2016 and 2015, respectively, and $301 and $294 for the nine months ended September 30, 2016 and 2015, respectively. See also Note 15 regarding compensation arrangements between the Company and its CEO. Transactions with ECC Parties In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and which also are party to a collaboration with the Company are considered to be related parties. In September 2016, Fibrocell Science, Inc. ("Fibrocell"), one of the Company's collaborators, sold promissory notes convertible into shares of Fibrocell common stock ("convertible note") and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid $2,604 for a convertible note and warrants. As of September 30, 2016, the value of the convertible note and warrants totaled $1,990 and is included in other assets on the accompanying consolidated balance sheet. In conjunction with the ECC with Oragenics, the Company is entitled to, at its election, purchase up to 30% of securities offerings that may be conducted by Oragenics in the future, subject to certain conditions and limitations. In June 2016, the Company purchased 2,261,419 shares of Oragenics common stock at $0.52 per share. The Company recognized $26,688 and $31,740 of collaboration revenues from related parties in the three months ended September 30, 2016 and 2015, respectively, and $70,299 and $59,775 in the nine months ended September 30, 2016 and 2015, respectively. Other Related Parties In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development opportunities that the Company offers to Harvest. These are investment proposals that are suitable for pursuit by a start-up venture, characterized by the agreement as "start-up opportunities." For such start-up opportunities, the Company provides Harvest with exclusive rights of first-look and first negotiation. For any opportunities it decides to pursue, Harvest establishes new collaboration entities which enter into an ECC with the Company in a designated field. The terms of such ECCs are negotiated between the Company and Harvest. In addition, the agreement provides the Company the right to present to Harvest the opportunity to invest in other ventures, including investment opportunities with respect to the Company's existing collaborations. Any such opportunities are presented at the Company's discretion on a non-exclusive basis. The agreement with Harvest does not limit the Company's ability to execute other collaborations and joint ventures with third parties. As consideration for providing exclusive rights of first-look and first negotiation for start-up opportunities, the Company receives a portion of the management fee collected by the fund sponsor of Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled $613 and $1,871 for the three and nine months ended September 30, 2016, respectively, and totaled $697 for the three and nine months ended September 30, 2015.

XML 37 R26.htm IDEA: XBRL DOCUMENT

Net Loss per Share

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Net Loss per Share

The following table presents the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2016 and 2015:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Historical net loss per share:
Numerator:
Net loss attributable to Intrexon	$	(28,982	)	$	(38,213	)	$	(142,475	)	$	(51,779	)
Denominator:
Weighted average shares outstanding, basic and diluted	118,346,782			112,244,129			117,785,160			109,244,641
Net loss attributable to Intrexon per share, basic and diluted	$	(0.24	)	$	(0.34	)	$	(1.21	)	$	(0.47	)



	September 30,
	2016	2015
Options	12,103,407	10,660,040
Warrants	30,191	194,719
Total	12,133,598	10,854,759

XML 38 R27.htm IDEA: XBRL DOCUMENT

Subsequent Events Subsequent Events	9 Months Ended
Subsequent Events Subsequent Events	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In November 2016, the Company entered into a stock purchase agreement with AquaBounty pursuant to which the Company will purchase 72,632,190 shares of AquaBounty's common stock for $25,000 subject to AquaBounty's common stock being approved for listing on the NASDAQ Capital Market ("NASDAQ") and other closing conditions as defined in the agreement. In November 2016, AquaBounty filed a Form 10 registration statement with the Securities and Exchange Commission as an initial step towards the listing of its common stock. The Company anticipates converting up to $10,000 of convertible promissory notes, plus accrued interest thereon, into shares of AquaBounty common stock in conjunction with these transactions. The Company also announced its intent to distribute a portion of its previously held shares of AquaBounty common stock to shareholders of Intrexon as a special stock dividend once AquaBounty shares are available to trade on NASDAQ. The number of shares to be distributed by the Company is subject to final determination and approval by the Board of Directors of the Company. After consideration of all transactions contemplated herein, the Company expects to continue to be the majority owner of AquaBounty.

XML 39 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2016 and results of operations and cash flows for the interim periods ended September 30, 2016 and 2015. The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2016, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.
Consolidation	The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Restricted Cash	Restricted Cash Restricted cash represents funds deposited with the U.S. Treasury, as required by a court decision resulting from litigation against Trans Ova (Note 17).
Investment in Preferred Stock	Investment in Preferred Stock The Company holds preferred stock received from one of its collaborators, ZIOPHARM Oncology, Inc. ("ZIOPHARM"), which may be converted to common stock upon the occurrence of certain events in the future (Note 7). The Company elected the fair value option to account for its investment in preferred stock whereby the value of preferred stock is adjusted to fair value as of each reporting date and unrealized gains and losses are reported in the consolidated statement of operations. This investment is subject to fluctuation in the future due to, among other things, the likelihood and timing of conversion of the preferred stock into common stock, the volatility of ZIOPHARM's common stock, and changes in general economic and financial conditions of ZIOPHARM. The investment is classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell the investment nor expect it to be converted into shares of common stock within one year. Until such time as the Company converts the instrument into common stock, the Company is entitled to a monthly dividend payable in additional shares of preferred stock and records dividend income based on the fair value of the preferred shares.
Equity Method Investments	Equity Method Investments The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest") (Note 18) using the equity method of accounting because the Company has the ability to exercise significant influence, but not control, over the operating activities of these entities. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Segment Information	Segment Information While the Company generates revenues from multiple sources, including collaboration agreements, licensing, and products and services associated with bovine reproduction, management is organized around a singular research and development focus to further the development of the Company's underlying synthetic biology technologies. Accordingly, the Company has determined that it operates in one segment.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-15, Statement of Cash Flows (Topic 230) - Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). The provisions of ASU 2016-15 address eight specific cash flow issues and how those certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017, with early adoption permitted, and is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Stock Compensation (Topic 718) - Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). The provisions of ASU 2016-09 simplify various aspects of the accounting for employee share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, with early adoption permitted, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In March 2016, the FASB issued ASU 2016-07, Investments-Equity Method and Joint Ventures (Topic 323) - Simplifying the Transition to the Equity Method of Accounting ("ASU 2016-07"). The provisions of ASU 2016-07 eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, with early adoption permitted, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The provisions of ASU 2016-02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases today. ASU 2016-02 supersedes the previous lease standard, Topic 840 Leases. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). The provisions of ASU 2016-01 make targeted improvements to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017, and is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes ("ASU 2015-17"). The provisions of ASU 2015-17 simplify the presentation of deferred income taxes by requiring an entity to classify deferred tax liabilities and assets as noncurrent on a classified balance sheet. The Company elected to early adopt this guidance during the first quarter of 2016 and applied it prospectively, and there was no significant impact on the Company's consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) - Simplifying the Measurement of Inventory ("ASU 2015-11"). The provisions of ASU 2015-11 provide guidance for simplifying the calculation for subsequent measurement of inventory measured using the first-in-first-out or average cost methods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2016, and is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). The FASB issued ASU 2014-09 to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance was originally effective for annual periods and interim periods within those annual periods beginning after December 15, 2016 and early adoption was not permitted. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date ("ASU 2015-14"), which deferred the effective date of the guidance in ASU 2014-09 by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016, and is effective for the Company for the year ending December 31, 2018. In March, April and May 2016, the FASB clarified the implementation guidance on principal versus agent, identifying performance obligations, licensing, narrow-scope improvements and practical expedients by issuing ASU 2016-08, Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations ("ASU 2016-08"), ASU 2016-10, Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing ("ASU 2016-10"), and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) - Narrow-Scope Improvements and Practical Expedients ("ASU 2016-12"). The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

XML 40 R29.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summarized Unaudited Financial Information for the Equity Method Investments



	September 30, 2016		December 31, 2015
Current assets	$	81,049	$	28,123
Non-current assets	10,992		1,539
Total assets	92,041		29,662
Current liabilities	8,325		6,274
Net assets	$	83,716	$	23,388



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Revenues	$	65		$	330		$	394		$	1,480
Operating expenses	18,363			8,687			50,406			118,180
Operating loss	(18,298		)	(8,357		)	(50,012		)	(116,700		)
Other	75			(34		)	1,502			(31		)
Net loss	$	(18,223	)	$	(8,391	)	$	(48,510	)	$	(116,731	)

XML 41 R30.htm IDEA: XBRL DOCUMENT

Mergers and Acquisitions (Tables)

9 Months Ended

Sep. 30, 2016

Oxitec

Business Acquisition [Line Items]

Fair Value of Consideration Transferred

The fair value of the total consideration transferred was $146,394. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:



Cash	$	90,199
Common shares	56,195
	$	146,394

Fair Value of Assets Acquired and Liabilities Assumed

The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	3,780
Trade receivables	125
Other receivables	7,395
Prepaid expenses and other	121
Property, plant, and equipment	1,198
Intangible assets	96,854
Total assets acquired	109,473
Accounts payable	1,187
Accrued compensation and benefits	246
Other accrued liabilities	210
Deferred revenue	120
Deferred tax liabilities	12,584
Total liabilities assumed	14,347
Net assets acquired	95,126
Goodwill	51,268
Total consideration	$	146,394

Okanagan

Business Acquisition [Line Items]

Fair Value of Consideration Transferred

The fair value of the total consideration transferred was $40,933. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	10,000
Common shares	30,933
	$	40,933

Fair Value of Assets Acquired and Liabilities Assumed

The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	58
Trade receivables	16
Other receivables	49
Property, plant, and equipment	32
Intangible assets	36,500
Total assets acquired	36,655
Accounts payable	181
Deferred revenue	181
Deferred tax liabilities	8,847
Total liabilities assumed	9,209
Net assets acquired	27,446
Goodwill	13,487
Total consideration	$	40,933

ActoGeniX NV

Business Acquisition [Line Items]

Fair Value of Consideration Transferred

The fair value of the total consideration transferred was $72,474. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	32,739
Common shares	39,735
	$	72,474

Fair Value of Assets Acquired and Liabilities Assumed

The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	3,180
Other receivables	305
Prepaid expenses and other	31
Property, plant and equipment	209
Intangible assets	68,100
Other non-current assets	23
Total assets acquired	71,848
Accounts payable	230
Accrued compensation and benefits	196
Other accrued liabilities	253
Deferred revenue	732
Deferred tax liabilities	612
Total liabilities assumed	2,023
Net assets acquired	69,825
Goodwill	2,649
Total consideration	$	72,474

2015 Business Acquisitions

Business Acquisition [Line Items]

Pro forma Financial Information

The following unaudited condensed pro forma financial information for the three and nine months ended September 30, 2015 is presented as if the acquisitions had been consummated on January 1, 2014:



	Three Months Ended September 30, 2015			Nine Months Ended September 30, 2015
	Pro Forma
Revenues	$	53,754		$	133,060
Loss before income taxes	(43,979		)	(66,686		)
Net loss	(43,057		)	(66,319		)
Net loss attributable to the noncontrolling interests	816			2,940
Net loss attributable to Intrexon	(42,241		)	(63,379		)

XML 42 R31.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Revenue (Tables)

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the three and nine months ended September 30, 2016 and 2015.



	Three Months Ended September 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	4,843	$	5,586	$	10,429
Oragenics, Inc.	262		294		556
Fibrocell Science, Inc.	604		563		1,167
Genopaver, LLC	68		1,625		1,693
S & I Ophthalmic, LLC	—		2,782		2,782
OvaXon, LLC	—		709		709
Intrexon Energy Partners, LLC	625		4,230		4,855
Persea Bio, LLC	125		208		333
Ares Trading S.A.	1,597		719		2,316
Thrive Agrobiotics, Inc.	46		379		425
Intrexon Energy Partners II, LLC	500		372		872
Exotech Bio, Inc.	139		82		221
Relieve Genetics, Inc.	120		342		462
Intrexon T1D Partners, LLC	276		511		787
AD Skincare, Inc.	120		65		185
Other	895		1,903		2,798
Total	$	10,220	$	20,370	$	30,590



	Three Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	645	$	4,006	$	4,651
Oragenics, Inc.	4,868		332		5,200
Fibrocell Science, Inc.	4,823		1,317		6,140
Genopaver, LLC	68		993		1,061
S & I Ophthalmic, LLC	—		1,193		1,193
OvaXon, LLC	—		549		549
Intrexon Energy Partners, LLC	625		3,185		3,810
Persea Bio, LLC	125		297		422
Ares Trading S.A.	1,597		260		1,857
Other	7,841		2,002		9,843
Total	$	20,592	$	14,134	$	34,726



	Nine Months Ended September 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	6,687	$	17,693	$	24,380
Oragenics, Inc.	786		1,083		1,869
Fibrocell Science, Inc.	1,814		2,604		4,418
Genopaver, LLC	205		4,703		4,908
S & I Ophthalmic, LLC	—		6,326		6,326
OvaXon, LLC	—		2,211		2,211
Intrexon Energy Partners, LLC	1,875		11,180		13,055
Persea Bio, LLC	375		613		988
Ares Trading S.A.	4,791		2,148		6,939
Thrive Agrobiotics, Inc.	138		1,171		1,309
Intrexon Energy Partners II, LLC	1,500		816		2,316
Exotech Bio, Inc.	278		82		360
Relieve Genetics, Inc.	240		572		812
Intrexon T1D Partners, LLC	554		543		1,097
AD Skincare, Inc.	120		65		185
Other	4,684		6,287		10,971
Total	$	24,047	$	58,097	$	82,144



	Nine Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	1,933	$	11,769	$	13,702
Oragenics, Inc.	5,437		408		5,845
Fibrocell Science, Inc.	5,719		4,500		10,219
Genopaver, LLC	205		2,460		2,665
S & I Ophthalmic, LLC	—		2,838		2,838
OvaXon, LLC	—		1,855		1,855
Intrexon Energy Partners, LLC	1,875		8,101		9,976
Persea Bio, LLC	375		553		928
Ares Trading S.A.	2,336		260		2,596
Other	9,446		6,620		16,066
Total	$	27,326	$	39,364	$	66,690

Summary of Deferred Revenue

Deferred revenue consists of the following:



	September 30, 2016		December 31, 2015
Upfront and milestone payments	$	309,126	$	181,331
Prepaid research and development services	7,057		10,938
Prepaid product and service revenues	5,594		4,759
Other	620		701
Total	$	322,397	$	197,729
Current portion of deferred revenue	$	54,937	$	35,366
Long-term portion of deferred revenue	267,460		162,363
Total	$	322,397	$	197,729

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement:



	September 30, 2016		December 31, 2015
ZIOPHARM Oncology, Inc.	$	143,651	$	30,338
Oragenics, Inc.	8,027		8,813
Fibrocell Science, Inc.	19,631		21,445
Genopaver, LLC	2,045		2,250
Intrexon Energy Partners, LLC	18,750		20,625
Persea Bio, LLC	4,125		4,500
Ares Trading S.A.	48,776		53,567
Thrive Agrobiotics, Inc.	1,483		1,621
Intrexon Energy Partners II, LLC	16,333		17,833
Exotech Bio, Inc.	4,722		—
Relieve Genetics, Inc.	4,093		—
Intrexon T1D Partners, LLC	9,383		—
AD Skincare, Inc.	4,213		—
Genten Therapeutics, Inc.	4,523		—
CRS Bio, Inc.	2,111		—
Other	17,260		20,339
Total	$	309,126	$	181,331

XML 43 R32.htm IDEA: XBRL DOCUMENT

Short-term and Long-term Investments (Tables)

9 Months Ended

Sep. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Investments

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of September 30, 2016:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	210,620	$	79	$	(10	)	$	210,689
Certificates of deposit	272		—		—			272
Total	$	210,892	$	79	$	(10	)	$	210,961

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2015:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	208,223	$	21	$	(540	)	$	207,704
Certificates of deposit	271		—		—			271
Total	$	208,494	$	21	$	(540	)	$	207,975

Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities

The estimated fair value of available-for-sale investments classified by their contractual maturities as of September 30, 2016 was:



Due within one year	$	166,839
After one year through two years	44,122
Total	$	210,961

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

XML 44 R33.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		September 30, 2016
Assets
U.S. government debt securities	$	—	$	210,689	$	—	$	210,689
Equity securities	31,245		8,187		—		39,432
Preferred stock	—		—		123,676		123,676
Other	—		2,296		—		2,296
Total	$	31,245	$	221,172	$	123,676	$	376,093



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2015
Assets
U.S. government debt securities	$	—	$	207,704	$	—	$	207,704
Equity securities	65,850		17,803		—		83,653
Other	—		405		—		405
Total	$	65,850	$	225,912	$	—	$	291,762

XML 45 R34.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following:



	September 30, 2016		December 31, 2015
Supplies, semen and embryos	$	1,278	$	1,402
Work in process	5,831		6,290
Livestock	12,588		16,907
Feed	2,183		1,964
Total inventory	$	21,880	$	26,563

XML 46 R35.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net (Tables)

9 Months Ended

Sep. 30, 2016

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment consist of the following:



	September 30, 2016			December 31, 2015
Land and land improvements	$	11,276		$	9,119
Buildings and building improvements	7,965			7,520
Furniture and fixtures	1,234			1,283
Equipment	41,343			36,016
Leasehold improvements	10,479			6,888
Computer hardware and software	6,912			5,960
Construction and other assets in progress	7,523			2,193
	86,732			68,979
Less: Accumulated depreciation and amortization	(32,303		)	(26,240		)
Property, plant and equipment, net	$	54,429		$	42,739

XML 47 R36.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets, Net (Tables)

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the nine months ended September 30, 2016 are as follows:



Balance at December 31, 2015	$	165,169
Foreign currency translation adjustments	(5,376		)
Balance at September 30, 2016	$	159,793

Schedule of Intangible Assets

Intangible assets consist of the following at September 30, 2016:



	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Patents, related technologies and know-how	15.3	$	170,520	$	(26,596	)	$	143,924
Customer relationships	6.5	10,700		(4,189		)	6,511
Trademarks	9.3	6,800		(1,598		)	5,202
Covenant not to compete	2.0	395		(312		)	83
In-process research and development		82,861		—			82,861
Total		$	271,276	$	(32,695	)	$	238,581

Intangible assets consist of the following at December 31, 2015:



	Gross Carrying Amount		Accumulated Amortization			Net
Patents, related technologies and know-how	$	157,411	$	(17,775	)	$	139,636
Customer relationships	10,700		(2,739		)	7,961
Trademarks	6,800		(1,018		)	5,782
Covenant not to compete	384		(160		)	224
In-process research and development	93,932		—			93,932
Total	$	269,227	$	(21,692	)	$	247,535

XML 48 R37.htm IDEA: XBRL DOCUMENT

Lines of Credit and Long Term Debt (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Schedule of Long Term Debt Instruments

Long term debt consists of the following:



	September 30, 2016		December 31, 2015
Notes payable	$	5,769	$	6,477
Royalty-based financing	2,003		1,807
Other	649		244
Long term debt	8,421		8,528
Less current portion	471		930
Long term debt, less current portion	$	7,950	$	7,598

Schedule of Future Maturities of Long Term Debt

Future maturities of long term debt are as follows:



2016	$	168
2017	404
2018	549
2019	364
2020	335
2021	774
Thereafter	3,824
Total	$	6,418

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

XML 49 R38.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	September 30, 2016			December 31, 2015
Unrealized gain (loss) on investments	$	69		$	(519	)
Foreign currency translation adjustments	(25,371		)	(12,233		)
Total accumulated other comprehensive loss	$	(25,302	)	$	(12,752	)

XML 50 R39.htm IDEA: XBRL DOCUMENT

Share-Based Payments (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-Based Compensation Costs

Stock-based compensation costs included in the consolidated statements of operations are presented below:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Cost of products	$	21	$	21	$	61	$	76
Cost of services	68		98		206		301
Research and development	2,236		2,234		6,979		6,141
Selling, general and administrative	8,467		6,032		23,385		20,006
Total	$	10,792	$	8,385	$	30,631	$	26,524

Schedule of Stock Option Activity

Stock option activity was as follows:



	Number of Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2015	11,043,528		$	32.66		8.49
Granted	4,384,860		29.42
Exercised	(1,162,843	)	(15.63		)
Forfeited	(2,127,334	)	(43.29		)
Expired	(34,804	)	(35.76		)
Balances at September 30, 2016	12,103,407		31.24			8.50
Exercisable at September 30, 2016	3,369,252		27.99			7.25
Vested and Expected to Vest at September 30, 2016(1)	10,177,058		30.99			8.37


(1)	The number of stock options expected to vest takes into account an estimate of expected forfeitures.

XML 51 R40.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Future Minimum Lease Payments Under Noncancelable Operating Leases

At September 30, 2016, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:



2016	$	705
2017	6,362
2018	5,695
2019	5,434
2020	5,487
2021	4,888
Thereafter	20,179
Total	$	48,750

XML 52 R41.htm IDEA: XBRL DOCUMENT

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table presents the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2016 and 2015:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Historical net loss per share:
Numerator:
Net loss attributable to Intrexon	$	(28,982	)	$	(38,213	)	$	(142,475	)	$	(51,779	)
Denominator:
Weighted average shares outstanding, basic and diluted	118,346,782			112,244,129			117,785,160			109,244,641
Net loss attributable to Intrexon per share, basic and diluted	$	(0.24	)	$	(0.34	)	$	(1.21	)	$	(0.47	)

Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share



	September 30,
	2016	2015
Options	12,103,407	10,660,040
Warrants	30,191	194,719
Total	12,133,598	10,854,759

XML 53 R42.htm IDEA: XBRL DOCUMENT

Organization (Details)	Sep. 30, 2016
AquaBounty Technologies, Inc.
Noncontrolling Interest [Line Items]
Parent ownership interest	63.00%
Biological & Popular Culture, Inc.
Noncontrolling Interest [Line Items]
Parent ownership interest	51.00%

XML 54 R43.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis	$ 376,093		$ 376,093		$ 291,762
Oragenics
Schedule of Equity Method Investments [Line Items]
Company's ownership percentage	29.50%		29.50%		30.70%
Equity securities
Schedule of Equity Method Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis	$ 39,432		$ 39,432		$ 83,653
Equity securities \| Oragenics
Schedule of Equity Method Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis	6,171		6,171		$ 16,601
Unrealized appreciation (depreciation) in fair value of equity securities	$ (455)	$ 2,404	$ (11,597)	$ 6,283

XML 55 R44.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Maximum risk of loss related to the identified VIEs	$ 145,786	$ 3,598

XML 56 R45.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Segment Information - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) segment	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)
Segment Reporting Information [Line Items]
Number of segments \| segment			1
Property, plant and equipment, net	$ 54,429		$ 54,429		$ 42,739
Revenues	48,985	$ 53,367	144,924	$ 132,107
Foreign Countries
Segment Reporting Information [Line Items]
Property, plant and equipment, net	11,331		11,331		$ 3,877
Revenues	$ 3,502	$ 1,183	$ 8,678	$ 3,446

XML 57 R46.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Summarized Unaudited Financial Information for the Equity Method Investments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Operating expenses	$ 77,806	$ 61,283	$ 237,500	$ 244,576
Operating loss	(28,821)	(7,916)	(92,576)	(112,469)
Other	4,647	(29,607)	(39,125)	65,121
Equity Method Investments
Schedule of Equity Method Investments [Line Items]
Current assets	81,049		81,049		$ 28,123
Non-current assets	10,992		10,992		1,539
Total assets	92,041		92,041		29,662
Current liabilities	8,325		8,325		6,274
Net assets	83,716		83,716		$ 23,388
Revenues	65	330	394	1,480
Operating expenses	18,363	8,687	50,406	118,180
Operating loss	(18,298)	(8,357)	(50,012)	(116,700)
Other	75	(34)	1,502	(31)
Net loss	$ (18,223)	$ (8,391)	$ (48,510)	$ (116,731)

XML 58 R47.htm IDEA: XBRL DOCUMENT

Mergers and Acquisitions - Oxitec - Additional Information (Details) - Oxitec $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2015 USD ($) shares	Sep. 30, 2015 USD ($)	Sep. 30, 2015 USD ($)
Business Acquisition [Line Items]
Percentage of outstanding common stock acquired	100.00%	100.00%	100.00%
Consideration transferred, shares issued or issuable \| shares	1,359,343
Cash	$ 90,199
Consideration transferred, cash and working capital adjustments	$ 9,449
Equity interest issued or issuable, number of shares withheld as escrow \| shares	480,422
Cash consideration withheld as escrow	$ 1,991
Consideration withheld as escrow, transfer period after closing	18 months
Consideration transferred	$ 146,394
Acquisition related costs	$ 1,675
Selling, general and administrative
Business Acquisition [Line Items]
Acquisition related costs		$ 1,644	$ 1,644

XML 59 R48.htm IDEA: XBRL DOCUMENT

Mergers and Acquisitions - Fair Value of Consideration Transferred (Details) - USD ($) $ in Thousands	1 Months Ended
	Sep. 30, 2015	Apr. 30, 2015	Feb. 28, 2015
Oxitec
Business Acquisition [Line Items]
Cash	$ 90,199
Common shares	56,195
Total consideration transferred	$ 146,394
ActoGeniX NV
Business Acquisition [Line Items]
Cash			$ 32,739
Common shares			39,735
Total consideration transferred			$ 72,474
Okanagan
Business Acquisition [Line Items]
Cash		$ 10,000
Common shares		30,933
Total consideration transferred		$ 40,933

XML 60 R49.htm IDEA: XBRL DOCUMENT

Mergers and Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Apr. 30, 2015	Feb. 28, 2015
Business Acquisition [Line Items]
Goodwill	$ 159,793	$ 165,169
Oxitec
Business Acquisition [Line Items]
Cash			$ 3,780
Trade receivables			125
Other receivables			7,395
Prepaid expenses and other			121
Property, plant and equipment			1,198
Intangible assets			96,854
Total assets acquired			109,473
Accounts payable			1,187
Accrued compensation and benefits			246
Other accrued liabilities			210
Deferred revenue			120
Deferred tax liabilities			12,584
Total liabilities assumed			14,347
Net assets acquired			95,126
Goodwill			51,268
Total consideration			$ 146,394
Okanagan
Business Acquisition [Line Items]
Cash				$ 58
Trade receivables				16
Other receivables				49
Property, plant and equipment				32
Intangible assets				36,500
Total assets acquired				36,655
Accounts payable				181
Deferred revenue				181
Deferred tax liabilities				8,847
Total liabilities assumed				9,209
Net assets acquired				27,446
Goodwill				13,487
Total consideration				$ 40,933
ActoGeniX NV
Business Acquisition [Line Items]
Cash					$ 3,180
Other receivables					305
Prepaid expenses and other					31
Property, plant and equipment					209
Intangible assets					68,100
Other non-current assets					23
Total assets acquired					71,848
Accounts payable					230
Accrued compensation and benefits					196
Other accrued liabilities					253
Deferred revenue					732
Deferred tax liabilities					612
Total liabilities assumed					2,023
Net assets acquired					69,825
Goodwill					2,649
Total consideration					$ 72,474

XML 61 R50.htm IDEA: XBRL DOCUMENT

Mergers and Acquisitions - Okanagan - Additional Information (Details) - Okanagan - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 30, 2015	Sep. 30, 2015
Business Acquisition [Line Items]
Percentage of outstanding common stock acquired	100.00%
Consideration transferred, shares issued or issuable	707,853
Cash	$ 10,000
Consideration transferred	$ 40,933
Expected useful life of intangible asset	14 years
Acquisition related costs	$ 341
Selling, general and administrative
Business Acquisition [Line Items]
Acquisition related costs		$ 267

XML 62 R51.htm IDEA: XBRL DOCUMENT

Mergers and Acquisitions - ActoGeniX - Additional Information (Details) - ActoGeniX NV - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	Aug. 31, 2015	Feb. 28, 2015	Sep. 30, 2015
Business Acquisition [Line Items]
Percentage of outstanding common stock acquired		100.00%
Consideration transferred, shares issued or issuable		965,377
Cash		$ 32,739
Consideration transferred		72,474
Expected useful life of intangible asset	18 years
Acquisition related costs		$ 418
Selling, general and administrative
Business Acquisition [Line Items]
Acquisition related costs			$ 381

XML 63 R52.htm IDEA: XBRL DOCUMENT

Mergers and Acquisitions - 2015 Acquisitions - Pro Forma Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Loss before income taxes	$ (30,429)	$ (39,952)	$ (148,652)	$ (53,913)
Net loss	(30,011)	(39,029)	(145,362)	(54,719)
Net loss attributable to the noncontrolling interests	$ 1,029	816	$ 2,887	2,940
2015 Business Acquisitions \| Pro Forma
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenues		53,754		133,060
Loss before income taxes		(43,979)		(66,686)
Net loss		(43,057)		(66,319)
Net loss attributable to the noncontrolling interests		816		2,940
Net loss attributable to Intrexon		$ (42,241)		$ (63,379)

XML 64 R53.htm IDEA: XBRL DOCUMENT

Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)	1 Months Ended
	Mar. 31, 2016 USD ($)	Sep. 30, 2016 USD ($) board_seat	Dec. 31, 2015 USD ($)
Schedule of Equity Method Investments [Line Items]
Investment		$ 25,847,000	$ 9,977,000
Intrexon T1D Partners
Schedule of Equity Method Investments [Line Items]
Membership interest	50.00%
Maximum additional capital contribution committed	$ 5,000,000
Additional capital contributions committed, remaining commitment		$ 3,650,000
Total number of seats on the joint venture's governing board \| board_seat		5
Intrexon T1D Partners \| Investors
Schedule of Equity Method Investments [Line Items]
Membership interest	50.00%
Capital contributions	$ 10,000,000
Maximum additional capital contribution committed	5,000,000
Intrexon T1D Partners \| Upfront \| Upfront and Milestone Payments
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 10,000,000
Intrexon T1D Partners \| Investments In Affiliates
Schedule of Equity Method Investments [Line Items]
Investment		$ 1,078,000

XML 65 R54.htm IDEA: XBRL DOCUMENT

Investments in Joint Ventures - EnviroFlight - Additional Information (Details) - USD ($)	1 Months Ended		9 Months Ended
	Oct. 31, 2016	Feb. 29, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Cash paid in asset acquisition			$ 7,244,000	$ 0
Shares issued in asset acquisition			4,401,000	0
Contingent consideration assumed in asset acquisition			3,660,000	$ 0
Investment			25,847,000		$ 9,977,000
Significant Unobservable Inputs (Level 3)
Schedule of Equity Method Investments [Line Items]
Fair value of financial liabilities measured at fair value on a recurring basis			3,839,000
EnviroFlight
Schedule of Equity Method Investments [Line Items]
Cash paid in asset acquisition		$ 4,244,000
Shares issued in asset acquisition (in shares)		136,340
Shares issued in asset acquisition		$ 4,401,000
Contingent consideration assumed in asset acquisition		3,660,000
Capital contributions		$ 3,000,000
Membership interest		50.00%
Maximum additional capital contribution committed		$ 5,000,000
Estimated fair value of investment		5,425,000
Contingent consideration for commercial milestones payable in common stock, maximum		4,000,000
EnviroFlight \| Investments In Affiliates
Schedule of Equity Method Investments [Line Items]
Investment			4,611,000
EnviroFlight \| Significant Unobservable Inputs (Level 3)
Schedule of Equity Method Investments [Line Items]
Fair value of financial liabilities measured at fair value on a recurring basis			$ 3,839,000
EnviroFlight \| Patents, related technologies and know-how
Schedule of Equity Method Investments [Line Items]
Estimated fair value of developed technology acquired		$ 9,880,000
Expected useful life of intangible asset		21 years
EnviroFlight \| Investors
Schedule of Equity Method Investments [Line Items]
Membership interest		50.00%
Maximum additional capital contribution committed		$ 5,000,000
EnviroFlight \| Subsequent Event
Schedule of Equity Method Investments [Line Items]
Shares issued for contingent consideration (in shares)	59,337
Shares issued for contingent consideration	$ 1,583,000

XML 66 R55.htm IDEA: XBRL DOCUMENT

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	1 Months Ended
	Dec. 31, 2015 USD ($)	Sep. 30, 2016 USD ($) board_seat
Schedule of Equity Method Investments [Line Items]
Investment	$ 9,977,000	$ 25,847,000
Intrexon Energy Partners II
Schedule of Equity Method Investments [Line Items]
Membership interest	50.00%
Maximum additional capital contribution committed	$ 10,000,000
Total number of seats on the joint venture's governing board \| board_seat		5
Intrexon Energy Partners II \| Investments In Affiliates
Schedule of Equity Method Investments [Line Items]
Investment	$ 2,000,000	$ 1,591,000
Intrexon Energy Partners II \| Investors
Schedule of Equity Method Investments [Line Items]
Membership interest	50.00%
Capital contributions	$ 18,000,000
Maximum additional capital contribution committed	10,000,000
Intrexon Energy Partners II \| All Investors
Schedule of Equity Method Investments [Line Items]
Capital contributions	4,000,000
Intrexon Energy Partners II \| Upfront and Milestone Payments \| Upfront
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 18,000,000

XML 67 R56.htm IDEA: XBRL DOCUMENT

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	1 Months Ended
	Mar. 31, 2014 USD ($)	Sep. 30, 2016 USD ($) board_seat	Dec. 31, 2015 USD ($)
Schedule of Equity Method Investments [Line Items]
Investment		$ 25,847,000	$ 9,977,000
Intrexon Energy Partners
Schedule of Equity Method Investments [Line Items]
Membership interest	50.00%
Maximum additional capital contribution committed	$ 25,000,000
Additional capital contributions committed, remaining commitment		$ 12,367,000
Total number of seats on the joint venture's governing board \| board_seat		5
Intrexon Energy Partners \| Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment		$ (627,000)	$ (1,270,000)
Intrexon Energy Partners \| Investors
Schedule of Equity Method Investments [Line Items]
Membership interest	50.00%
Capital contributions	$ 25,000,000
Maximum additional capital contribution committed	25,000,000
Upfront and Milestone Payments \| Intrexon Energy Partners \| Upfront
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 25,000,000

XML 68 R57.htm IDEA: XBRL DOCUMENT

Investments in Joint Ventures - OvaXon - Additional Information (Details) $ in Thousands	1 Months Ended
	Jan. 31, 2014 USD ($)	Sep. 30, 2016 USD ($) board_seat	Dec. 31, 2015 USD ($)
Schedule of Equity Method Investments [Line Items]
Investment		$ 25,847	$ 9,977
OvaXon, LLC
Schedule of Equity Method Investments [Line Items]
Capital contributions	$ 1,500
Membership interest	50.00%
Total number of seats on the joint venture's governing board \| board_seat		4
OvaXon, LLC \| Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment			$ (144)
OvaXon, LLC \| Investments In Affiliates
Schedule of Equity Method Investments [Line Items]
Investment		$ 435
OvaXon, LLC \| Investors
Schedule of Equity Method Investments [Line Items]
Capital contributions	$ 1,500
Membership interest	50.00%

XML 69 R58.htm IDEA: XBRL DOCUMENT

Investments in Joint Ventures - S & I Ophthalmic - Additional Information (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2013 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2016 USD ($) board_seat
Schedule of Equity Method Investments [Line Items]
Investment		$ 9,977	$ 25,847
S & I Ophthalmic, LLC
Schedule of Equity Method Investments [Line Items]
Capital contributions	$ 5,000	5,000
Membership interest	50.00%
Total number of seats on the joint venture's governing board \| board_seat			4
S & I Ophthalmic, LLC \| Investors
Schedule of Equity Method Investments [Line Items]
Capital contributions	$ 5,000	5,000
Membership interest	50.00%
S & I Ophthalmic, LLC \| Investments In Affiliates
Schedule of Equity Method Investments [Line Items]
Investment		$ 6,379	$ 3,737

XML 70 R59.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	$ 30,590	$ 34,726	$ 82,144	$ 66,690
Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	10,220	20,592	24,047	27,326
Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	20,370	14,134	58,097	39,364
ZIOPHARM Oncology, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	10,429	4,651	24,380	13,702
ZIOPHARM Oncology, Inc. \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	4,843	645	6,687	1,933
ZIOPHARM Oncology, Inc. \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	5,586	4,006	17,693	11,769
Oragenics, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	556	5,200	1,869	5,845
Oragenics, Inc. \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	262	4,868	786	5,437
Oragenics, Inc. \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	294	332	1,083	408
Fibrocell Science, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	1,167	6,140	4,418	10,219
Fibrocell Science, Inc. \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	604	4,823	1,814	5,719
Fibrocell Science, Inc. \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	563	1,317	2,604	4,500
Genopaver, LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	1,693	1,061	4,908	2,665
Genopaver, LLC \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	68	68	205	205
Genopaver, LLC \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	1,625	993	4,703	2,460
S & I Ophthalmic, LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	2,782	1,193	6,326	2,838
S & I Ophthalmic, LLC \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	0	0	0	0
S & I Ophthalmic, LLC \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	2,782	1,193	6,326	2,838
OvaXon, LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	709	549	2,211	1,855
OvaXon, LLC \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	0	0	0	0
OvaXon, LLC \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	709	549	2,211	1,855
Intrexon Energy Partners, LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	4,855	3,810	13,055	9,976
Intrexon Energy Partners, LLC \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	625	625	1,875	1,875
Intrexon Energy Partners, LLC \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	4,230	3,185	11,180	8,101
Persea Bio, LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	333	422	988	928
Persea Bio, LLC \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	125	125	375	375
Persea Bio, LLC \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	208	297	613	553
Ares Trading S.A.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	2,316	1,857	6,939	2,596
Ares Trading S.A. \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	1,597	1,597	4,791	2,336
Ares Trading S.A. \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	719	260	2,148	260
Thrive Agrobiotics, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	425		1,309
Thrive Agrobiotics, Inc. \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	46		138
Thrive Agrobiotics, Inc. \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	379		1,171
Intrexon Energy Partners II, LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	872		2,316
Intrexon Energy Partners II, LLC \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	500		1,500
Intrexon Energy Partners II, LLC \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	372		816
Exotech Bio, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	221		360
Exotech Bio, Inc. \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	139		278
Exotech Bio, Inc. \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	82		82
Relieve Genetics, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	462		812
Relieve Genetics, Inc. \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	120		240
Relieve Genetics, Inc. \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	342		572
Intrexon T1D Partners
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	787		1,097
Intrexon T1D Partners \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	276		554
Intrexon T1D Partners \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	511		543
AD Skincare, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	185		185
AD Skincare, Inc. \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	120		120
AD Skincare, Inc. \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	65		65
Other
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	2,798	9,843	10,971	16,066
Other \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	895	7,841	4,684	9,446
Other \| Research and Development Services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration and licensing revenues	$ 1,903	$ 2,002	$ 6,287	$ 6,620

XML 71 R60.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Revenue - Additional Information (Details) - USD ($)	1 Months Ended			5 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	May 31, 2016
Exotech Bio, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement			90 days
Exotech Bio, Inc. \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product			$ 52,500,000
Exotech Bio, Inc. \| Upfront \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value			$ 5,000,000
Relieve Genetics, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement			90 days
Relieve Genetics, Inc. \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product			$ 52,500,000
Relieve Genetics, Inc. \| Upfront \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value			$ 4,333,000
Intrexon T1D Partners
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement			90 days
Intrexon T1D Partners \| Upfront \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value			$ 10,000,000
AD Skincare, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement		90 days
AD Skincare, Inc. \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product		$ 2,000,000
Milestone payments to be received upon successful achievement, one-time		17,000,000
AD Skincare, Inc. \| Upfront \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value		$ 4,333,000
ZIOPHARM Oncology, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty rate as a percentage of net profit		20.00%		50.00%
ZIOPHARM Oncology, Inc. \| Other Contractual Payments \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value		$ 120,000,000
Collaborative arrangement consideration received, number of preferred shares (in shares)		100,000
Genten Therapeutics, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement	90 days
Genten Therapeutics, Inc. \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product	$ 82,000,000
Genten Therapeutics, Inc. \| Upfront \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value	3,000,000
Collaborative arrangement consideration received in the form of cash	$ 1,500,000
CRS Bio, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement	90 days
CRS Bio, Inc. \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product	$ 75,000,000
CRS Bio, Inc. \| Upfront \| Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value	$ 2,100,000

XML 72 R61.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 322,397	$ 197,729
Current portion of deferred revenue	54,937	35,366
Long-term portion of deferred revenue	267,460	162,363
Deferred revenue	322,397	197,729
Upfront and milestone payments
Deferred Revenue Arrangement [Line Items]
Deferred revenue	309,126	181,331
Deferred revenue	309,126	181,331
Prepaid research and development services
Deferred Revenue Arrangement [Line Items]
Deferred revenue	7,057	10,938
Deferred revenue	7,057	10,938
Prepaid product and service revenues
Deferred Revenue Arrangement [Line Items]
Deferred revenue	5,594	4,759
Deferred revenue	5,594	4,759
Other
Deferred Revenue Arrangement [Line Items]
Deferred revenue	620	701
Deferred revenue	$ 620	$ 701

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

XML 73 R62.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 322,397	$ 197,729
Upfront and Milestone Payments
Deferred Revenue Arrangement [Line Items]
Deferred revenue	309,126	181,331
Upfront and Milestone Payments \| ZIOPHARM Oncology, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	143,651	30,338
Upfront and Milestone Payments \| Oragenics, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	8,027	8,813
Upfront and Milestone Payments \| Fibrocell Science, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	19,631	21,445
Upfront and Milestone Payments \| Genopaver, LLC
Deferred Revenue Arrangement [Line Items]
Deferred revenue	2,045	2,250
Upfront and Milestone Payments \| Intrexon Energy Partners, LLC
Deferred Revenue Arrangement [Line Items]
Deferred revenue	18,750	20,625
Upfront and Milestone Payments \| Persea Bio, LLC
Deferred Revenue Arrangement [Line Items]
Deferred revenue	4,125	4,500
Upfront and Milestone Payments \| Ares Trading S.A.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	48,776	53,567
Upfront and Milestone Payments \| Thrive Agrobiotics, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	1,483	1,621
Upfront and Milestone Payments \| Intrexon Energy Partners II
Deferred Revenue Arrangement [Line Items]
Deferred revenue	16,333	17,833
Upfront and Milestone Payments \| Exotech Bio, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	4,722	0
Upfront and Milestone Payments \| Relieve Genetics, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	4,093	0
Upfront and Milestone Payments \| Intrexon T1D Partners, LLC
Deferred Revenue Arrangement [Line Items]
Deferred revenue	9,383	0
Upfront and Milestone Payments \| AD Skincare, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	4,213	0
Upfront and Milestone Payments \| Genten Therapeutics, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	4,523	0
Upfront and Milestone Payments \| CRS Bio, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	2,111	0
Upfront and Milestone Payments \| Other
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 17,260	$ 20,339

XML 74 R63.htm IDEA: XBRL DOCUMENT

Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term and Long-term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 210,892	$ 208,494
Gross Unrealized Gains	79	21
Gross Unrealized Losses	(10)	(540)
Aggregate Fair Value	210,961	207,975
U.S. government debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	210,620	208,223
Gross Unrealized Gains	79	21
Gross Unrealized Losses	(10)	(540)
Aggregate Fair Value	210,689	207,704
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	272	271
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 272	$ 271

XML 75 R64.htm IDEA: XBRL DOCUMENT

Short-term and Long-term Investments - Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Due within one year	$ 166,839
After one year through two years	44,122
Total	$ 210,961	$ 207,975

XML 76 R65.htm IDEA: XBRL DOCUMENT

Investment in Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 30, 2016	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis		$ 376,093	$ 376,093		$ 291,762
Noncash dividend income on preferred shares			3,676	$ 0
Preferred stock
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis		$ 123,676	$ 123,676
ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Preferred shares, stated value (in usd per share)	$ 1,200
Threshold consecutive trading days, conversion of shares			20 days
Preferred shares, dividend rate (in usd per share)			$ 12.00
Preferred shares, dividend rate, for unconverted shares after conversion event (in usd per share)			24.00
ZIOPHARM Oncology, Inc. \| Minimum
Schedule of Investments [Line Items]
Preferred shares, conversion calculation, divisor (in usd per share)			$ 1.00
Other Contractual Payments \| Upfront and Milestone Payments \| ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Collaborative arrangement consideration received, number of preferred shares (in shares)	100,000
ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Dividend income, number of preferred shares received (in shares)		3,063	3,063
Noncash dividend income on preferred shares		$ 3,676	$ 3,676

XML 77 R66.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 376,093	$ 291,762
U.S. government debt securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	210,689	207,704
Equity securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	39,432	83,653
Preferred stock
Assets
Fair value of financial assets measured at fair value on a recurring basis	123,676
Other
Assets
Fair value of financial assets measured at fair value on a recurring basis	2,296	405
Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	31,245	65,850
Quoted Prices in Active Markets (Level 1) \| U.S. government debt securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Quoted Prices in Active Markets (Level 1) \| Equity securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	31,245	65,850
Quoted Prices in Active Markets (Level 1) \| Preferred stock
Assets
Fair value of financial assets measured at fair value on a recurring basis	0
Quoted Prices in Active Markets (Level 1) \| Other
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	221,172	225,912
Significant Other Observable Inputs (Level 2) \| U.S. government debt securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	210,689	207,704
Significant Other Observable Inputs (Level 2) \| Equity securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	8,187	17,803
Significant Other Observable Inputs (Level 2) \| Preferred stock
Assets
Fair value of financial assets measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) \| Other
Assets
Fair value of financial assets measured at fair value on a recurring basis	2,296	405
Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	123,676	0
Significant Unobservable Inputs (Level 3) \| U.S. government debt securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Equity securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Preferred stock
Assets
Fair value of financial assets measured at fair value on a recurring basis	123,676
Significant Unobservable Inputs (Level 3) \| Other
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 0	$ 0

XML 78 R67.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2016 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Adjustments to fair value of financial liabilities measured at fair value on a recurring basis	$ 179
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial liabilities measured at fair value on a recurring basis	$ 3,839

XML 79 R68.htm IDEA: XBRL DOCUMENT

Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Inventory	$ 21,880	$ 26,563
Supplies, semen and embryos
Inventory [Line Items]
Inventory	1,278	1,402
Work in process
Inventory [Line Items]
Inventory	5,831	6,290
Livestock
Inventory [Line Items]
Inventory	12,588	16,907
Feed
Inventory [Line Items]
Inventory	$ 2,183	$ 1,964

XML 80 R69.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 11,276	$ 9,119
Buildings and building improvements	7,965	7,520
Furniture and fixtures	1,234	1,283
Equipment	41,343	36,016
Leasehold improvements	10,479	6,888
Computer hardware and software	6,912	5,960
Construction and other assets in progress	7,523	2,193
Property, plant and equipment, gross	86,732	68,979
Less: Accumulated depreciation and amortization	(32,303)	(26,240)
Property, plant and equipment, net	$ 54,429	$ 42,739

XML 81 R70.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,332	$ 1,987	$ 6,769	$ 5,768

XML 82 R71.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Goodwill
Beginning balance	$ 165,169
Foreign currency translation adjustments	(5,376)
Ending balance	$ 159,793

XML 83 R72.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill accumulated impairment losses	$ 0		$ 0		$ 0
Amortization expense	$ 3,651,000	$ 2,857,000	$ 10,888,000	$ 6,434,000

XML 84 R73.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 271,276	$ 269,227
Accumulated Amortization	(32,695)	(21,692)
Net	238,581	247,535
Patents, related technologies and know-how
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	170,520	157,411
Accumulated Amortization	(26,596)	(17,775)
Net	143,924	139,636
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	10,700	10,700
Accumulated Amortization	(4,189)	(2,739)
Net	6,511	7,961
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,800	6,800
Accumulated Amortization	(1,598)	(1,018)
Net	5,202	5,782
Covenant not to compete
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	395	384
Accumulated Amortization	(312)	(160)
Net	83	224
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	82,861	93,932
Accumulated Amortization	0	0
Net	$ 82,861	$ 93,932
Weighted Average \| Patents, related technologies and know-how
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life	15 years 3 months 18 days
Weighted Average \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life	6 years 6 months
Weighted Average \| Trademarks
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life	9 years 3 months 18 days
Weighted Average \| Covenant not to compete
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life	2 years

XML 85 R74.htm IDEA: XBRL DOCUMENT

Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) - Revolving Line of Credit	9 Months Ended
	Sep. 30, 2016 USD ($)
Trans Ova Genetics, LC \| First National Bank of Omaha
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 6,000,000
Line of credit facility, interest rate at period end	3.48%
Line of credit facility, outstanding balance	$ 0
Trans Ova Genetics, LC \| First National Bank of Omaha \| Minimum
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	3.00%
Trans Ova Genetics, LC \| First National Bank of Omaha \| London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Line of credit facility, basis spread on variable rate	2.95%
Exemplar Genetics, LLC \| American State Bank
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 700,000
Debt instrument, interest rate, stated percentage	4.50%
Line of credit facility, outstanding balance	$ 549,000

XML 86 R75.htm IDEA: XBRL DOCUMENT

Lines of Credit and Long Term Debt - Schedule of Long Term Debt Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long term debt	$ 8,421	$ 8,528
Less current portion	471	930
Long term debt, net of current portion	7,950	7,598
Notes payable
Debt Instrument [Line Items]
Long term debt	5,769	6,477
Royalty-based financing
Debt Instrument [Line Items]
Long term debt	2,003	1,807
Other
Debt Instrument [Line Items]
Long term debt	$ 649	$ 244

XML 87 R76.htm IDEA: XBRL DOCUMENT

Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Mar. 31, 2013
Debt Instrument [Line Items]
Long term debt	$ 8,421,000	$ 8,528,000
Notes payable to banks \| Trans Ova Genetics, LC \| American State Bank
Debt Instrument [Line Items]
Long term debt	5,338,000
Debt instrument, periodic payment	$ 39,000
Debt instrument, interest rate, stated percentage	3.95%
Notes payable
Debt Instrument [Line Items]
Long term debt	$ 5,769,000	6,477,000
Notes payable \| Exemplar Genetics, LLC
Debt Instrument [Line Items]
Long term debt	431,000
Notes payable \| Exemplar Genetics, LLC \| Minimum
Debt Instrument [Line Items]
Debt instrument, periodic payment	$ 1,000
Debt instrument, interest rate, stated percentage	0.00%
Notes payable \| Exemplar Genetics, LLC \| Maximum
Debt Instrument [Line Items]
Debt instrument, periodic payment	$ 4,000
Debt instrument, interest rate, stated percentage	3.00%
Other
Debt Instrument [Line Items]
Long term debt	$ 649,000	244,000
Other \| AquaBounty Technologies, Inc. \| Finance PEI
Debt Instrument [Line Items]
Long term debt	543,000
Debt instrument, periodic payment	$ 4,000
Debt instrument, interest rate, stated percentage	4.00%
Royalty-based financing
Debt Instrument [Line Items]
Long term debt	$ 2,003,000	$ 1,807,000
Royalty-based financing \| AquaBounty Technologies, Inc. \| Atlantic Canada Opportunities Agency
Debt Instrument [Line Items]
Long term debt	2,003,000
Amount available under the grant for research and development	$ 2,185,000
Claims period	5 years
Royalty on products, percentage	10.00%
Amount claimed			$ 1,952,000
Long term debt, fair value at date of business combination			1,107,000
Accreted difference between face value of amount drawn and acquisition date fair value			$ 845,000

XML 88 R77.htm IDEA: XBRL DOCUMENT

Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) $ in Thousands	Sep. 30, 2016 USD ($)
Debt Disclosure [Abstract]
2016	$ 168
2017	404
2018	549
2019	364
2020	335
2021	774
Thereafter	3,824
Total	$ 6,418

XML 89 R78.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating Loss Carryforwards [Line Items]
Deferred income tax expense (benefit)	$ (308,000)	$ (578,000)	$ (2,967,000)	$ 374,000
Deferred tax liabilities	18,060,000		18,060,000
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Taxable income (loss)	8,334,000	(15,865,000)	(9,346,000)	22,935,000
Current income tax expense (benefit)	0	(318,000)	0	459,000
Operating loss carryforwards	257,700,000		257,700,000
Federal and state research and development tax credits	7,060,000		7,060,000
Operating loss carryforward benefits from stock compensation deductions	54,400,000		54,400,000
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Current income tax expense (benefit)	(110,000)	$ (27,000)	(323,000)	$ (27,000)
Operating loss carryforwards	$ 120,600,000		$ 120,600,000

XML 90 R79.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Dividend to Shareholders (Details) $ / shares in Units, $ in Thousands	1 Months Ended
	Jun. 30, 2015 USD ($) $ / shares shares
Intrexon Stock Option Plans
Class of Stock [Line Items]
Adjustment due to dividend (in shares)	312,795
Adjustment due to dividend (in usd per share) \| $ / shares	$ 25.40
ZIOPHARM Oncology, Inc.
Class of Stock [Line Items]
Noncash dividend, shares	17,830,305
Realized investment gains \| $	$ 81,401

XML 91 R80.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ 600,473	$ 694,078
Unrealized gain (loss) on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	69	(519)
Foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	(25,371)	(12,233)
Total accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ (25,302)	$ (12,752)

XML 92 R81.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation costs	$ 10,792	$ 8,385	$ 30,631	$ 26,524
Cost of products
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation costs	21	21	61	76
Cost of services
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation costs	68	98	206	301
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation costs	2,236	2,234	6,979	6,141
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation costs	$ 8,467	$ 6,032	$ 23,385	$ 20,006

XML 93 R82.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	9 Months Ended
	Oct. 31, 2016	Nov. 30, 2015	Sep. 30, 2016	Sep. 30, 2016	Apr. 30, 2016	Dec. 31, 2015	Aug. 31, 2013
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly compensation, in the form of equity		$ 200
Lock-up period		3 years
Initial term of compensation arrangement		12 months
Chief Executive Officer \| Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of shares issued			$ 463	$ 1,397
Intrexon Stock Option Plan - 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)							0
Options outstanding (in shares)			570,977	570,977
Intrexon Stock Option Plan - 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)			3,982,064	3,982,064
Options outstanding (in shares)			10,532,430	10,532,430
Number of shares authorized for issuance (in shares)			16,000,000	16,000,000
Intrexon Stock Option Plan - Other Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)			1,000,000	1,000,000
Intrexon Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)			12,103,407	12,103,407		11,043,528
Unrecognized compensation costs related to nonvested awards			$ 106,649	$ 106,649		$ 113,655
Recognized over weighted-average period				3 years
Weighted average exercise price of option (in usd per share)			$ 31.24	$ 31.24		$ 32.66
Shares exercisable at end of period (in shares)			3,369,252	3,369,252
AquaBounty Stock Option Plan - 2006 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)					0
Options outstanding (in shares)			5,567,000	5,567,000		5,382,000
Weighted average exercise price of option (in usd per share)			$ 0.26	$ 0.26		$ 0.26
Shares exercisable at end of period (in shares)			5,321,598	5,321,598		4,320,333
AquaBounty Stock Option Plan - 2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)			0	0
Subsequent Event \| Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial term of compensation arrangement	2 months

XML 94 R83.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Schedule of Stock Option Activity (Details) - Intrexon Stock Option Plans - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Number of Shares
Balances at beginning of period (in shares)	11,043,528
Granted (in shares)	4,384,860
Exercised (in shares)	(1,162,843)
Forfeited (in shares)	(2,127,334)
Expired (in shares)	(34,804)
Balances at end of period (in shares)	12,103,407	11,043,528
Exercisable at end of period (in shares)	3,369,252
Vested and Expected to Vest at end of period (in shares)	10,177,058
Weighted Average Exercise Price
Balances at beginning of period (in usd per share)	$ 32.66
Granted (in usd per share)	29.42
Exercised (in usd per share)	(15.63)
Forfeited (in usd per share)	(43.29)
Expired (in usd per share)	(35.76)
Balances at period end (in usd per share)	31.24	$ 32.66
Exercisable, weighted average exercise price, at end of period (in usd per share)	27.99
Vested and Expected to Vest, weighted average exercise price at end of period (in usd per share)	$ 30.99
Weighted Average Remaining Contractual Term (Years)
Balances, weighted average remaining contractual period	8 years 6 months	8 years 5 months 27 days
Exercisable at period end, weighted average remaining contractual period	7 years 2 months 30 days
Vested and Expected to Vest at period end, weighted average remaining contractual period	8 years 4 months 12 days

XML 95 R84.htm IDEA: XBRL DOCUMENT

License Agreement (Details)	1 Months Ended
License Agreement (Details)	Jan. 31, 2015 USD ($) shares
Other Commitments [Line Items]
Shares issued as consideration of license agreement (in shares) \| shares	2,100,085
ZIOPHARM Oncology, Inc.
Other Commitments [Line Items]
Annual funding commitment, term	3 years
ZIOPHARM Oncology, Inc. \| Minimum
Other Commitments [Line Items]
Annual funding commitment, amount	$ 15,000,000
ZIOPHARM Oncology, Inc. \| Maximum
Other Commitments [Line Items]
Annual funding commitment, amount	20,000,000
Research and development
Other Commitments [Line Items]
Payment of license fees	$ 59,579,000

XML 96 R85.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) $ in Thousands	Sep. 30, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2016	$ 705
2017	6,362
2018	5,695
2019	5,434
2020	5,487
2021	4,888
Thereafter	20,179
Total	$ 48,750

XML 97 R86.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Operating Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 2,075	$ 2,167	$ 6,410	$ 6,548
Rental income under sublease agreement	184	$ 334	854	$ 1,153
Future rental income under sublease agreements, 2016	9		9
Future rental income under sublease agreements, 2017	$ 36		$ 36

XML 98 R87.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Contingencies - Additional Information (Details) $ in Thousands	1 Months Ended		9 Months Ended	50 Months Ended
	May 31, 2016 claim	Apr. 30, 2016 USD ($)	Sep. 30, 2016 USD ($)	Apr. 30, 2016 USD ($)
Licensing and patent infringement suit
Loss Contingencies [Line Items]
Damages awarded to (against) Trans Ova		$ 528
Cumulative payments for royalties and licenses				$ 3,170
Royalty payments not yet deposited			$ 2,759
Licensing and patent infringement suit \| Selling, general and administrative
Loss Contingencies [Line Items]
Litigation settlement expense			$ 4,228
Licensing and patent infringement suit \| XY, LLC
Loss Contingencies [Line Items]
Damages awarded to (against) Trans Ova		$ (6,066)
Hoffman v. Intrexon Corporation et al. and Gibrall v. Intrexon Corporation et al.
Loss Contingencies [Line Items]
Number of lawsuits \| claim	2

XML 99 R88.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Nov. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Shares issued as payment for services						$ 8,284
Fair value of financial assets measured at fair value on a recurring basis	$ 376,093			$ 376,093		376,093		$ 291,762
Collaboration and licensing revenues				30,590	$ 34,726	82,144	$ 66,690
Third Security, LLC
Related Party Transaction [Line Items]
Expense for services				$ 156	142	$ 301	294
Initial term of services agreement			1 year
Shares issued as payment for services (in shares)				89,326		254,496
Shares issued as payment for services				$ 2,132		$ 6,542
Third Security, LLC \| Common Stock
Related Party Transaction [Line Items]
Expense for services			$ 800
Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Payments to acquire convertible notes and warrants	$ 2,604
Oragenics, Inc.
Related Party Transaction [Line Items]
Common stock purchased from collaborative partners, shares		2,261,419
Price per share of common shares (usd per share)		$ 0.52
Oragenics, Inc. \| Maximum
Related Party Transaction [Line Items]
Maximum percentage of shares of future securities offerings of collaborative partners to which the entity is entitled to purchase	30.00%			30.00%		30.00%
Related Parties, Aggregated
Related Party Transaction [Line Items]
Collaboration and licensing revenues				$ 26,688	31,740	$ 70,299	59,775
Harvest Intrexon Enterprise Fund I, LP \| Other nonoperating income
Related Party Transaction [Line Items]
Management fees revenue				613	$ 697	1,871	$ 697
Convertible Note and Warrants \| Other Assets \| Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Fair value of financial assets measured at fair value on a recurring basis	$ 1,990			$ 1,990		$ 1,990

XML 100 R89.htm IDEA: XBRL DOCUMENT

Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net loss attributable to Intrexon	$ (28,982)	$ (38,213)	$ (142,475)	$ (51,779)
Denominator:
Weighted average shares outstanding, basic and diluted (in shares)	118,346,782	112,244,129	117,785,160	109,244,641
Net loss attributable to Intrexon per share, basic and diluted (in usd per share)	$ (0.24)	$ (0.34)	$ (1.21)	$ (0.47)

XML 101 R90.htm IDEA: XBRL DOCUMENT

Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	12,133,598	10,854,759	12,133,598	10,854,759
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	12,103,407	10,660,040	12,103,407	10,660,040
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	30,191	194,719	30,191	194,719

XML 102 R91.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - Subsequent Event $ in Thousands	Nov. 09, 2016 USD ($) shares
AquaBounty Technologies, Inc.
Subsequent Event [Line Items]
Commitment to purchase additional shares of majority-owned subsidiary upon approval for NASDAQ listing, in shares \| shares	72,632,190
Commitment to purchase additional shares of majority-owned subsidiary upon approval for NASDAQ listing	$ 25,000
Maximum \| AquaBounty Technologies, Inc.
Subsequent Event [Line Items]
Principal balance of convertible promissory note receivable with a related party	$ 10,000

EXCEL 103 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 107 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 509 381 1 false 119 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.dna.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.dna.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.dna.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.dna.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Shareholders' and Total Equity Sheet http://www.dna.com/role/ConsolidatedStatementsOfShareholdersAndTotalEquity Consolidated Statements of Shareholders' and Total Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.dna.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Organization Sheet http://www.dna.com/role/Organization Organization Notes 8 false false R9.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2103100 - Disclosure - Mergers and Acquisitions Sheet http://www.dna.com/role/MergersAndAcquisitions Mergers and Acquisitions Notes 10 false false R11.htm 2111100 - Disclosure - Investments in Joint Ventures Sheet http://www.dna.com/role/InvestmentsInJointVentures Investments in Joint Ventures Notes 11 false false R12.htm 2112100 - Disclosure - Collaboration and Licensing Revenue Sheet http://www.dna.com/role/CollaborationAndLicensingRevenue Collaboration and Licensing Revenue Notes 12 false false R13.htm 2114100 - Disclosure - Short-term and Long-term Investments Sheet http://www.dna.com/role/ShortTermAndLongTermInvestments Short-term and Long-term Investments Notes 13 false false R14.htm 2115100 - Disclosure - Investment in Preferred Stock Sheet http://www.dna.com/role/InvestmentInPreferredStock Investment in Preferred Stock Notes 14 false false R15.htm 2116100 - Disclosure - Fair Value Measurements Sheet http://www.dna.com/role/FairValueMeasurements Fair Value Measurements Notes 15 false false R16.htm 2117100 - Disclosure - Inventory Sheet http://www.dna.com/role/Inventory Inventory Notes 16 false false R17.htm 2119100 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net Notes 17 false false R18.htm 2120100 - Disclosure - Goodwill and Intangible Assets, Net Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNet Goodwill and Intangible Assets, Net Notes 18 false false R19.htm 2121100 - Disclosure - Lines of Credit and Long Term Debt Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebt Lines of Credit and Long Term Debt Notes 19 false false R20.htm 2122100 - Disclosure - Income Taxes Sheet http://www.dna.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2123100 - Disclosure - Shareholders' Equity Sheet http://www.dna.com/role/ShareholdersEquity Shareholders' Equity Notes 21 false false R22.htm 2124100 - Disclosure - Share-Based Payments Sheet http://www.dna.com/role/ShareBasedPayments Share-Based Payments Notes 22 false false R23.htm 2125100 - Disclosure - License Agreement Sheet http://www.dna.com/role/LicenseAgreement License Agreement Notes 23 false false R24.htm 2126100 - Disclosure - Commitments and Contingencies Sheet http://www.dna.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 24 false false R25.htm 2127100 - Disclosure - Related Party Transactions Sheet http://www.dna.com/role/RelatedPartyTransactions Related Party Transactions Notes 25 false false R26.htm 2128100 - Disclosure - Net Loss per Share Sheet http://www.dna.com/role/NetLossPerShare Net Loss per Share Notes 26 false false R27.htm 2129100 - Disclosure - Subsequent Events Subsequent Events Sheet http://www.dna.com/role/SubsequentEventsSubsequentEvents Subsequent Events Subsequent Events Notes 27 false false R28.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.dna.com/role/SummaryOfSignificantAccountingPolicies 28 false false R29.htm 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.dna.com/role/SummaryOfSignificantAccountingPolicies 29 false false R30.htm 2303301 - Disclosure - Mergers and Acquisitions (Tables) Sheet http://www.dna.com/role/MergersAndAcquisitionsTables Mergers and Acquisitions (Tables) Tables http://www.dna.com/role/MergersAndAcquisitions 30 false false R31.htm 2312301 - Disclosure - Collaboration and Licensing Revenue (Tables) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueTables Collaboration and Licensing Revenue (Tables) Tables http://www.dna.com/role/CollaborationAndLicensingRevenue 31 false false R32.htm 2314301 - Disclosure - Short-term and Long-term Investments (Tables) Sheet http://www.dna.com/role/ShortTermAndLongTermInvestmentsTables Short-term and Long-term Investments (Tables) Tables http://www.dna.com/role/ShortTermAndLongTermInvestments 32 false false R33.htm 2316301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.dna.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.dna.com/role/FairValueMeasurements 33 false false R34.htm 2317301 - Disclosure - Inventory (Tables) Sheet http://www.dna.com/role/InventoryTables Inventory (Tables) Tables http://www.dna.com/role/Inventory 34 false false R35.htm 2319301 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNetTables Property, Plant and Equipment, Net (Tables) Tables http://www.dna.com/role/PropertyPlantAndEquipmentNet 35 false false R36.htm 2320301 - Disclosure - Goodwill and Intangible Assets, Net (Tables) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetTables Goodwill and Intangible Assets, Net (Tables) Tables http://www.dna.com/role/GoodwillAndIntangibleAssetsNet 36 false false R37.htm 2321301 - Disclosure - Lines of Credit and Long Term Debt (Tables) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtTables Lines of Credit and Long Term Debt (Tables) Tables http://www.dna.com/role/LinesOfCreditAndLongTermDebt 37 false false R38.htm 2323301 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.dna.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.dna.com/role/ShareholdersEquity 38 false false R39.htm 2324301 - Disclosure - Share-Based Payments (Tables) Sheet http://www.dna.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.dna.com/role/ShareBasedPayments 39 false false R40.htm 2326301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.dna.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.dna.com/role/CommitmentsAndContingencies 40 false false R41.htm 2328301 - Disclosure - Net Loss per Share (Tables) Sheet http://www.dna.com/role/NetLossPerShareTables Net Loss per Share (Tables) Tables http://www.dna.com/role/NetLossPerShare 41 false false R42.htm 2401401 - Disclosure - Organization (Details) Sheet http://www.dna.com/role/OrganizationDetails Organization (Details) Details http://www.dna.com/role/Organization 42 false false R43.htm 2402403 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesEquityMethodInvestmentsAdditionalInformationDetails Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) Details 43 false false R44.htm 2402404 - Disclosure - Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesVariableInterestEntitiesAdditionalInformationDetails Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) Details 44 false false R45.htm 2402405 - Disclosure - Summary of Significant Accounting Policies - Segment Information - Additional Information (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetails Summary of Significant Accounting Policies - Segment Information - Additional Information (Details) Details 45 false false R46.htm 2402406 - Disclosure - Summary of Significant Accounting Policies - Summarized Unaudited Financial Information for the Equity Method Investments (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesSummarizedUnauditedFinancialInformationForEquityMethodInvestmentsDetails Summary of Significant Accounting Policies - Summarized Unaudited Financial Information for the Equity Method Investments (Details) Details 46 false false R47.htm 2403402 - Disclosure - Mergers and Acquisitions - Oxitec - Additional Information (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsOxitecAdditionalInformationDetails Mergers and Acquisitions - Oxitec - Additional Information (Details) Details 47 false false R48.htm 2403403 - Disclosure - Mergers and Acquisitions - Fair Value of Consideration Transferred (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsFairValueOfConsiderationTransferredDetails Mergers and Acquisitions - Fair Value of Consideration Transferred (Details) Details 48 false false R49.htm 2403404 - Disclosure - Mergers and Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails Mergers and Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 49 false false R50.htm 2403405 - Disclosure - Mergers and Acquisitions - Okanagan - Additional Information (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsOkanaganAdditionalInformationDetails Mergers and Acquisitions - Okanagan - Additional Information (Details) Details 50 false false R51.htm 2403406 - Disclosure - Mergers and Acquisitions - ActoGeniX - Additional Information (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsActogenixAdditionalInformationDetails Mergers and Acquisitions - ActoGeniX - Additional Information (Details) Details 51 false false R52.htm 2403407 - Disclosure - Mergers and Acquisitions - 2015 Acquisitions - Pro Forma Financial Information (Details) Sheet http://www.dna.com/role/MergersAndAcquisitions2015AcquisitionsProFormaFinancialInformationDetails Mergers and Acquisitions - 2015 Acquisitions - Pro Forma Financial Information (Details) Details 52 false false R53.htm 2411401 - Disclosure - Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesIntrexonT1DPartnersAdditionalInformationDetails Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details) Details 53 false false R54.htm 2411402 - Disclosure - Investments in Joint Ventures - EnviroFlight - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesEnviroflightAdditionalInformationDetails Investments in Joint Ventures - EnviroFlight - Additional Information (Details) Details 54 false false R55.htm 2411403 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesIntrexonEnergyPartnersIiAdditionalInformationDetails Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details) Details 55 false false R56.htm 2411404 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details) Details 56 false false R57.htm 2411405 - Disclosure - Investments in Joint Ventures - OvaXon - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesOvaxonAdditionalInformationDetails Investments in Joint Ventures - OvaXon - Additional Information (Details) Details 57 false false R58.htm 2411406 - Disclosure - Investments in Joint Ventures - S & I Ophthalmic - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesSIOphthalmicAdditionalInformationDetails Investments in Joint Ventures - S & I Ophthalmic - Additional Information (Details) Details 58 false false R59.htm 2412402 - Disclosure - Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueSummarizedCollaborationAndLicensingRevenuesDetails Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) Details 59 false false R60.htm 2412403 - Disclosure - Collaboration and Licensing Revenue - Additional Information (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueAdditionalInformationDetails Collaboration and Licensing Revenue - Additional Information (Details) Details 60 false false R61.htm 2412404 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueSummaryOfDeferredRevenueDetails Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) Details 61 false false R62.htm 2412405 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueSummaryOfDeferredRevenueByCollaboratorDetails Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) Details 62 false false R63.htm 2414402 - Disclosure - Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term and Long-term Investments (Details) Sheet http://www.dna.com/role/ShortTermAndLongTermInvestmentsSummaryOfAmortizedCostGrossUnrealizedGainsAndLossesAndFairValueOfShortTermAndLongTermInvestmentsDetails Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term and Long-term Investments (Details) Details 63 false false R64.htm 2414403 - Disclosure - Short-term and Long-term Investments - Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities (Details) Sheet http://www.dna.com/role/ShortTermAndLongTermInvestmentsSummaryOfEstimatedFairValueOfAvailableForSaleInvestmentsClassifiedByContractualMaturitiesDetails Short-term and Long-term Investments - Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities (Details) Details 64 false false R65.htm 2415401 - Disclosure - Investment in Preferred Stock (Details) Sheet http://www.dna.com/role/InvestmentInPreferredStockDetails Investment in Preferred Stock (Details) Details http://www.dna.com/role/InvestmentInPreferredStock 65 false false R66.htm 2416402 - Disclosure - Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.dna.com/role/FairValueMeasurementsSummaryOfPlacementInFairValueHierarchyOfFinancialAssetsThatAreMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Details 66 false false R67.htm 2416403 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 67 false false R68.htm 2417402 - Disclosure - Inventory (Details) Sheet http://www.dna.com/role/InventoryDetails Inventory (Details) Details http://www.dna.com/role/InventoryTables 68 false false R69.htm 2419402 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) Details 69 false false R70.htm 2419403 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Details) Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNetAdditionalInformationDetails Property, Plant and Equipment, Net - Additional Information (Details) Details 70 false false R71.htm 2420402 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetScheduleOfChangesInCarryingAmountOfGoodwillDetails Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) Details 71 false false R72.htm 2420403 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails Goodwill and Intangible Assets, Net - Additional Information (Details) Details 72 false false R73.htm 2420404 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) Details 73 false false R74.htm 2421402 - Disclosure - Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtLinesOfCreditAdditionalInformationDetails Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) Details 74 false false R75.htm 2421403 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Long Term Debt Instruments (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtScheduleOfLongTermDebtInstrumentsDetails Lines of Credit and Long Term Debt - Schedule of Long Term Debt Instruments (Details) Details 75 false false R76.htm 2421404 - Disclosure - Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtLongTermDebtAdditionalInformationDetails Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) Details 76 false false R77.htm 2421405 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) Details 77 false false R78.htm 2422401 - Disclosure - Income Taxes (Details) Sheet http://www.dna.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.dna.com/role/IncomeTaxes 78 false false R79.htm 2423402 - Disclosure - Shareholders' Equity - Dividend to Shareholders (Details) Sheet http://www.dna.com/role/ShareholdersEquityDividendToShareholdersDetails Shareholders' Equity - Dividend to Shareholders (Details) Details 79 false false R80.htm 2423403 - Disclosure - Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.dna.com/role/ShareholdersEquityComponentsOfAccumulatedOtherComprehensiveLossDetails Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) Details 80 false false R81.htm 2424402 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense (Details) Sheet http://www.dna.com/role/ShareBasedPaymentsScheduleOfStockBasedCompensationExpenseDetails Share-Based Payments - Schedule of Stock-Based Compensation Expense (Details) Details 81 false false R82.htm 2424403 - Disclosure - Share-Based Payments - Additional Information (Details) Sheet http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails Share-Based Payments - Additional Information (Details) Details 82 false false R83.htm 2424404 - Disclosure - Share-Based Payments - Schedule of Stock Option Activity (Details) Sheet http://www.dna.com/role/ShareBasedPaymentsScheduleOfStockOptionActivityDetails Share-Based Payments - Schedule of Stock Option Activity (Details) Details 83 false false R84.htm 2425401 - Disclosure - License Agreement (Details) Sheet http://www.dna.com/role/LicenseAgreementDetails License Agreement (Details) Details http://www.dna.com/role/LicenseAgreement 84 false false R85.htm 2426402 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) Sheet http://www.dna.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) Details 85 false false R86.htm 2426403 - Disclosure - Commitments and Contingencies - Operating Leases - Additional Information (Details) Sheet http://www.dna.com/role/CommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails Commitments and Contingencies - Operating Leases - Additional Information (Details) Details 86 false false R87.htm 2426404 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Details) Sheet http://www.dna.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetails Commitments and Contingencies - Contingencies - Additional Information (Details) Details 87 false false R88.htm 2427401 - Disclosure - Related Party Transactions (Details) Sheet http://www.dna.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.dna.com/role/RelatedPartyTransactions 88 false false R89.htm 2428402 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Sheet http://www.dna.com/role/NetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Details 89 false false R90.htm 2428403 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) Sheet http://www.dna.com/role/NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) Details 90 false false R91.htm 2429401 - Disclosure - Subsequent Events (Details) Sheet http://www.dna.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.dna.com/role/SubsequentEventsSubsequentEvents 91 false false All Reports Book All Reports xon-20160930.xml xon-20160930.xsd xon-20160930_cal.xml xon-20160930_def.xml xon-20160930_lab.xml xon-20160930_pre.xml true true ZIP 109 0001356090-16-000129-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001356090-16-000129-xbrl.zip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end